<allTrials totalCount="67" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2026-09-30T09:29:50.131861222Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN80009790" publicIdentifierDateAssigned="2026-09-30T09:45:17.973318Z">
    <isrctn dateAssigned="2026-09-30T09:45:17.973318Z">80009790</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Investigating and improving care (education) and treatment reviews (C(E)TRs)</title>
      <scientificTitle>Optimising community C(E)TRs through understanding the experience of people with learning disability and autistic people and investigating their impact on care</scientificTitle>
      <acronym>OptiCaT</acronym>
      <studyHypothesis>1. Do C(E)TRs reduce hospital admissions (primary outcome) and duration of hospital stay in people with learning disability and/or autistic people who are at risk of psychiatric hospital admission? 
2. Do C(E)TRs improve other clinical, health and social outcomes? 
3. Are C(E)TRs cost-effective?</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Care (Education) and Treatment Reviews, or C(E)TRs, were introduced in England in 2015 to help people with a learning disability and autistic people get the right support in the community and avoid unnecessary admission to a mental health hospital. However, there is limited evidence about how well C(E)TRs work. This study aims to find out whether community C(E)TRs reduce hospital admissions and improve people’s health, wellbeing and care. 

Who can participate?
The study is for people aged 14 years or older who have a learning disability and/or are autistic, are receiving support from an NHS community mental health services, and are considered at increased risk of admission to a mental health hospital. Family members and paid carers of participants can also take part.

What does the study involve?
People with a learning disability and autistic people from different parts of England will be recruited to the study and followed-up over time. Researchers will collect information about hospital admissions, mental health, behaviour, quality of life, medication, use of health and social care services, and the care and support people receive. The information will be collected at the point of recruitment, at 6 months, and at 9 months. The information will be collected by questionnaires that a researcher will go through with the participant. The data that are collected will allow researchers to compare people who have a C(E)TR with people who do not.

What are the possible benefits and risks of participating?
People taking part may not receive a direct personal benefit. However, the information they provide may help improve C(E)TRs and the support provided to people with a learning disability and autistic people in the future.
The study is considered to be low risk. Completing questionnaires and assessments will take some time and may be tiring. Interviews may involve discussing difficult experiences, including times when community care has broken down or when hospital admission has been needed, and this could be upsetting. Participants can take a break or stop an interview if they wish, and the research team will help them access appropriate support if needed.

Where is the study run from?
The study is led by King’s College London (UK), in partnership with Queen Mary University of London and other universities and NHS organisations. Participants are being recruited through NHS services in different parts of England so that the study includes people from a range of geographical areas and communities. 

When is the study starting and how long is it expected to run for?
August 2025 to February 2028

Who is funding the study?
The study is funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research Programme (reference NIHR158490)

Who is the main contact?
Dr Rory Sheehan, opticatstudy@kcl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="cf7f4c9f-53d7-4d55-bf9f-c10d98b49ce0">
	  <variable>Admission to psychiatric hospital</variable>
	  <method>the modified version of the Adult Service Use Schedule (AD-SUS) and also provided by the clinician</method>
	  <timepoints>baseline, 6 months, and 9 months</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Psychiatric symptoms measured using the Moss Psychiatric Assessment Schedule - Check (Moss-PAS (Check)) at baseline, 6 months, and 9 months
2. Behaviour that challenges measured using the Behaviour Problems Inventory - Short Form (BPI-S) at baseline, 6 months, and 9 months
3. Unmet care needs measured using the Camberwell Assessment of Needs for Adults with Developmental and Intellectual Disabilities - Research version (CANDID-R) at baseline, 6 months, and 9 months
4. Quality of Life measured using the 13-item WHOQOL Disabilities module (WHOQOL-DIS) at baseline, 6 months, and 9 months
5. Health-related quality of life measured using the EuroQoL Five Dimensions - Three Levels questionnaire (EQ-5D-3L) at baseline, 6 months, and 9 months
6. Service use (health and social care contacts) measured using a modified version of the Adult Service Use Schedule (AD-SUS) at baseline, 6 months, and 9 months
7. Family carer distress measured using the Kessler Psychological Distress Scale (K6) at baseline, 6 months, and 9 months
8. Family carer health-related quality of life measured using the EuroQol 5-Dimension 5-Level questionnaire at baseline, 6 months, and 9 months
9. Clinician-rated participant symptom severity measured using the Clinical Global Impression-Severity (CGI-S) Scale at baseline, 6 months, and 9 months
10. Clinician-rated participant health and social functioning measured using the Health of the Nation Outcome Scales (HoNOS) at baseline, 6 months, and 9 months
11. Clinician-rated participant exposure to restrictive practices (physical, mechanical, or chemical restraint) measured using a questionnaire created by the research team at baseline, 6 months, and 9 months
12. Psychotropic medication prescribing measured using a questionnaire created by the research team at baseline, 6 months, and 9 months</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="444d349d-37ee-402d-95a0-7d27ff568b2e" approvalStatus="approved" statusDate="2025-07-31T00:00:00.000Z">
	  <committeeName>Leeds West Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>NHSBT Newcastle Blood Donor Centre
Holland Drive</address>
	    <city>Newcastle upon Tyne</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>NE2 4NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/YH/0119 </committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN80009790</doi>
      <eudraCTNumber/>
      <irasNumber>335048</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NIHR: 158490</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="a8529dce-a654-4418-b14a-ad6967352af8" numberType="iras" canonicalSecondaryNumber="IRAS335048">335048</secondaryNumber>
	<secondaryNumber id="652f8526-e929-4e33-93f9-63b1ee8dc891" numberType="nihr" canonicalSecondaryNumber="NIHR158490">158490</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Longitudinal study</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2a539c7d-6248-4eca-a8d4-bd1e316216e9">
	  <name>Oxleas NHS Foundation Trust</name>
	  <address>Pinewood House
Pinewood PLACE</address>
	  <city>Dartford</city>
	  <state/>
	  <country>England</country>
	  <zip>DA2 7WG</zip>
	  <rtsId>RPG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="602b96de-ba56-4011-bf7c-567d678a0f14">
	  <name>South London and Maudsley NHS Foundation Trust</name>
	  <address>Bethlem Royal Hospital
Monks Orchard Road</address>
	  <city>Beckenham</city>
	  <state/>
	  <country>England</country>
	  <zip>BR3 3BX</zip>
	  <rtsId>RV5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="ef2b351d-157a-4e3c-af4f-dbdcac294264">
	  <name>North London NHS Foundation Trust</name>
	  <address>4th Floor, East Wing
St. Pancras Hospital
4 St. Pancras Way</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 0PE</zip>
	  <rtsId>G6V2S@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1c258490-7c22-44a9-ba03-cd45bee2e57a">
	  <name>East London NHS Foundation Trust</name>
	  <address>Robert Dolan House
9 Alie Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 8DE</zip>
	  <rtsId>RWK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="37fd0b66-7d9a-4f5e-88dc-35e37e35dcb5">
	  <name>Central and North West London NHS Foundation Trust</name>
	  <address>Trust Headquarters
350 Euston Road
Regents PLACE</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 3AX</zip>
	  <rtsId>RV3@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="486912aa-4b0e-40d6-b706-a1c383422c68">
	  <name>Lincolnshire Partnership NHS Foundation Trust Hq</name>
	  <address>NHS Foundation Trust
Carholme Court
Long Leys Road</address>
	  <city>Lincoln</city>
	  <state/>
	  <country>England</country>
	  <zip>LN1 1FS</zip>
	  <rtsId>RP7SG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bdddd0d6-88dd-43c5-9dd6-1a217e3c8740">
	  <name>Sussex Partnership NHS Foundation Trust</name>
	  <address>Trust Hq
Swandean
Arundel Road</address>
	  <city>Worthing</city>
	  <state/>
	  <country>England</country>
	  <zip>BN13 3EP</zip>
	  <rtsId>RX2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="a10e8854-ad70-43c6-9cc2-041361f7d1e4">
	  <name>Cornwall Partnership NHS Foundation Trust</name>
	  <address>Carew House
Beacon Technology Park
Dunmere Road</address>
	  <city>Bodmin</city>
	  <state/>
	  <country>England</country>
	  <zip>PL31 2QN</zip>
	  <rtsId>RJ8@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6dbc9c49-1392-4f12-a11f-3726dddde28d">
	  <name>Cheshire and Wirral Partnership NHS Foundation Trust</name>
	  <address>Trust Headquarters Redesmere
The Countess of Chester Health Park
Liverpool Road</address>
	  <city>Chester</city>
	  <state/>
	  <country>England</country>
	  <zip>CH2 1BQ</zip>
	  <rtsId>RXA@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f17dfe83-8dc6-4500-8538-670d9de4d236">
	  <name>Tees, Esk and Wear Valleys NHS Foundation Trust</name>
	  <address>Trust Headquarters
West Park Hospital
Edward Pease Way</address>
	  <city>Darlington</city>
	  <state/>
	  <country>England</country>
	  <zip>DL2 2TS</zip>
	  <rtsId>RX3@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4021224c-d5c8-4e41-a61d-66056f79b08e">
	  <name>Hertfordshire Partnership N H S</name>
	  <address>Harper Lane
Shenley</address>
	  <city>Radlett</city>
	  <state/>
	  <country>England</country>
	  <zip>WD7 9HQ</zip>
	  <rtsId>V09887@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1578ec26-bc8f-4a04-b351-37d2459d8fd4">
	  <name>North East London NHS Foundation Trust</name>
	  <address>Goodmayes Hospital
157 Barley Lane</address>
	  <city>Ilford</city>
	  <state/>
	  <country>England</country>
	  <zip>IG3 8XJ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c2fc0a3d-7f0c-47c5-9caf-e4e7f976b0f3">
	  <name>Surrey and Borders Partnership NHS Trust Hq</name>
	  <address>18 Mole Business Park
Randalls Road</address>
	  <city>Leatherhead</city>
	  <state/>
	  <country>England</country>
	  <zip>KT22 7AD</zip>
	  <rtsId>RXXHQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="603a91fb-8c7f-49f7-94eb-d93d61828675">
	  <name>South West London and St George's Mental Health NHS Trust</name>
	  <address>Springfield Hospital
61 Glenburnie Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW17 7DJ</zip>
	  <rtsId>RQY@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Children/adolescents (aged between 14 and 17 years, inclusive) or adults (≥18 years) with a clinical diagnosis of learning disability (of any degree) or autism (diagnosis based on service records, expected to conform to ICD-10 chapter F7- criteria for learning disability or ICD-10 F84 criteria for autism)  
2. Under the care of a community mental health service (e.g., Child and Adolescent Mental Health Services [CAMHS], Community Learning Disability Team [CLDT], Community Mental Health Team [CMHT])  in a participating Trust
3. Rated as red or amber on the Dynamic Support Register (DSR)
4. Provide informed consent to taking part or, where an adult lacks capacity to consent to participate, a personal or nominated consultee has signed a declaration form or, in the case of children/adolescents (&lt;18 years), a parent/guardian has signed a consent form</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="14.0">14 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. No clinically-confirmed diagnosis of learning disability or autism 
2. Not on the Dynamic Support Register
3. Currently admitted to a psychiatric hospital
4. Does not provide informed consent or, where an adult lacks capacity, there is no consultee declaration or, in the case of children/adolescents (&lt;18 years) a parent/guardian has not signed a consent form</exclusion>
      <recruitmentStart>2025-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intellectual (learning) disability or autism spectrum disorder</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is an observational prospective cohort study recruiting people aged 14 years and over with a learning disability and/or autism who are considered at increased risk of psychiatric hospital admission (as identified by being rated red or amber on the Dynamic Support Register [DSR]). Participants will be recruited through NHS community mental health services across diverse areas of England. Family or paid carers may also take part.

Participants will complete assessments at the start of the study and again at 6 and 9 months. Information will be collected from participants, carers and clinicians about psychiatric hospital admissions, mental health and behaviour, quality of life, unmet needs, use of health and social care services, medication and restrictive practices. Assessments can be completed face-to-face, by telephone or online. We would expect some people to receive a C(E)TR during follow-up and others will not. 

The main outcome is admission to psychiatric hospital during follow-up. Secondary outcomes include psychiatric symptoms (measured by the Moss-PAS Check), behaviour that challenges (Behaviour Problems Inventory - Short form), unmet need (CANDID-R), quality of life (WHOQOL-DIS), health-related quality of life (EuroQoL Five Dimensions), service use (contacts with health and social care using a modified version of the Adult Service Use Schedule), all of which will be completed by the participant with learning disability or autism. Family carers who are enrolled will complete measures of family carer distress (Kessler Psychological Distress Scale), and carer health-related quality of live (EQ-5D-5L). Clinicians providing care to recruited participants will provide information on participant symptom severity (using the Clinical Global Impression-Severity scale), participant health and social functioning (measured with Health of the Nation Outcome Scale, HoNOS), use of restrictive practices (i.e. Mental Health Act, Deprivation of Liberty Safeguards), psychotropic medication, and whether a C(E)TR was conducted. 

The main outcome will be psychiatric hospital admission during follow-up. Outcomes will be compared between participants who receive a C(E)TR and those who do not, to investigate whether C(E)TRs are associated with a reduced likelihood of hospital admission and better health and care outcomes.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>7ec7713b-595d-402c-8112-c08062629892</funderId>
      <contactId>51829bab-ef10-4763-8132-5e6692178f42</contactId>
      <sponsorId>1c435748-e516-4e3f-a3f5-a034fa55a259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="51829bab-ef10-4763-8132-5e6692178f42">
    <title>Dr</title>
    <forename>Rory</forename>
    <surname>Sheehan</surname>
    <orcid>https://orcid.org/0000-0002-4164-9661</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Psychiatry, Psychology &amp; Neuroscience
King's College London</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SE5 8AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7848 0002</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rory.sheehan@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="1c435748-e516-4e3f-a3f5-a034fa55a259">
    <organisation>South London and Maudsley NHS Foundation Trust</organisation>
    <sponsorType/>
    <rorId>https://ror.org/015803449</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="7ec7713b-595d-402c-8112-c08062629892">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-03-30T10:05:39.574932673Z" version="16" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN10087117" publicIdentifierDateAssigned="2026-03-30T10:05:39.691538Z">
    <isrctn dateAssigned="2026-03-30T10:05:39.691538Z">10087117</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Trial of Empowered Conversations dementia carer training</title>
      <scientificTitle>A multi-centre effectiveness and cost-effectiveness superiority randomised controlled trial of a group-based intervention for family carers of people living with dementia, called Empowered Conversations, compared to treatment as usual</scientificTitle>
      <acronym/>
      <studyHypothesis>Primary objectives are: 
(1) Assess the effectiveness of EC in reducing carer stress ([Perceived Stress Scale [PSS] at 26-weeks post-randomisation) compared to a TAU Control; 
(2) determine the cost-effectiveness of EC.
 
Secondary objectives are: 
(3) Assess the effectiveness of EC on secondary outcomes: anxiety and depression [Hospital Anxiety and Depression Scale (HADs)]; relationship strain [Dyadic Relational Scale]; quality of Life [Carer QOL and carer perceived rating for person living with dementia)]; Carer goals [Goal-based outcome measure]; Activities of daily living; Peer Support; Communication at 16 and 26 weeks post-randomisation 
(4) Assess the effectiveness of EC in reducing carer stress (PSS) at 16 weeks, 
(5) Assess fidelity to the intervention protocol using a fidelity checklist that is observer and facilitator rated, 
(6) Provide the first examination of whether effectiveness is different in the in-person version compared to the online version of EC, 
(7) Explore whether effectiveness varies according to key carer status factors (e.g. providing ‘full-time’ vs ‘part-time’ support; and an estimate of symptom severity of the person living with dementia), 
(8) Provide initial psychometric properties and analysis of the Peer Support measure, 
(9) Provide the first full evaluation of safety indices in a definitive clinical trial of EC, 
(10) Provide initial acceptability data on the adaptations made to EC, and additional training for facilitators, to make EC more accessible to minoritised (global majority) communities.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
There are 700,000 family carers for people living with dementia in the UK. Sixty-four percent of carers who are unpaid in England say they have limited support for the range of psychological and social needs they experience. It can be difficult to keep communicating well due to thinking and memory changes that arise when someone is living with dementia. This can lead to frustration, low-mood and stress for both people living with dementia and their carers. The 6-session Empowered Conversations (EC) course is designed to enable carers to establish and maintain good communication and relationships with those they support. Course facilitators are trained to provide specific communication techniques, ways of managing conflicts and working with difficult emotions. EC can be delivered in person or online.
 
The main goal of the study is to find out if EC, a group-based support program for people who care for someone with dementia, helps and is worth the cost. The study aims to: (1) see how well EC works; (2) find out if it provides good value for money.
 
Who can participate?
Current unpaid or family carer for someone living with dementia (any subtype or severity) in the community. Participants should provide emotional or practical support at least weekly, be aged 18 or over, and have the capacity to give informed consent for the study. Either the carer or the person living with dementia that they are supporting should live within the boundaries of the recruiting Trusts.
 
What does the study involve?
During the first appointment, participants will be asked to complete some brief demographic questionnaires that should take about 15-20 minutes. Participants will be able to complete these online, over the phone, or at home. During the second appointment, participants will be asked to complete several questionnaires that should take about 45- 60 minutes. Participants will be able to complete these online, over the phone, or at home.
 
Participants will then be randomised to either receive the six-week EC course during the study’s duration or continue as usual. Participants who are selected to continue as usual will be offered to receive the online EC course after the study has finished. 
 
Approximately 4 and 6 months after the first appointment, participants will be invited to complete further questionnaires. Participants will be able to complete these online, over the phone, or at home. 
 
What are the possible benefits and risks of participating?
The anticipated benefits for carer trial participants are improvements in carer psychological well-being, communication and quality of life. Outcomes from our feasibility trial indicate that carers experience significant reductions in stress and improvements in communication following the EC course. Qualitative data suggests that these improvements in carer stress and communication have an impact on the well-being of the person living with dementia that they are supporting.
 
It is not anticipated that there are any significant risks or burdens for trial participants. Although talking about the problems of being a carer could be upsetting, in our experience, carers do not find it distressing and usually find it helpful. Some participants may find completion of questionnaire measures burdensome; the researchers will provide practical (splitting sessions up) and emotional support (distress management) if required.
 
Where is the study run from?
Lancashire Clinical Trials Unit, University of Lancashire (UK) 
 
When is the study starting and how long is it expected to run for?
April 2026 to June 2028
 
Who is funding the study?
National Institute for Health and Care Research (NIHR), Research for Patient Benefit (RfPB) Programme, UK.
 
 Who is the main contact?
Dr Lydia Morris lydia.morris@manchester.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="3240093d-9438-4d77-801d-7e6ca4f54ceb">
	  <variable>Stress</variable>
	  <method>the Perceived Stress Scale</method>
	  <timepoints>baseline, 16 weeks and 26 weeks</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="83c3c4bf-28dd-481c-be49-b101a5f9ca83">
	  <variable>Perceived support from other group members</variable>
	  <method>the Peer Support Questionnaire</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="749371bc-8f26-4a01-96c0-6c81c3b10e19">
	  <variable>Relationship strain</variable>
	  <method>the Dyadic Relationship Scale (Caregiver)</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="71fa704d-823f-46a9-a62c-e8367fcd7e15">
	  <variable>Specific goals that the carer has for the course</variable>
	  <method>the Goal-Based Outcome Measure</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9ba92a13-0d70-4801-a55f-1585f2ada8ca">
	  <variable>Carer perceptions of communication</variable>
	  <method>the Carer Communication Questionnaire</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="15caf5e0-45ed-43e6-9141-2d83b0b0f6d9">
	  <variable>Quality of life (carer)</variable>
	  <method>the C-DEMQOL questionnaire</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d3a6708c-8312-4159-a144-441fa2b52361">
	  <variable>Quality of life (person living with dementia)</variable>
	  <method>the DEMQOL-Proxy questionnaire</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="52719997-d271-4499-b188-5e75e0cea3d3">
	  <variable>Anxiety and depression</variable>
	  <method>the Hospital Anxiety &amp; Depression Scale (HADS)</method>
	  <timepoints>baseline, 16 weeks and 26 week</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6307e696-bd80-4853-b61e-a890a0fc9abe">
	  <variable>Ability of someone with dementia to carry out daily activities, such as dressing and preparing food</variable>
	  <method>the Bristol Activities of Daily Living Scale (BADLS)</method>
	  <timepoints>baseline</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="cc94ab1a-2e87-41c1-a5a5-cbc73803410b">
	  <variable>Demographics</variable>
	  <method>the Demographic questionnaire</method>
	  <timepoints>baseline</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="472f7bea-2191-4e41-b824-852e4931faf4">
	  <variable>Health-related quality of life</variable>
	  <method>EQ-5D-5L tool</method>
	  <timepoints>baseline, 16 weeks and 26 weeks</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f31662ba-b46d-4438-b998-31af57fafa73">
	  <variable>Hospital, primary, community and social care use</variable>
	  <method>the Healthcare Service Use questionnaire</method>
	  <timepoints>baseline, 16 weeks and 26 weeks</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d730b5a3-cb9b-4b53-ae93-d8e75b975cd6">
	  <variable>Harms and adverse effects</variable>
	  <method>adverse event reports throughout the study and Adapted Adverse Effects of Therapy Checklist</method>
	  <timepoints>16 weeks and 26 weeks</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="dd99997b-6421-4fea-813b-012f59646680" approvalStatus="approved" statusDate="2026-03-13T00:00:00.000Z">
	  <committeeName>East of England - Cambridge South Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Equinox House, City Link</address>
	    <city>Nottingham</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>NG2 4LA</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/EE/0022</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10087117</doi>
      <eudraCTNumber/>
      <irasNumber>346849</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 63791, NIHR: 208874</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="c7e7ebd1-3578-4875-9cc4-9c9359356c5b" numberType="iras" canonicalSecondaryNumber="IRAS346849">346849</secondaryNumber>
	<secondaryNumber id="89ffb576-5f50-435d-888e-4bbd325ee29b" numberType="cpms" canonicalSecondaryNumber="CPMS63791">63791</secondaryNumber>
	<secondaryNumber id="31b0f71a-6b53-4832-a7bb-d249771a22fa" numberType="nihr" canonicalSecondaryNumber="NIHR208874">208874</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2028-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="87bd2b07-8024-4250-b790-6780ad41d931">
	  <name>Greater Manchester Mental Health NHS Foundation Trust</name>
	  <address>Prestwich Hospital
Bury New Road
Prestwich</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M25 3BL</zip>
	  <rtsId>RXV@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4aa488fc-be3d-4130-96df-ed7e647f7c14">
	  <name>Pennine Care NHS Foundation Trust</name>
	  <address>225 Old Street</address>
	  <city>Ashton-under-lyne</city>
	  <state/>
	  <country>England</country>
	  <zip>OL6 7SR</zip>
	  <rtsId>RT2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1d8e6efe-b77a-4a05-a2d1-ce31daddcad0">
	  <name>Lancashire &amp; South Cumbria NHS Foundation Trust Hq</name>
	  <address>Sceptre Point
Sceptre Way
Bamber Bridge</address>
	  <city>Preston</city>
	  <state/>
	  <country>England</country>
	  <zip>PR5 6AW</zip>
	  <rtsId>RW501@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="0bd70d32-6968-4fa6-a7dd-67928209761c">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Current unpaid or family carer for someone living with dementia (any subtype or severity) in the community
2. Provide emotional or practical support at least weekly
3. Aged 18 or over
4. Have the capacity to give informed consent for the study
5. Either the carer or the person living with dementia that they are supporting, and live within the boundaries of recruiting Trusts</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>336</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Unable to provide informed consent  
2. Currently enrolled in a concurrent non-pharmacological (psychosocial intervention) carer research study
3. Caring for someone living with dementia in a Nursing or residential care home 
4. The person living with dementia being cared for is receiving palliative care or considered to be in the last six months of their life</exclusion>
      <recruitmentStart>2026-04-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Specialty: Social Care, Primary sub-specialty: Social Care; Health Category: Neurological; Disease/Condition: Organic, including symptomatic, mental disorders</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The trial will recruit 336 participants to compare two approaches to treatment. Two-thirds of the participants (224 people) will receive both a course called 'Empowered Conversations' and the
standard care they usually get (called Treatment-As-Usual, or TAU). The other third will receive just the standard care. This selection is chosen at random by a computer program, with the research team having no input on what someone receives.

Empowered Conversations (EC): EC is group-based and delivered across six weeks. It is designed to enable carers to establish and maintain good communication and relationships with those they support. Course facilitators are trained to provide specific communication techniques, ways of managing conflicts and working with difficult emotions. EC can be delivered in person or online.

Treatment-As-Usual (TAU): EC will be compared with TAU, which is likely to be limited in terms of support, but can include support from services (e.g. Age UK or Alzheimer’s Society) in some cases. Given that there is rarely a specific carer service or pathway offered within the NHS, the nature of this support will vary. Participants allocated to TAU will be offered the EC course following completion of their participation in the trial.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in a publicly available repository. In line with NIHR guidelines, fully anonymised quantitative data will be deposited in a public repository (https://figshare.com/). This is a publicly available and searchable platform where it will be permanently stored. Researchers at other institutions and others can access the anonymised data directly from the repository and use it for further research or to check the analysis and results.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3e4d3cc2-30bb-415f-bac7-8810ec477630" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-02-23T00:00:00.000Z" dateUploaded="2026-03-26T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="d755b954-bbf8-4b61-9129-16d778137d36" originalFilename="49188_Protocol_v1.1_23Feb2026.pdf" downloadFilename="49188_Protocol_v1.1_23Feb2026.pdf" version="1.1" mimeType="application/pdf" length="681595" md5sum="1273a151793d8df9a4052cb8be2fdcd7"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>5be85efe-a9cc-4642-8aa0-8a458c5f4640</funderId>
      <contactId>c076b5c9-47b4-4f60-93bc-37a97b66b6a4</contactId>
      <contactId>84013834-8384-439a-877e-6f829b338292</contactId>
      <sponsorId>698a5d00-7a75-4674-b41c-2f1615d48843</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/d755b954-bbf8-4b61-9129-16d778137d36/49188">
	<description>Protocol file</description>
	<name>49188_Protocol_v1.1_23Feb2026.pdf</name>
	<id>d755b954-bbf8-4b61-9129-16d778137d36</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>681595</length>
	<md5sum>1273a151793d8df9a4052cb8be2fdcd7</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="c076b5c9-47b4-4f60-93bc-37a97b66b6a4">
    <title>Dr</title>
    <forename>Lydia</forename>
    <surname>Morris</surname>
    <orcid>https://orcid.org/0000-0002-3337-8144</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Chief Investigator, Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Booth Street East Building, Booth Street East</address>
      <city>Manchester</city>
      <state/>
      <country>United Kingdom</country>
      <zip>M13 9PL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 01613061194</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lydia.morris@manchester.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="84013834-8384-439a-877e-6f829b338292">
    <title>Dr</title>
    <forename>Egle</forename>
    <surname>Saviciute</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Trial Manager, Lancashire Clinical Trials Unit, University of Lancashire</address>
      <city>Preston</city>
      <state/>
      <country>United Kingdom</country>
      <zip>PR1 7QS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">LCTUEC@lancashire.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="698a5d00-7a75-4674-b41c-2f1615d48843">
    <organisation>University of Manchester</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/027m9bs27</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="5be85efe-a9cc-4642-8aa0-8a458c5f4640">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-30T14:43:21.413300943Z" version="27" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN12117573" publicIdentifierDateAssigned="2025-12-02T15:36:27.740521Z">
    <isrctn dateAssigned="2025-12-02T15:36:27.740521Z">12117573</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Online parent-led treatment for obsessive-compulsive disorder in preadolescent children</title>
      <scientificTitle>Feasibility of a randomised controlled trial to compare an adapted online parent-led treatment to treatment as usual for preadolescent children with obsessive compulsive disorder (OCD)</scientificTitle>
      <acronym/>
      <studyHypothesis>a.	Establish the feasibility of (a) the novel intervention and (b) a future definitive non-inferiority RCT comparing the clinical outcomes and cost-effectiveness of OSI for OCD to usual treatment
b.	Conduct a process evaluation to explore (a) the implementation and acceptability, (b) mechanisms of impact, and (c) contextual factors that affect delivery, engagement, and outcomes for OSI for OCD to optimise the design of a future definitive non-inferiority trial RCT and subsequent wider implementation of OSI for OCD, if indicated.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Childhood Obsessive-Compulsive Disorder (OCD) is a serious mental health condition that often starts around the age of 10 years old and affects up to 3% of preadolescent children worldwide. Cognitive Behavioural Therapy (CBT), including Exposure and Response Prevention (ERP), is a current treatment that helps many preadolescent children with OCD; however, current treatments are often long (requiring more than 10 hours of specialist therapist support), which can limit access to care. 

Online Support and Intervention (OSI) is a brief online, therapist-supported, parent-led CBT programme that has the potential to increase access to support for affected families. OSI only requires around 3 hours of direct therapist support and can be delivered by trained non-specialist therapists. OSI has been evaluated for childhood anxiety problems and is acceptable to families and therapists, effective, and likely to be cost-effective compared to usual treatment (mostly CBT) in services. OSI has been co-adapted for OCD by working with parents of children with OCD, children with OCD, and clinicians to ensure that the OSI-OCD is acceptable, relevant, and appropriate for families. This study will be a preliminary evaluation of OSI-OCD.   

This project will test the feasibility of OSI adapted for parent/carers of preadolescent children (aged 5 – 12 years old) with OCD, and a future large Randomised Controlled Trial (RCT) to test whether OSI for OCD is non-inferior to (i.e., no worse than) usual treatment in services. 

This feasibility RCT will establish the likely recruitment rates, the number of participants who complete treatment, the number of participants who take part in the research follow-ups, and help us to describe what ‘usual treatment’ looks like in routine clinical services, and identify suitable clinical, daily functioning, and cost-effectiveness measures. The study will also explore the clinical outcomes in the OSI group at 20- and 32-week follow-ups (i.e., whether OSI for OCD appears to help children overcome OCD), explore what key stakeholders (e.g., parents, children, therapists) think of the treatment and trial procedures, and describe any negative effects of the treatment.  

A ‘process evaluation’ will be conducted, which is a way of taking a closer look at how an intervention is being carried out. This evaluation will explore how OSI for OCD can be implemented into clinical services, how the treatment might bring about change for families, and factors affecting treatment delivery, engagement, and outcomes for OSI for OCD to inform the design of a future RCT and potential wider use of OSI for OCD.

Who can participate?
Children aged between 5 and 12 (inclusive) years who have OCD (confirmed by the research team) and their parent/carer(s) from approximately  6 mental health services that provide treatment on behalf of the National Health Service (NHS).

What does the study involve?
Eligible participants will be randomly assigned to one of two groups: one group will receive the new OSI for OCD treatment, and the other will receive the usual treatment for OCD. Measures will be collected at baseline, 20 weeks and 32 weeks post-randomisation. Additionally, parent-reported session-by-session measures will be collected for participants (i.e., parents and their children) randomised to OSI for OCD. Interviews with some parents, children, therapists, clinical supervisors, service leads and commissioners involved in the trial will help to inform the process evaluation.

What are the possible benefits and risks of participating?
Benefits: 
Both treatments could be helpful for children with OCD, but it is unknown which treatment works best or if they work equally well. That’s why this research is being done. By taking part, participants will be helping the research team understand whether this treatment is feasible and acceptable for helping children to overcome OCD, and their participation will contribute to improving treatment options for others in the future.

Risks: 
The parent and their child will be asked to complete some additional questionnaires that they wouldn’t normally do as part of usual care. These are to gather information about the child’s difficulties and the impact these difficulties have on their life.

Some of the questions in the interviews or questionnaires may ask about difficult topics, such as the child’s thoughts and feelings. While these questions are similar to those asked in clinical care, the research team understands they might be upsetting. The research team will monitor the parents' and children's responses during these assessments and, if signs of significant distress are noticed, the team will contact the parent to check in. If necessary, and with the parent’s agreement (or sooner if there are concerns about safety), the team may contact the child’s clinical team. If the parent or child feels uncomfortable or distressed at any point, they can contact their therapist or the research team, and support will be provided. They can also choose to stop answering questions or leave the study at any time without affecting the child’s future care.

Taking part in the study will require the parent and child to spend extra time completing interviews and questionnaires and participating in treatment sessions. These additional tasks might take time away from other activities or routines, but the research team will work to make the process as convenient as possible.

The research team does not expect any harm or significant risks to come from taking part in the study. All research team members have undergone criminal record checks and have been approved by the University of Oxford to work with children. If at any point the parent feels that participating in the study is not right for them, they are free to withdraw with no negative impact on the child’s care or treatment.

Where is the study run from?
This study is sponsored by the University of Oxford, and is being run by the Oxford Psychological Interventions for Children and adolescents (TOPIC) research group, based in Experimental Psychology, UK.

When is the study starting and how long is it expected to run for?
September 2025 to June 2027. 

Who is funding the study?
The Medical Research Council (MRC). 

Who is the main contact?
Dr Chloe Chessell (Chief Investigator), Postdoctoral Researcher and Fellow at The Oxford Psychological Interventions for Children and adolescents (TOPIC) research group, based in Experimental Psychology, chloe.chessell@psych.ox.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="43356032-8d11-4fe4-a835-266d8eec083c">
	  <variable>Trial feasibility</variable>
	  <method>willingness of participants (parents and their children) to be randomised</method>
	  <timepoints>throughout study</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="41cd4fa6-14c6-4afe-ba02-3ace4efa4c59">
	  <variable>OCD symptom severity</variable>
	  <method>Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS) (parent and child report)</method>
	  <timepoints>baseline, 20 weeks post randomisation, and 32 weeks post randomisation</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1.  Anxiety disorders and OCD are measured using the Anxiety Disorder Interview Schedule (ADIS-C and ADIS-P) at screening, 20 weeks post-randomisation, and 32 weeks post-randomisation
2.  OCD symptom severity is measured using the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
3.  OCD symptom severity is measured using the Obsessive Compulsive Inventory (OCI-CV-R) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
4.  OCD symptom severity is measured using the Obsessional Compulsive Inventory (ChOCI-R-P) at baseline, at the start of each OSI-OCD module, and at 20 weeks and 32 weeks post-randomisation
5.  Parental stress is measured using the Parental Stress Scale (PSS) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
6.  Health-related quality of life for parents is measured using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
7.  Health-related quality of life in children and young people is measured using the EuroQol 5-Dimension Youth 3-Level questionnaire (EQ-5D-Y-3L) and Child Health Utility 9D (CHU-9D) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
8.  Health and social care resource use is measured using the Client Service Receipt Inventory (CSRI) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
9.  Parents’ beliefs about treatment credibility and expectations of improvement are measured using the Credibility and Expectation of Improvement Scale – Parent report (CEI) immediately post-randomisation and at 20 weeks post-randomisation
10. Therapists’ beliefs about treatment credibility and expectations of improvement are measured using the Credibility and Expectation of Improvement Scale – Therapist report (CEI) immediately post-randomisation and at 20 weeks post-randomisation
11. Family accommodation of obsessive–compulsive symptoms is measured using the Family Accommodation Scale for Obsessive-Compulsive Disorder – Parent Report (FAS-PR) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
12. Parent-reported OCD-related interference is measured using the Children’s Obsessive Compulsive Impact Scale – Revised, Parent version (COIS-R-P) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
13. Child-reported OCD-related interference is measured using the Children’s Obsessive Compulsive Impact Scale – Revised, Child version (COIS-R-C) at baseline, 20 weeks post-randomisation, and 32 weeks post-randomisation
14. Parents’ knowledge and confidence to help their child overcome OCD are measured using 3 items at the start of each OSI-OCD module and at 20 weeks and 32 weeks post-randomisation
15. Parents’ perception of their child’s learning and coping ability is measured using 2 items at the start of each OSI-OCD module and at 20 weeks and 32 weeks post-randomisation
16. Child anxiety and depression symptoms are measured using the Revised Child Anxiety and Depression Scale – Parent version (RCADS-P) with the full scale completed at the start of OSI-OCD modules 0, 8, and 9, and the OCD subscale completed at the start of modules 1–7
17. Child functioning and wellbeing are measured using the Outcome Rating Scale (ORS) at the start of each OSI-OCD module
18. Therapeutic alliance is measured using the Session Rating Scale (SRS) at the start of each OSI-OCD module
19. Progress towards individually agreed goals is measured using Goal-Based Outcomes (GBOs) at the start of each OSI-OCD module
20. Overall clinical improvement is measured using the Clinical Global Impressions – Improvement scale (CGI-I) at 20 weeks post-randomisation and 32 weeks post-randomisation
21. Therapist treatment and supervision activity is measured using therapist treatment and supervision logs collected during OSI-OCD modules 0–9 and during treatment as usual
22. Treatment feasibility and acceptability are measured using qualitative interviews with parents, children, therapists, and stakeholders within four weeks after OSI-OCD treatment has finished
23. Feasibility parameters including willingness of therapists to recruit participants, number of eligible participants, follow-up rates, and questionnaire response rates are measured using trial records at end of study</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="806c4761-6559-44be-8f71-5ffc156f1b9b" approvalStatus="approved" statusDate="2025-07-28T00:00:00.000Z">
	  <committeeName>East Midlands - Leicester Central Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/EM/0159</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12117573</doi>
      <eudraCTNumber/>
      <irasNumber>354658</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 69337, MR/Z503642/1</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="2ca39ef3-01ee-44fd-8211-d26e13846046" numberType="iras" canonicalSecondaryNumber="IRAS354658">354658</secondaryNumber>
	<secondaryNumber id="7061cae5-6f5c-42bd-bb75-2230e55bcc8c" numberType="cpms" canonicalSecondaryNumber="CPMS69337">69337</secondaryNumber>
	<secondaryNumber id="876431fe-a84f-4f2c-9450-fe0c7040fcf3" numberType="Medical Research Council (MRC) grant code">MR/Z503642/1</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Placebo</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2027-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9eafefd8-3e6b-4782-8792-b6378d348787">
	  <name>Berkshire Healthcare NHS Foundation Trust</name>
	  <address>London House
London Road</address>
	  <city>Bracknell</city>
	  <state/>
	  <country>England</country>
	  <zip>RG12 2UT</zip>
	  <rtsId>RWX@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="792e4c64-13cb-423f-aabf-d2881aab92c5">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="db451bba-5837-4411-a931-b0e395b6a100">
	  <name>Mersey Care NHS Foundation Trust</name>
	  <address>V7 Building
Kings Business Park
Kings Drive</address>
	  <city>Prescot</city>
	  <state/>
	  <country>England</country>
	  <zip>L34 1PJ</zip>
	  <rtsId>RW4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="151ecf16-4d2b-4d9e-8731-1b3bf6e958a6">
	  <name>Northamptonshire Healthcare NHS Foundation Trust</name>
	  <address>St Marys Hospital
77 London Road</address>
	  <city>Kettering</city>
	  <state/>
	  <country>England</country>
	  <zip>NN15 7PW</zip>
	  <rtsId>RP1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="ca1968a7-f044-4564-94dd-6a1f6294c9ba">
	  <name>Herefordshire and Worcestershire Health and Care NHS Trust</name>
	  <address>Unit 2 Kings Court
Charles Hastings Way</address>
	  <city>Worcester</city>
	  <state/>
	  <country>England</country>
	  <zip>WR5 1JR</zip>
	  <rtsId>R1A@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4943e897-df97-4de5-ab3c-65dd74243d08">
	  <name>Manchester University NHS Foundation Trust</name>
	  <address>Cobbett House
Oxford Road</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M13 9WL</zip>
	  <rtsId>R0A@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1.	Child has been diagnosed with OCD on the basis of the ADIS-C or ADIS-P by the research team. 
2.	Parent/carer is willing and able to give informed consent for participation in the study on behalf of their child and themselves.
3.	Child is willing and able to give informed assent for participation in the study.
4.	Child aged 5–12 years.
5.	Child has been referred to services that provide psychological support for child mental health problems on behalf of the NHS.
6.	Child and parent/carer are able to understand, read, and communicate in English.
7.	Parent/carer is willing and able to engage with the online intervention platform (OSI) if randomised to the OSI for OCD treatment arm. 
8.	Parent/carer is willing and able to complete required assessments.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="years" value="5.0">5 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="12.0">12 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1.	The child is currently receiving any other psychological intervention.
2.	The child is receiving psychotropic medication and the dose has not been stable for at least two months.
3.	The child has a confirmed or likely diagnosis of autism (indicated by a score &gt; 15 on the Social Communication Questionnaire-lifetime version).
4.	If the child has profound learning difficulties evidenced by attending a specialist school.
5.	If there are risk and/or safeguarding concerns which are paramount and would interfere with treatment delivery, including suicidal intention, recurrent or potentially life-limiting self-harm, or if the child has a child protection plan/is on the child protection register/the research team consider the child to be suffering, or likely to suffer, significant harm.
6.	Parent/carer or child is unable to understand, read, or communicate in English, which would prevent meaningful participation in the intervention or assessments.
7.	The child is referred to a clinical team where the only usual treatment option is the University of Oxford’s face-to-face/telephone version of brief therapist guided, parent-led CBT for OCD</exclusion>
      <recruitmentStart>2025-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Specialty: Mental Health, Primary sub-specialty: Personality disorder - OCD; Health Category: Mental health; Disease/Condition: Neurotic, stress-related and somatoform disorders</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Families taking part in the study will be randomly assigned to one of two groups: either the OSI for OCD intervention or treatment as usual (TAU) within mental health services that provide treatment on behalf of the NHS.

Stratified randomisation will be conducted using a web-based randomisation tool designed for clinical trials and research studies to ensure balance across key variables, including: Child’s age (e.g., ≤8 years; &gt;8 years), Gender and OCD symptom severity (measured by baseline CY-BOCS scores). We will use a randomisation tool that operates through a secure online platform, accessible only to authorised study personnel.

Participants will  be randomly assigned to either the OSI for OCD (n=24) or treatment as usual (TAU) arms (n=24), within one month of completing baseline assessments. Families allocated to the OSI for OCD treatment will be added to the online intervention platform by the research team, from which they can start their treatment, with therapist support. This includes completing 10 online modules, with 10 x 20-30 minute phone calls (including 8 therapist sessions, and 2 check-ins). For families in the OSI for OCD group, routine outcome measures (ROMs) that are collected as part of this treatment will also be available to the research team. OSI treatment lasts for approximately 4 months. Families assigned to TAU will receive their usual care, and information on the nature of this treatment will be collected from therapists and supervision logs.

Parents and children will be invited to complete post-treatment and follow-up questionnaires and interviews online at 20 and 32 weeks after randomisation. To address researcher bias, outcome assessors, who will conduct the diagnostic and clinical assessments, will be blinded to the treatment allocation of participants. This is to ensure that data collection for primary and secondary outcomes remains unbiased. Note. The research team will call all families to let them know the outcomes of the ADIS-C/P and CY-BOCS at 20 weeks and 32 weeks post randomisation. All families who complete these interviews will be provided with a letter summarising the outcomes following their final interview.

Trial therapists will be identified through the participating trial sites.

An embedded process evaluation will explore how to optimise the design of a future definitive non-inferiority trial RCT and subsequent wider implementation of OSI for OCD, if indicated. A subset of parents (~15) and children (~15) from the OSI for OCD treatment arm will be invited to take part in qualitative interviews. This may include those who completed the OSI for OCD treatment, as well as those who did not fully complete it, so we can understand a range of perspectives. We will also invite up to 15 therapists, clinical supervisors, clinical leads, and commissioners from the OSI for OCD arm. These interviews will explore (a) the implementation and acceptability; (b) mechanisms of impact; and (c) contextual factors that affect delivery, engagement, and outcomes, for OSI for OCD. These interviews will involve up to 15 parents and 15 children from the OSI for OCD group, as well up to 15 therapists, clinical supervisors, clinical leads and commissioners. The adequacy of the sample size will be continually reviewed, and recruitment will end when the sample holds sufficient information power to provide a rich insight into the research questions.

Interviews will be conducted by research team members online and will be recorded and transcribed for analysis. In addition to qualitative interviews, the process evaluation aims to collect data to assess the acceptability of the intervention and how the intervention was implemented, including therapist treatment logs, usage data from the OSI platform, and clinical outcome measures. This information will help determine whether OSI for OCD is a feasible and effective approach for supporting families of children with OCD.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in a publicly available repository. 

Once analyses are complete and the linking document containing personal details is deleted, a sufficiently anonymised version of the data will be made available in a public repository, such as the UK Data Service. The data collected about participants (i.e., parents, their children, therapists and other stakeholders) will be preserved and made available in a form in which they cannot be identified. To ensure this, all data will be pseudonymised before archiving, and any direct identifiers (e.g., names, contact details) will be removed or stored separately. Data shared for future research or collaboration will be checked for potential identifiers before being made accessible.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2617dd20-42cf-4a5d-9cb2-e6b28f86f12e" outputType="protocolfile" artefactType="LocalFile" dateCreated="" dateUploaded="2026-10-30T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="eb334c49-1415-4d3e-82d8-69d2621f22da" originalFilename="ISRCTN12117573_PROTOCOL.pdf" downloadFilename="ISRCTN12117573_PROTOCOL.pdf" version="" mimeType="application/pdf" length="567124" md5sum="62b03aceb3569967e537bf79d730e9a0"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>6057a191-c581-4163-8d9f-e4aae53960d8</funderId>
      <contactId>c3b9b209-e161-4fac-8faa-2490cbf35bc3</contactId>
      <sponsorId>472c2e60-6c03-47cd-8310-b38dad1ad75e</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/eb334c49-1415-4d3e-82d8-69d2621f22da/48547">
	<description>Protocol file</description>
	<name>ISRCTN12117573_PROTOCOL.pdf</name>
	<id>eb334c49-1415-4d3e-82d8-69d2621f22da</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>567124</length>
	<md5sum>62b03aceb3569967e537bf79d730e9a0</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="c3b9b209-e161-4fac-8faa-2490cbf35bc3">
    <title>Dr</title>
    <forename>Chloe</forename>
    <surname>Chessell</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Postdoctoral Researcher, University of Oxford. Life and Mind Building, South Parks Rd</address>
      <city>Oxford</city>
      <state/>
      <country>United Kingdom</country>
      <zip>OX1 3EL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chloe.chessell@psych.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="472c2e60-6c03-47cd-8310-b38dad1ad75e">
    <organisation>University of Oxford</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/052gg0110</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="6057a191-c581-4163-8d9f-e4aae53960d8">
    <name>Medical Research Council</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-11T08:38:47.096888493Z" version="31" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN11309942" publicIdentifierDateAssigned="2025-11-11T08:53:42.045823Z">
    <isrctn dateAssigned="2025-11-11T08:53:42.045823Z">11309942</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Sleep apnoea and memory</title>
      <scientificTitle>Sleep apnoea symptoms and prevalence in people attending memory services</scientificTitle>
      <acronym>SAM</acronym>
      <studyHypothesis>The primary objective of this study is to determine prevalence of sleep apnoea in UK memory services, with an exploratory aim to determine whether sleep apnoea prevalence differs between different types of dementia diagnosis. Secondary objectives are to: determine clinical factors/symptoms that best predict sleep apnoea in people who present to memory clinics, determine the feasibility of remote questionnaires for sleep apnoea screening, and pilot methodology for observing the effect of treating sleep apnoea on blood biomarkers for Alzheimer’s disease and neurodegeneration.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
This study wants to find out how many people who have memory and thinking problems also have sleep apnoea. It will also look at what symptoms are related to having sleep apnoea in people with memory and thinking problems.  	

What is sleep apnoea?
Sleep apnoea is when your breathing stops and starts while you sleep. Pauses in breathing are called “apnoeas” and can last from a few seconds up to a minute. Too many apnoeas might affect how deep and restful your sleep is. Many people do not know they have sleep apnoea. 

Who can participate?
People attending memory clinics at a participating site.

What does the study involve?
First, patients will be asked to complete a consent form to say they are happy to take part. Some information will be taken from medical records, and participants will be asked to complete some questionnaires (online if possible, but on paper or by telephone otherwise) about themselves and their sleep. Participants will be asked to wear a device called a WatchPAT for one night whilst sleeping at home. The device looks like a watch but also has a finger sleeve and a sticky pad that attaches to the chest. The WatchPAT will check for sleep apnoea. Participants and their GP will be informed of the results (whether they have sleep apnoea) and what the next steps are.

If referred for sleep apnoea treatment in the Bristol area, the study team may ask to take some blood samples before and after treatment to see if levels of certain proteins change after treatment for sleep apnoea.

Taking part is optional. Patients can also decide to take part and change their minds later. This decision won’t have an impact on their healthcare. 

What are the possible benefits and risks of participating?
Participants may get a new diagnosis of sleep apnoea. Treating sleep apnoea may improve sleep quality, reduce the risk of other health conditions such as strokes, and help people feel better in the daytime. If someone has severe sleep apnoea or feels very sleepy in the day, they may be asked to stop driving or take a driving test to make sure they and others around them are safe. 

This is an observational study which carries no significant risks. The main risks has already been listed (implications on insurance and driving). 

Where is the study run from?
The memory clinic that the patient attends and from home. Several memory clinics across the country are taking part. The research is being led by North Bristol NHS Trust, UK.

When is the study starting and how long is it expected to run for?
The study is scheduled to start in late 2025 and recruit until August 2026 (or 10 months from opening). Most participants will only be involved in the study for a very short time, though participants referred for sleep apnoea treatment at the Bristol site may be involved for several months, with blood tests every 4-8 weeks. 

Who is funding the study?
1. The National Institute for Health and Care Research (NIHR), UK.
2. Goldman Foundation.

Who is the main contact?
Study coordinator Victoria Gabb, victoria.gabb@bristol.ac.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>The proportion of people in memory clinics who have at least mild sleep apnoea (Oxygen Desaturation Index 3% &gt; 5) according to a single night of overnight polygraphy (WatchPAT)</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. The proportion of people with different aetiological diagnoses in memory clinics who have at least mild sleep apnoea (Oxygen Desaturation Index (ODI)3% &gt; 5) according to a single night of overnight polygraphy (WatchPAT).
2. The proportion of people in memory clinics who have mild (ODI 3% &gt; 5-15), moderate (ODI 3% &gt; 15-30) or severe (ODI 3% &gt; &gt;30) sleep apnoea according to a single night of overnight polygraphy (WatchPAT).
3. Proportion of people in memory clinics who have at least mild sleep apnoea (Oxygen Desaturation Index 4% &gt; 5) according to a single night of overnight polygraphy (WatchPAT).
4. Diagnostic accuracy of STOP-BANG, Epworth Sleepiness scale and extra questions for at least mild sleep apnoea
5. Data completeness for online (or telephone, face-to-face) questionnaires in this population.</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="b6d4607a-d251-40ac-946f-e036a13c357a" approvalStatus="approved" statusDate="2025-09-05T00:00:00.000Z">
	  <committeeName>North West - Greater Manchester South Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>3rd Floor, Barlow House 4 Minshull Street</address>
	    <city>Manchester</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>M1 3DZ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/NW/0221</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11309942</doi>
      <eudraCTNumber/>
      <irasNumber>340207</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 61703, NIHR: 207185</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="3db99740-6b27-4271-bdcc-dcd97588917b" numberType="iras" canonicalSecondaryNumber="IRAS340207">340207</secondaryNumber>
	<secondaryNumber id="29cf352b-adfe-47fb-b45c-18d180d769b5" numberType="cpms" canonicalSecondaryNumber="CPMS61703">61703</secondaryNumber>
	<secondaryNumber id="9cd05718-5802-42df-8609-98f4df2ef61e" numberType="nihr" canonicalSecondaryNumber="NIHR207185">207185</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centre observational cross-sectional study with a longitudinal observational cohort sub-study at one site</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cross sectional study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Other</trialType>
      </trialTypes>
      <overallEndDate>2026-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5b2cd261-5690-4245-908b-50a52c41a26e">
	  <name>North Bristol NHS Trust</name>
	  <address>Southmead Hospital
Southmead Road
Westbury-on-trym</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS10 5NB</zip>
	  <rtsId>RVJ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="75953b33-ef1f-4845-b346-4e0d7c9d98a1">
	  <name>Bradford District Care Trust</name>
	  <address>New Mill
Victoria Road</address>
	  <city>Shipley</city>
	  <state/>
	  <country>England</country>
	  <zip>BD18 3LD</zip>
	  <rtsId>Y04099@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d21e0bd7-2210-4f40-862c-bcbbcdf59707">
	  <name>Cornwall Partnership NHS Foundation Trust</name>
	  <address>Carew House
Beacon Technology Park
Dunmere Road</address>
	  <city>Bodmin</city>
	  <state/>
	  <country>England</country>
	  <zip>PL31 2QN</zip>
	  <rtsId>RJ8@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="43e2df0f-dfd9-402f-b7a9-f4ceaec9866a">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="281b719b-263d-4b9a-8bed-d7d4ed613ade">
	  <name>Northumbria Healthcare NHS Foundation Trust</name>
	  <address>North Tyneside General Hospital
Rake Lane</address>
	  <city>North Shields</city>
	  <state/>
	  <country>England</country>
	  <zip>NE29 8NH</zip>
	  <rtsId>RTF@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient attending an NHS memory clinic at an included recruitment site
2. Adults aged 18 or over
3. Patients who are able to consent for themselves 

Bloods sub-study only
1. New diagnosis of sleep apnoea   
2. Recruited at the Bristol recruitment site
3. Referred to the sleep clinic
4. Consented to optional bloods sub-study when joining the study</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>453</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Adults without capacity to consent to the research study.
2. Being unwilling to use the WatchPAT device.

Bloods sub-study only
1. Being unwilling or unable to travel to the Bristol Brain Centre for blood tests, where blood tests at home are not feasible.</exclusion>
      <recruitmentStart>2025-11-28T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sleep apnoea in patients attending memory clinics</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Main study 
Participants will be asked to complete questionnaires to identify risk factors and symptoms relating to sleep apnoea and undergo a night of sleep apnoea screening using the WatchPAT polygraphy device. Data will also be collected from medical records. Participants will be informed of their results. 

Bloods sub-study
Participants with sleep apnoea who are referred to treatment at the North Bristol site will be invited to undergo blood tests before and after treatment to assess whether blood biomarkers change following treatment for sleep apnoea. 

The study will also pilot a methodology for determining the change in serum biomarkers of Alzheimer’s disease and neurodegeneration after starting sleep apnoea treatment and report the change over time in biomarkers.</description>
	<interventionType>Not Specified</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails>2026 Protocol article in https://doi.org/10.3389/fnagi.2026.1862599 (added 14/08/2026)</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="de24ed0d-485e-4668-8064-39b651a054b7" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2026-07-17T00:00:00.000Z" dateUploaded="2026-08-14T00:00:00.000Z" peerReviewed="true" patientFacing="false" createdBy="">
	<externalLink url="https://doi.org/10.3389/fnagi.2026.1862599"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>ed63387c-8427-46fa-9ca9-98c53c4e2cad</funderId>
      <funderId>494f40d9-4283-49c8-8399-2bac559278c8</funderId>
      <contactId>0f8dfbf7-a251-4628-8486-f40dde5868d9</contactId>
      <contactId>afd0d6e2-cadc-4f61-8618-8be0888702d3</contactId>
      <sponsorId>4c81de5d-a772-42d3-91e3-cad67f79313a</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="0f8dfbf7-a251-4628-8486-f40dde5868d9">
    <title>Ms</title>
    <forename>Victoria</forename>
    <surname>Gabb</surname>
    <orcid>https://orcid.org/0000-0002-7688-766X</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Victoria Gabb
ReMemBr Group Research Team
Bristol Brain Centre
Elgar House
Southmead Hospital</address>
      <city>Bristol</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BS10 5NB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">0117 456 0700</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">victoria.gabb@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="afd0d6e2-cadc-4f61-8618-8be0888702d3">
    <title>Prof</title>
    <forename>Elizabeth</forename>
    <surname>Coulthard</surname>
    <orcid>https://orcid.org/0000-0002-0017-9595</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dementia Research Team
Bristol Brain Centre
Elgar House
Southmead Hospital</address>
      <city>Bristol</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BS10 5NB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">0117 414 7801</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">elizabeth.coulthard@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="4c81de5d-a772-42d3-91e3-cad67f79313a">
    <organisation>North Bristol NHS Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/036x6gt55</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="ed63387c-8427-46fa-9ca9-98c53c4e2cad">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
  <funder id="494f40d9-4283-49c8-8399-2bac559278c8">
    <name>Goldman Foundation</name>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-07-03T13:38:44.637119981Z" version="29" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN67429289" publicIdentifierDateAssigned="2025-10-20T13:12:11.389124Z">
    <isrctn dateAssigned="2025-10-20T13:12:11.389124Z">67429289</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A peer support programme to help adults with psychosis talk about mental health and reduce stigma</title>
      <scientificTitle>A peer-delivered programme for mental health disclosure distress and internalised stigma (Let’s Talk) in comparison to treatment as usual in adults with psychosis: A randomised controlled trial to investigate the efficacy of a peer intervention targeted at stigma-related mechanisms</scientificTitle>
      <acronym>Let's Talk 2</acronym>
      <studyHypothesis>The study objective is to establish Let’s Talk’s clinical efficacy in a multisite Randomised Controlled Trial (RCT) for adults with psychosis who report moderate to severe Internalised Stigma (IS) and disclosure-related distress; and to assess whether improved measures of personal recovery are mediated via key stigma variables. The objective is to recruit 352 participants to detect a target difference of 4.5 points on the QPR.
Eligible participants will be randomised to either the intervention arm (Let’s Talk + Treatment as Usual (TAU)) or the control arm (TAU alone). Participants allocated to the intervention will be offered up to 16 sessions over a four-month intervention window with up to one booster session. Outcome data will be collected at baseline, at 4-month assessment (end of treatment) and at 12-month assessment (12 months post-randomisation). The study will determine whether the treatment effect on recovery is mediated by key mechanisms targeted in the intervention: (1) reduced IS (primary mechanism), (2) reduced stigma stress (degree to which perceived stigma is exceeded by personal coping resources for stigma) and (3) reduced disclosure distress.</studyHypothesis>
      <plainEnglishSummary>Background and study aim
People who experience psychosis often face stigma and discrimination, which can negatively affect how they consider themselves and their identities. This is referred to as ‘internalising’ stigma. This can cause serious problems with self-esteem, cause depression and anxiety, and lead to withdrawal from others, study or work.

To help people with psychosis feel less troubled by ‘internalised stigma’, mental health researchers in Manchester adapted an American intervention into a new intervention called ‘Let’s Talk’. A small trial was conducted to test this intervention. Let’s Talk involved Peer Support Workers (PSWs), who also have experience of psychosis, meeting with people taking part in the trial (Peers). PSWs and Peers discussed mental health stigma, and how to talk about mental health difficulties with others. Many sessions focused on helping Peers understand how to decide whether they want to discuss their mental health difficulties with others, or not. The trial found that people were interested in taking part, that most participants offered the intervention attended the sessions, and most participants attended the research assessments.

A larger trial of Let’s Talk is planned to understand more clearly how it can help improve the personal wellbeing of people who experience psychosis. In a larger trial, more participants can be included and more advanced research tests can be run to see what parts of the Let’s Talk approach are most helpful. This would help make Let’s Talk as effective as possible, and it could then be offered in NHS mental health services.

Who can participate?  
People in four UK areas aged 16+ who meet an ICD-11 Schizophrenia or other primary psychotic disorders diagnosis (as determined by the participant’s clinical team) or are receiving care for psychosis from Early Intervention Services (EIS), or under the care of a secondary or tertiary mental health service at the point of referral to ensure provision of care. They will also report moderate to severe self-reported disclosure-related distress (scoring &gt;3 on the disclosure distress screening item), and moderate to severe internalised stigma (scoring of ≥3 on at least one of the Internalised Stigma domains of the Semi-structured Interview Measure of Stigma (SIMS)).

What does the study involve?
Participants will meet with a research assistant (RA), and they will complete a range of questionnaires, including the Questionnaire about the Process of Recovery (QPR). Participants will be randomly allocated (50:50 chance) to either receive the peer-delivered Let’s Talk intervention (plus their usual mental health treatment) or receive their usual mental health care alone (TAU). Participants who are allocated to receive the Let’s Talk intervention will be offered sessions with a peer support worker over 16 weeks, which will involve completing an 8-module workbook together. Participants will meet with research assistants again at 4 and 12 months to complete the same set of questionnaires. 

What are the possible benefits and risks of participating? 
If the Let’s Talk intervention is found to improve personal recovery outcomes, this could add to the current evidence base for helpful psychological interventions and potentially benefit future mental health services for people experiencing psychosis. A potential risk is that participants may find the research assessment process distressing. Participants will be offered choices around their assessments, including the option of breaks and assessments spread across multiple occasions. 

Where is the study run from? 
The lead site is Greater Manchester Mental Health NHS Foundation Trust (GMMH). Avon and Wiltshire Mental Health Partnership NHS Trust (AWP), South London and Maudsley NHS Foundation Trust (SLaM) and North East London NHS Foundation Trust (NELFT) are also sites from which the Let’s Talk 2 study is run.

When is the study starting and how long is it expected to run for? 
May 2025 to August 2028. The study will begin enrolling participants in November 2025 to May 2027. Overall, the study is expected to run for 40 months. 

Who is funding the study? 
National Institute for Health and Care Research (NIHR), UK.

Who is the main contact? 
Dr Melissa Pyle, based at Greater Manchester Mental Health NHS Foundation Trust (GMMH), melissa.pyle@gmmh.nhs.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Personal recovery will be measured using the total score on the 15-item Questionnaire about the Process of Recovery (QPR) at 4 months</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>The following secondary outcome measures will assess relevant dimensions of psychiatric distress and quality of life at baseline, 4  and 12 months:
1. Social anxiety will be measured using the Social Interaction Anxiety Scale (SIAS)
2. Depression will be measured using the Patient Health Questionnaire-9 (PHQ-9)
3. Satisfaction in multiple life domains and in treatment aspects will be measured using the DIALOG
4. Paranoia will be measured using the revised Green et al. Paranoid Thoughts Scale (R-GPTS)
5. The presence and impact of non-auditory hallucinations will be assessed using The Psychotic Symptoms Rating Scale: Multimodal Hallucinations. This is an unpublished scale adapted from PSYRATS-AH.

The proposed mechanisms of action for Let’s Talk will also be measured with the following instruments at baseline, 4 months and 12 months: 
1. Experienced, perceived, and internalised stigma will be measured using the Semi-structured Interview Measure for Stigma in Psychosis (SIMS)
2. Stigma stress will be assessed by the 8-item Stigma Stress Scale (SSCI-8)
3. Disclosure distress will be measured using the single-item Distress Disclosure Index (DDI)</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="5aa3ea9a-b4f9-41e6-bcfe-c2caa17c8c4a" approvalStatus="approved" statusDate="2025-09-16T00:00:00.000Z">
	  <committeeName>Cambridge South Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Equinox House, City Link</address>
	    <city>Nottingham</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>NG2 4LA</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/EE/0718</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67429289</doi>
      <eudraCTNumber/>
      <irasNumber>343302</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 62177, NIHR: 163493</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="bd9fca3e-a270-43e3-9571-daf4fd6095fe" numberType="iras" canonicalSecondaryNumber="IRAS343302">343302</secondaryNumber>
	<secondaryNumber id="7a56bb0e-b520-4af0-a687-66369c0343c4" numberType="cpms" canonicalSecondaryNumber="CPMS62177">62177</secondaryNumber>
	<secondaryNumber id="8b1e872a-b83e-40d7-b097-650ba94aba8d" numberType="nihr" canonicalSecondaryNumber="NIHR163493">163493</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2028-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="49b98e74-5fef-4872-a705-89a03ff1dbe6">
	  <name>Greater Manchester Mental Health NHS Foundation Trust</name>
	  <address>Prestwich Hospital
Bury New Road
Prestwich</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M25 3BL</zip>
	  <rtsId>RXV@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="aabbc7c1-54f2-4721-9949-a5c62b195e9e">
	  <name>Bethlem Royal Hospital</name>
	  <address>Monks Orchard Road</address>
	  <city>Beckenham</city>
	  <state/>
	  <country>England</country>
	  <zip>BR3 3BX</zip>
	  <rtsId>Y7O8M@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="3c440eb0-7a83-479e-ab76-85c532b57bdc">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="10b21015-9a5b-4db0-9a74-a0e55c976e56">
	  <name>Avon and Wiltshire Mental Health Partnership NHS Trust</name>
	  <address>Bath NHS House
Newbridge Hill</address>
	  <city>Bath</city>
	  <state/>
	  <country>England</country>
	  <zip>BA1 3QE</zip>
	  <rtsId>RVN@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Current inclusion criteria as of 03/07/2026:
1. Age 16+ years
2. Meet the ICD-11 schizophrenia or other primary psychotic disorders diagnosis (as determined by the participant’s clinical team) or be receiving care for psychosis from Early Intervention Services (EIS) to account for diagnostic uncertainty in the early stages of psychosis or be attending NHS mental health services for the treatment of psychosis.
3. Under the care of a secondary or tertiary mental health service at point of referral to ensure provision of care.
4. Able to provide written, informed consent (for ethical considerations).
5. Willing to engage in a peer support intervention.
6. Moderate to severe self-reported disclosure-related distress as determined by scoring &gt;3 on the disclosure distress screening item.
7. Moderate to severe internalised stigma as determined by a score of &gt;=3 on at least one of the Internalised Stigma domains of the Semi-structured Interview Measure of Stigma.

Previous inclusion criteria:
1. Age 16+ years
2. Meet the ICD-11 schizophrenia or other primary psychotic disorders diagnosis (as determined by the participant’s clinical team) or be receiving care for psychosis from Early Intervention Services (EIS) to account for diagnostic uncertainty in the early stages of psychosis.
3. Under the care of a secondary or tertiary mental health service at point of referral to ensure provision of care. 
4. Able to provide written, informed consent (for ethical considerations).
5. Willing to engage in a peer support intervention.
6. Moderate to severe self-reported disclosure-related distress as determined by scoring &gt;3 on the disclosure distress screening item.
7. Moderate to severe internalised stigma as determined by a score of &gt;=3 on at least one of the Internalised Stigma domains of the Semi-structured Interview Measure of Stigma.</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>352</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. A primary diagnosis of alcohol or substance dependency, where this is clearly the cause of their psychotic symptoms. This does not exclude people who use substances or alcohol, only those with a primary diagnosis. This will be confirmed by participants' care teams.
2. A diagnosis of moderate to severe learning disability. This will be confirmed by participants' care teams.
3. An ICD-11 diagnosis of organic psychosis. This will be confirmed by participants' care teams.
4. Language barriers that are an obstacle to participation, since we are unable to provide translation of the intervention workbook or interpreters during intervention sessions.
5. Immediate risk to self or others. This will be confirmed by participants' care teams.
6. Currently receiving structured, individual psychological therapy.</exclusion>
      <recruitmentStart>2025-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Schizophrenia, schizotypal and delusional disorders, psychosis</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Design
A clinical efficacy randomised controlled trial (RCT) will be conducted across 4 NHS secondary or tertiary care mental health services in the UK: Avon and Wiltshire, Greater Manchester, North East London, and South London. Participants who meet all inclusion criteria and no exclusion criteria will be randomly allocated to either Let’s Talk plus treatment as usual (TAU), or TAU alone. Participants will be randomised at the individual level via a Clinical Trials Unit (CTU)-hosted, web-based system using random permuted blocks. Randomisation will be at a 1:1 ratio, stratified by site. Outcome and mediational variables will be collected in research assessments at baseline, 4 months (end of treatment) and 12 months post-randomisation. The assessments will be conducted by raters who are blind to participant allocation.

Clinical efficacy aims
1. To establish the efficacy of Let’s Talk + TAU in improving personal recovery (primary outcome) when delivered to adults with psychosis who report moderate to severe internalised stigma and disclosure-related distress compared to TAU alone.  
2. To establish the efficacy of Let’s Talk + TAU on secondary outcomes of improving quality of life, reducing depression, and reducing social interaction anxiety compared to TAU alone.

Clinical efficacy hypotheses
1. Let’s Talk plus TAU will result in improved measures of personal recovery at the end of treatment (4-month follow-up; primary outcome) and 12-month follow-up compared to TAU alone.  
2. Let’s Talk plus TAU will result in improved quality of life at the end of treatment (4-month follow-up) and 12-month follow-up compared to TAU alone.  
3. Let’s Talk plus TAU will result in a reduction in the level of depression and social interaction anxiety at the end of treatment (4-month follow-up) and 12-month follow-up.

Mechanistic aims
1. To examine the extent to which Let’s Talk plus TAU impacts on measures of personal recovery via a decrease in stigma-specific processes (Internalised stigma [IS], stigma stress, and disclosure distress).

Mechanistic hypotheses
1. Let’s Talk + TAU will lead to reductions in IS and stigma stress  
2. The mechanisms by which Let’s Talk + TAU lead to improvements in personal recovery are due to reductions in IS, stigma stress and disclosure distress.

Primary outcome
The primary outcome will be the total score on the 15-item Questionnaire about the Process of Recovery (QPR) at 4-month follow-up. The QPR was developed in collaboration with patients to assess personal recovery from psychosis, containing items that were initially derived from qualitative interviews about this topic. It has excellent reliability, validity, and sensitivity to change and is nationally adopted as a PROM for evaluation of early intervention for psychosis services, forming part of the Mental Health Services Data Set. Patients consistently prioritise personal recovery over specific symptom change, and the QPR has been cited as the only measure of recovery that directly maps onto all 5 processes of the influential CHIME framework of personal recovery.

Secondary outcomes
Secondary outcomes will assess relevant dimensions of psychiatric distress and quality of life.  
1. The Social Interaction Anxiety Scale (SIAS), a 20-item self-administered scale questionnaire, which reflects anxieties people may encounter in social situations. Items are rated on a 5-point scale from 0 (not at all) to 4 (extremely). The SIAS is a reliable and valid measure, with initial testing demonstrating high levels of internal consistency and test-retest reliability.  
2. Depression will be measured using the Patient Health Questionnaire-9 (PHQ-9), a validated, nine-item, patient-reported outcome measure (PROM). The PHQ-9 is a brief self-administered scale which reflects the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition) criteria. It classifies current symptoms on a scale of 0 (not at all) to 3 (nearly every day).  
3. The DIALOG scale is a validated, 11-item, patient-reported outcome and experience measure (PROM/PREM). The DIALOG scale assesses eight life domains (mental health, physical health, job situation, accommodation, leisure, partner/family, friendship, personal safety) and three treatment aspects (medication, practical help, meetings with healthcare professionals). The items are rated on a 7-point scale from “totally dissatisfied” to “totally satisfied” with the value 4 representing a neutral “in the middle.”  
4. The Psychotic Symptoms Rating Scale: Multimodal Hallucinations, an unpublished scale adapted from the PSYRATS: Auditory Hallucinations subscale for assessing the presence and impact of nonauditory hallucinations.  
5. The Revised Green et al Paranoid Thoughts Scale (R-GPTS), a reliable measure of paranoia comprising two subscales to assess ideas of reference (Part A; 8 items) and ideas of persecution (Part B; 10 items), over the past month. The two subscales are designed to be treated as distinct measures and should be scored separately. A total score for each subscale is obtained by adding together the items. Items are scored on a 4-point scale from 0 (Not at all) to 4 (Totally).

Mechanistic outcomes
The proposed mechanisms of action for Let’s Talk will also be measured with the following instruments:  
1. The Semi-structured Interview Measure for Stigma in Psychosis (SIMS), which assesses experienced, perceived, and internalised stigma.  
2. Stigma stress will be assessed by the 8-item Stigma Stress Scale.  
3. Disclosure-related distress will be assessed using a single item from the Disclosure Distress Scale.

Assessment schedule
Research assessments comprising the above measures will be completed at baseline, 4 months (end of treatment) and 12 months post-randomisation. Participants will receive £25 on completion of each research assessment as a token of appreciation for their time (£75 total).

Treatment condition (Let's Talk + TAU)
Let’s Talk will be delivered, in addition to TAU, on a one-to-one basis by Peer Support Workers (PSWs). A 4-month treatment window permits ≤16 sessions, with an option for 1 booster session to consolidate gains. The expectation for delivery is in-person, but the intervention can be delivered remotely via video call or telephone as a contingency. The aims of Let’s Talk are to: help participants weigh pros and cons of disclosing which vary by setting (e.g., disclosure at one’s employment has different costs and benefits than disclosure to one’s friendship network); teach relatively safe ways to disclose should the person decide to do so; help people craft stories that reflect their disclosure goals; support participants with internalised stigma and developing affirming self-beliefs. Sessions with the PSW will be structured around the Let's Talk manual and workbook, which have been refined based on qualitative feedback from participants and PSWs in the Let's Talk feasibility RCT. All participants allocated to Let’s Talk will receive a copy of the workbook. All routine or additional treatments in the comparator arm will be monitored.

Comparator condition (TAU)
The control condition is treatment as usual (TAU). All participants in the intervention and comparator arms are required to be under the care of a secondary or tertiary care mental health service as a condition of inclusion. In the UK, TAU for psychosis is based on the Care Programme Approach and typically includes psychiatric medication, assignment of community-based health and social care staff, care coordination, access to rehabilitative services, and outpatient care. Referrers for participants in the TAU arm will not be requested to withhold any treatment throughout the duration of the trial, and all routine or additional treatments will be monitored. Except for emergent risk issues, TAU alone will also not involve liaison between researchers and the participants’ healthcare teams. Research Assistants will identify any risks to self or others that require immediate action. All routine or additional treatments in the TAU arm will be monitored.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1489f48c-47da-4445-b338-6445473f19ed" outputType="pis" artefactType="LocalFile" dateCreated="2025-09-08T00:00:00.000Z" dateUploaded="2025-10-16T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="acb1f0de-12fc-4088-b5a4-262f760134b6" originalFilename="48087_PIS_V3_08Sept2025.pdf" downloadFilename="48087_PIS_V3_08Sept2025.pdf" version="3" mimeType="application/pdf" length="304066" md5sum="a6e5157f9f588469b3032ea140d1693a"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="43b1b79f-8772-4639-b610-381cdd44f5ef" outputType="pis" artefactType="LocalFile" dateCreated="2026-03-19T00:00:00.000Z" dateUploaded="2026-07-03T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="7d16f22b-6bcd-4d6f-936e-359058349b65" originalFilename="ISRCTN67429289_PIS_V4_19Mar2026.pdf" downloadFilename="ISRCTN67429289_PIS_V4_19Mar2026.pdf" version="4" mimeType="application/pdf" length="304194" md5sum="913611ee2cdba3fdb31190cc5bfb3c91"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="64029ca7-1e47-477f-ba09-e86b72db6718" outputType="protocolfile" artefactType="LocalFile" dateCreated="2025-09-22T00:00:00.000Z" dateUploaded="2025-10-16T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="6932fd62-0051-4487-9381-c93a98b39eef" originalFilename="48087_Protocol_V2.0_22Sept2025.pdf" downloadFilename="48087_Protocol_V2.0_22Sept2025.pdf" version="2.0" mimeType="application/pdf" length="745143" md5sum="60d880bd51153d9dc2c4f27ea9cfce79"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="9e9d30f7-d5bd-4804-bd64-039bda856644" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-03-19T00:00:00.000Z" dateUploaded="2026-07-03T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="570ab5e4-3cc8-407d-bdd9-5c8af6e866b8" originalFilename="ISRCTN67429289_Protocol_V4.0_19Mar2026.pdf" downloadFilename="ISRCTN67429289_Protocol_V4.0_19Mar2026.pdf" version="4.0" mimeType="application/pdf" length="831250" md5sum="f1e9b8abf702a68f1689f7939553a448"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="9e12d646-61e4-4ef2-bad6-c82910734119" outputType="trialwebsite" artefactType="ExternalLink" dateCreated="2025-11-11T00:00:00.000Z" dateUploaded="2025-11-11T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="Migration">
	<externalLink url="https://psychosisresearch.com"/>
	<description/>
	<productionNotes>Migrated from study website field</productionNotes>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>86951dcc-2709-4977-93e7-386473d73385</funderId>
      <contactId>ebf9cd3f-3712-4e66-8c43-5ffed88e1e87</contactId>
      <sponsorId>930f7421-94a2-4fe9-bdd7-45895906a077</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/6932fd62-0051-4487-9381-c93a98b39eef/48087">
	<description>Protocol file</description>
	<name>48087_Protocol_V2.0_22Sept2025.pdf</name>
	<id>6932fd62-0051-4487-9381-c93a98b39eef</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>745143</length>
	<md5sum>60d880bd51153d9dc2c4f27ea9cfce79</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/acb1f0de-12fc-4088-b5a4-262f760134b6/48087">
	<description>Participant information sheet</description>
	<name>48087_PIS_V3_08Sept2025.pdf</name>
	<id>acb1f0de-12fc-4088-b5a4-262f760134b6</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>304066</length>
	<md5sum>a6e5157f9f588469b3032ea140d1693a</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/570ab5e4-3cc8-407d-bdd9-5c8af6e866b8/48087">
	<description>Protocol file</description>
	<name>ISRCTN67429289_Protocol_V4.0_19Mar2026.pdf</name>
	<id>570ab5e4-3cc8-407d-bdd9-5c8af6e866b8</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>831250</length>
	<md5sum>f1e9b8abf702a68f1689f7939553a448</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/7d16f22b-6bcd-4d6f-936e-359058349b65/48087">
	<description>Participant information sheet</description>
	<name>ISRCTN67429289_PIS_V4_19Mar2026.pdf</name>
	<id>7d16f22b-6bcd-4d6f-936e-359058349b65</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>304194</length>
	<md5sum>913611ee2cdba3fdb31190cc5bfb3c91</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="ebf9cd3f-3712-4e66-8c43-5ffed88e1e87">
    <title>Dr</title>
    <forename>Melissa</forename>
    <surname>Pyle</surname>
    <orcid>https://orcid.org/0009-0004-5337-9031</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Greater Manchester Mental Health NHS Foundation Trust
The Psychosis Research Unit, R&amp;I
Central Park Hub, Building B
Northampton Road</address>
      <city>Manchester</city>
      <state/>
      <country>United Kingdom</country>
      <zip>M40 5BP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 271 0084</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.pyle@gmmh.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="930f7421-94a2-4fe9-bdd7-45895906a077">
    <organisation>Greater Manchester Mental Health NHS Foundation Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/05sb89p83</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="86951dcc-2709-4977-93e7-386473d73385">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2025-11-13T15:36:29.479290809Z" version="35" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN17977792" publicIdentifierDateAssigned="2025-10-16T08:08:21.394623Z">
    <isrctn dateAssigned="2025-10-16T08:08:21.394623Z">17977792</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Development and evaluation of open dialogue for severe mental illness: a feasibility study</title>
      <scientificTitle>Open Dialogue compared to usual care for adults experiencing a mental health crisis: a feasibility study for the ODDESSI trial</scientificTitle>
      <acronym>ODDESSI</acronym>
      <studyHypothesis>1.	To assess whether it is possible and acceptable to conduct a full-scale cluster randomised trial comparing Open Dialogue (OD) to Treatment as Usual (TaU) across multiple locations. We will measure recruitment, consent, and retention rates at 3 months.
2.	To assess the acceptability of primary and secondary outcome measures that will be used in the full scale trial, and to refine measures of cost-effectiveness of OD.
3.  To set up the randomisation system in preparation for the main trial and to  define and  randomise clusters in two catchment areas.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
This trial forms part of a NIHR programme grant investigating the development and evaluation of Open Dialogue (OD) for severe mental illness. OD is being developed and adapted for delivery in five NHS trusts and is a service delivery model for individuals in mental health crisis, developed in Finland, which has a collaborative approach and explicitly targets social networks. Appropriate pharmaceutical, psychological or social interventions are involved in shared decision making with social networks and healthcare professionals. This is in contrast to current models of care, in which families are rarely directly involved. Studies to date are promising and report reductions in hospital bed usage and improved recovery rates, but there is currently no high-quality evidence to support a NHS-wide adoption of this model. This approach offers the possibility of a potentially effective alternative to the current model

This trial aims to assess the feasibility of conducting a full multicentre cluster randomised controlled trial of the OD model compared to usual NHS crisis and longer-term community care (treatment as usual [TaU]) over 9 months. Participants will be eligible for the study if they are a service user in crisis with a primary diagnosis of a mental health disorder. The feasibility study will involve 2 OD teams and 2 TaU teams in two sites (NHS trusts). If the feasibility trial is successful, a multicentre cluster randomised controlled trial (RCT) with 28 clusters will be conducted over 3 years. This is a type of study where groups of participants (rather than individuals) are randomly assigned to different treatments, and the research is carried out at multiple locations or centres to improve the generalisability of the results.

Who can participate?
A service user in crisis within 24-48 hours of referral or having been discharged from in-patient care following a crisis admission to the Crisis Resolution and Home Treatment Team (CRHTT) for home treatment.

The service user must be over the age of 18, have a diagnosis of a mental health disorder, and be able to give informed consent (or consent is provided by a personal or nominated consultee).

What does the study involve?
All eligible service users will first be contacted by a member of the clinical team to obtain their agreement to be approached by a member of the research team. The screening process and recruitment process will be supported by the relevant clinical team in order to support decisions of capacity and risk. The researcher will then contact the potential participant to explain the research study and send an information sheet to them via post or email. Potential participants will be given time (48 hours) to consider the information before the researcher contacts them again to answer any questions.

Service users will already be receiving OD or Treatment as Usual (TaU) as part of their care, and their treatment will continue regardless of their participation in the study. Appropriate psychological and pharmacological treatments will be deployed in either treatment as necessary.

The participants randomised to the OD clusters will receive the OD intervention. The OD intervention focuses on the social network to improve outcomes for service users. Typically, in the first few network meetings, two OD staff members as well as the social network are present. The service user and their network decide the length and frequency of meetings as well as the focus of discussions. The OD staff members are present to facilitate the meetings amongst the social network. 

TaU will be routine crisis care and follow-up community care, which typically involves care from a CRHTT with an average duration of contact from 2-6 weeks, and, where appropriate, ongoing care from community services including psychological interventions.

Baseline interviews will be conducted over the phone or in patients' homes. Follow-up assessments will occur in the three months post-recruitment. The researcher will contact the participant to arrange a convenient time and date to meet. Participants will complete a set of outcome measures.

What are the possible benefits and risks of participating?
The benefits for participants are that they will be involved in the development of a potentially effective alternative to the current model of care for mental health crises. Service users randomised to the OD intervention will benefit from the coordinated and continuous care that the OD model offers. Service users randomised to the TaU intervention will benefit from a clear referral pathway to crisis services.

No major risks are anticipated for participants. The research interviews may, in some cases, involve discussing sensitive topics. There is the potential for participants to get upset. Although we anticipate this is unlikely, a member of the ODDESSI study team will be present during the interview if the service user does become distressed. A senior member of the research team will be able to support them and direct them to further support services. 

Where is the study run from?
The study will run across two UK NHS sites, North East London NHS Foundation Trust and Kent and Medway NHS and Social Care Partnership Trust. 

When is the study starting and how long is it expected to run for?
June 2018 to June 2019

Who is funding the study?
National Institute for Health and Care Research (NIHR), UK

Who is the main contact?
Dr Sandeep Toot, sandeep.toot@nelft.nhs.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>To assess the feasibility and acceptability of conducting a randomised controlled trial of the OD intervention versus TaU, the study will collect the following data: 
1. Recruitment to the trial, measured by observing the number of participants after recruitment
2. Consent rate, measured using the number of participants providing full consent after screening
3. Retention rates, measured using the number of participants who remained in the study at the end of the study period</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>Acceptability will be assessed through the successful completion of the following participant-level secondary outcome measures:  
The following measures are recorded at baseline:
1. Socio-demographics measured using data collected on a form created specifically for the trial, which records: date of birth, gender, ethnicity, country of birth, education, employment, marital status, and housing
2. Symptom severity measured using the Brief Psychiatric Rating Scale (BPRS)
3. Social network quality measured using the Social Provisions Scale (SPS), and social network size measured using the Lubben Social Network Scale - 6 item (LSNS-6) 
4. Burden of care on caregivers measured using the Burden Assessment Scale (BAS)
5. Health-related quality of life measured using the EQ-5D-5L
6. Hospitalisation rate, defined as an inpatient admission post-index admission, and re-referral to Crisis Resolution and Home Treatment Teams (CRHTT), measured using data collected from anonymised patient electronic medical records
The following outcome measures are recorded at 3-month follow-up: 
8.	Time to first relapse in days following recovery (primary outcome measure in the main trial), measured using anonymised case notes by the chief investigator, a psychiatrist and a senior clinician (to define point of recovery)
9.	Service user and carer satisfaction with care, measured by the Client Satisfaction Questionnaire (CSQ-8)
10.	Use of health, social care services and wider societal costs measured using an adapted version of the self-report Client Services Receipt Inventory (CSRI)
11.	Service user and primary clinician experience of shared decision making during treatment, measured by patient and clinician self-report on the dyadic OPTION scale
12.	Service user-defined recovery, measured by the Questionnaire about the Process of Recovery (QPR)</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="fa6c64a6-2add-406b-a3ef-6de68bfc3476" approvalStatus="approved" statusDate="2018-06-22T00:00:00.000Z">
	  <committeeName>London-Bromley Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Level 3, Block B, Whitefriars, Lewins Mead</address>
	    <city>Bristol</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>BS1 2NT</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>18/LO/0868</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17977792</doi>
      <eudraCTNumber/>
      <irasNumber>233243</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 36235</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="466c67b5-cad4-4c59-a3f1-e3c35ed64499" numberType="iras" canonicalSecondaryNumber="IRAS233243">233243</secondaryNumber>
	<secondaryNumber id="42b4489e-24be-48f4-9d42-ba38755972a0" numberType="cpms" canonicalSecondaryNumber="CPMS36235">36235</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Feasibility clustered randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Cluster randomised trial</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2019-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3e6f5754-26fa-4250-979e-75ce40b468ee">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing, CEME Centre, Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	</trialCentre>
	<trialCentre id="6d12f080-58ea-4be9-9ff8-5e2e2622b0b3">
	  <name>Kent and Medway NHS and Social Care Partnership Trust</name>
	  <address>Farm Villa
Hermitage Lane</address>
	  <city>Maidstone</city>
	  <state/>
	  <country>England</country>
	  <zip>ME16 9PH</zip>
	  <rtsId>RXY@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Service user</participantType>
      </participantTypes>
      <inclusion>Clusters must:
1. Be in a catchment area with a clear referral pathway to the community mental health service 
2. Have protocols in place to deliver either OD or TAU
3. Contain a set of 2 to 4 geographically coterminous GP practices where 
3.1. The cluster has an average number of referrals per cluster between 65 and 75 patients per year to crisis services
3.2. Each practice has a list size of over 2000 registered persons
3.3. Each practice refers only within the catchment area of the community MH service
3.4. Each practice only serves residents within the cluster catchment area (i.e. does not include practices which, as one of its primary functions, have the provisions of a student health service)

Service users from a cluster are eligible to take part in the study if they are:
1. Meeting criteria of a service user in crisis (meeting ICD criteria (WHO, 1992) for a mental health disorder) within 24-48 hours of referral or having been discharged from in-patient care following a crisis admission to the Crisis Resolution and Home Treatment Team (CRHTT) for home treatment. There will be some variability in the operational definition of ‘crisis’ across Trusts and, therefore, participants presenting to services.  However, this variation will increase the generalisability of trial findings.
2. 18 years and above
3. Able to provide informed consent, or have consent provided by a personal or nominated consultee</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment>59</totalFinalEnrolment>
      <exclusion>1. Having a diagnosis of dementia or a learning disability
2. Having a primary diagnosis of substance misuse
3. Having an acquired cognitive impairment
4. Being unable to comprehend both written and verbal English
5. Being under the care of forensic services
6. Being considered too high risk through participation in the study; that is, participation in the study is judged by the service users’ clinician to pose potential harm to themselves or the research/clinical team
7. Residing outside their GP catchment area
8. Having no fixed abode
9. Currently participating in another research trial, which could affect their participation in this trial</exclusion>
      <recruitmentStart>2018-07-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2019-02-18T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe mental illness</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Overview
The research team will undertake a feasibility trial to assess whether it is possible to conduct a full-scale trial comparing Open Dialogue (OD) to Treatment as Usual (TaU). They will undertake a cluster randomised controlled trial, comprising four clusters of two Open Dialogue (OD) teams and two Treatment as Usual (TaU) teams in two NHS sites. Each of the pilot sites will be staffed by a team of therapists trained in OD, and all staff have agreed at least in principle to participate in a rigorous RCT. Please note that these service users will already be receiving OD or TaU as part of their care, and their treatment will continue regardless of their participation in the study. This is approximately 10% of the total sample size to be recruited.

Randomisation
The study will take place in four clusters from two catchment areas. For this feasibility trial, two separate catchment areas, whose clusters have already been established and randomised in preparation for the future RCT, will each provide two clusters (one allocated OD, and another allocated to TaU) to the current study. Randomisation will be carried out by statisticians with support from King's Clinical Trials Unit (KCTU).

Recruitment &amp; Screening
The aim is to recruit 15 service users from each of four teams (two OD teams and two TaU teams). The study team has drawn upon their shared clinical and research experience to create a clear recruitment protocol for researchers to utilise during recruitment. Referrals to either the OD or Tau participating teams will be screened by a member of the clinical team or clinical studies officer for eligibility against the inclusion and exclusion criteria. All eligible service users will first be contacted by a member of the clinical team to obtain their agreement to be approached by a member of the research team. The screening and recruitment processes will be supported by the relevant clinical team to inform decisions regarding capacity and risk. The researcher will then contact the potential participant to explain the research study and send an information sheet to them via post or email. Potential participants will be given time (48 hours) to consider the information before the researcher contacts them again to answer any questions.

Consent and baseline
If the service user is interested in taking part in the study, the researcher will agree on a time and date to obtain informed consent between two days and two weeks of presentation to services. Participants will be recruited over 6 months by a member of the research team, and followed up for 3 months post-presentation to services. Baseline measures will be recorded in an interview after the researcher has obtained informed consent. For those who lack the capacity to consent, a personal consultee who has no professional interests or incentives in the research or treatment will be identified. If a personal consultee cannot be identified, a nominated consultee will be identified and approached from the panel of consultees. 

Intervention
Please note that these service users will already be receiving OD or Tau as part of their care, and their treatment will continue regardless of their participation in the study. Appropriate psychological and pharmacological treatments will be deployed in either treatment as necessary.

OD
The participants randomised to the OD clusters will receive the OD intervention. The OD intervention focuses on the social network to improve outcomes for service users. Typically, in the first few network meetings, two OD staff members as well as the social network are present. The service user and their network decide the length and frequency of meetings as well as the focus of discussions. The OD staff members are present to facilitate the meetings amongst the social network.

TaU
TaU will be routine crisis care and follow-up community care, which typically involves care from a (CRHTT) with an average duration of contact from 2-6 weeks, and, where appropriate, ongoing care from community services including psychological interventions.

Follow-ups
Follow-up assessments will occur in the three months post-recruitment. The researcher will contact the participant to arrange a convenient time and date to meet. The participant will complete a set of outcome measures.

Measures
The following measures will be delivered by researchers to assess their acceptability by participants. These outcome measures will be delivered by researchers. Each will be delivered at either baseline or follow-up and will be delivered only once to reduce time burden.

The measures given at baseline include;
-BPRS (Brief Psychiatric Rating Scale)
-BAS (Burden of care on caregivers)
-EQ-5D-5L (health-rated quality of life)
-LSN (Lubben Social Network)
-SPA (Social Provisions Scale)
-demographics form

The measures given at follow-up include:
-QPR (Questionnaire about the Process of Recovery)
-CSQ-8 (Service user and carer satisfaction with care)
-CSRI (Client Service Receipt Inventory)
-the dyadic OPTION scale (experience of shared decision making)

The following outcome measures will be obtained from anonymised patient electronic medical records.

-Time to first relapse in days following recovery
-Hospitalisation rate defined as an inpatient admission post index admission, and re-referral to CRHTTs, will be obtained from anonymised patient electronic medical records.

Analysis
Recruitment, retention, and consent rates will be measured and assessed against the predetermined stop-go criteria to inform progression to the multicentre cluster RCT in work package 3 of the programme:
-60 participants recruited (10% of the sample size to be recruited to the full trial)
-retention of 80% of participants at 3-month follow-up
-primary outcome data collected from 85% of participants at 3-month follow-up
-expected consent rate of 66%
-demonstration that all sites can establish clusters and that all OD teams operate within the agreed protocol (including referral pathways, caseload capacity and team composition)
-demonstration that all OD teams across all sites achieve adequate adherence and fidelity</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The researchers will be following the actions outlined by NIHR in regard to sharing research data. The datasets generated and analysed, and the corresponding statistical code, will be available in anonymised form from the research team on reasonable request, subject to review, following the publication of trial results. Dr Sandeep Toot, sandeep.toot@nelft.nhs.uk</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8d29f78f-7507-44b1-9977-0203694766ca" outputType="pis" artefactType="LocalFile" dateCreated="2018-06-28T00:00:00.000Z" dateUploaded="2025-09-17T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="38ccde46-f7e5-40cf-b222-023156d321f6" originalFilename="48000_PIS_Carer_v1.3_28June2018.pdf" downloadFilename="48000_PIS_Carer_v1.3_28June2018.pdf" version="1.3" mimeType="application/pdf" length="133173" md5sum="3bef5ca5541de76ae434a1936ded81ab"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="fd7ade30-c233-4856-b1dc-35b64095931a" outputType="pis" artefactType="LocalFile" dateCreated="2018-06-28T00:00:00.000Z" dateUploaded="2025-09-17T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="3e1634df-72bc-4ab8-9ebd-b7cb256a6968" originalFilename="48000_PIS_Consultee_v1.3_28June2018.pdf" downloadFilename="48000_PIS_Consultee_v1.3_28June2018.pdf" version="1.3" mimeType="application/pdf" length="136829" md5sum="908dc248d29b6dc0af85736d5c04c50c"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="a828c63b-7781-437c-835f-39b8b92a0f21" outputType="pis" artefactType="LocalFile" dateCreated="2018-06-28T00:00:00.000Z" dateUploaded="2025-09-17T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="3bfc316b-821c-4c80-9030-8d95abe745fd" originalFilename="48000_PIS_v1.3_28June2018.pdf" downloadFilename="48000_PIS_v1.3_28June2018.pdf" version="1.3" mimeType="application/pdf" length="133160" md5sum="b86b6525fce9d17d5c32cda9abbd36b3"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>0ebf0fca-88cd-44a0-ae44-7e6c4a599f81</funderId>
      <contactId>396e3f17-bf4f-43d4-99cb-9a2e23d06f63</contactId>
      <sponsorId>065d017d-cfc5-448a-a773-c74959d28a3b</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/38ccde46-f7e5-40cf-b222-023156d321f6/48000">
	<description>Participant information sheet</description>
	<name>48000_PIS_Carer_v1.3_28June2018.pdf</name>
	<id>38ccde46-f7e5-40cf-b222-023156d321f6</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>133173</length>
	<md5sum>3bef5ca5541de76ae434a1936ded81ab</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/3e1634df-72bc-4ab8-9ebd-b7cb256a6968/48000">
	<description>Participant information sheet</description>
	<name>48000_PIS_Consultee_v1.3_28June2018.pdf</name>
	<id>3e1634df-72bc-4ab8-9ebd-b7cb256a6968</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>136829</length>
	<md5sum>908dc248d29b6dc0af85736d5c04c50c</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/3bfc316b-821c-4c80-9030-8d95abe745fd/48000">
	<description>Participant information sheet</description>
	<name>48000_PIS_v1.3_28June2018.pdf</name>
	<id>3bfc316b-821c-4c80-9030-8d95abe745fd</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>133160</length>
	<md5sum>b86b6525fce9d17d5c32cda9abbd36b3</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="396e3f17-bf4f-43d4-99cb-9a2e23d06f63">
    <title>Prof</title>
    <forename>Stephen</forename>
    <surname>Pilling</surname>
    <orcid>https://orcid.org/0000-0002-7361-8202</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Department of Clinical, Educational and Health Psychology (CEHP), University College London, 1-19 Torrington Place</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1E 7HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7679185</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.pilling@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="065d017d-cfc5-448a-a773-c74959d28a3b">
    <organisation>North East London NHS Foundation Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/023e5m798</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="0ebf0fca-88cd-44a0-ae44-7e6c4a599f81">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-08T13:39:51.950018926Z" version="40" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN29596999" publicIdentifierDateAssigned="2025-08-18T09:03:25.32254Z">
    <isrctn dateAssigned="2025-08-18T09:03:25.32254Z">29596999</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Helping people with severe mental illness lower their risk of heart disease through peer support groups</title>
      <scientificTitle>A peer-led group programme for people with severe mental illness to reduce risk of cardiovascular disease (PEGASUS): A feasibility evaluation study</scientificTitle>
      <acronym>PEGASUS feasibility study</acronym>
      <studyHypothesis>The aim of this research is to feasibility test a trained peer-supported group clinic intervention for people with SMI who have increased risk of CVD. Building on development work, evidence from a systematic review and an experience-based co-design process leading to the development of a co-produced peer-supported group clinic intervention, the objectives of this study are: 
1.	To establish the feasibility of the intervention for future evaluation in a randomised controlled trial (RCT), specifically: 
1.1.	Establish the feasibility of recruitment and retention strategies for the main trial 
1.2.	Assess the acceptability of, and retention to the planned intervention for individuals with SMI and elevated CVD risk 
1.3.	Determine the feasibility of collecting primary and secondary outcome data for the main trial  
2.	Estimate the location (proportion) and variability (confidence intervals) of the primary outcome to refine the power calculations for the main trial 
3.	To refine the content and delivery strategies for the intervention 
4.	To determine the best method of evaluating intervention implementation and fidelity</studyHypothesis>
      <plainEnglishSummary>Background and study aims
People living with severe mental illness (SMI), such as schizophrenia or bipolar disorder, often have poorer physical health and can die 15–20 years earlier than the general population. One of the main causes of early death is heart disease. This risk is even higher for people from Black, Asian and minority ethnic communities. The PEGASUS study is testing a new group programme designed to help people with SMI reduce their risk of heart disease. The programme includes support with healthy eating, physical activity, and managing health goals, and is co-led by peer support workers (people with lived experience of mental health difficulties) and healthcare professionals.

Who can participate?
Adults who have a diagnosis of severe mental illness and also an elevated risk of cardiovascular disease may be able to take part.

What does the study involve?
Participants will be invited to join a group of 8–12 people for 10 sessions over 6 months. Each session lasts 2 hours and is led by a peer support worker and a healthcare professional. The sessions focus on different aspects of health and wellbeing. Participants will also have an individual ‘onboarding’ session before the group starts, four one-to-one sessions with a peer worker during the programme, and a reunion session after the programme ends. The study will also involve completing questionnaires and health checks at the beginning, middle, and end of the programme. Some participants may be invited to take part in an interview or focus group to share their views on the programme.

What are the possible benefits and risks of participating?
Taking part may help participants improve their physical health, feel more confident about managing their health, and feel more socially connected. There are no major risks, but some people may find it difficult to talk about their health or take part in group sessions. Support will be available throughout.

Where is the study run from?
City St George’s, University of London (UK)

When is the study starting and how long is it expected to run for?
August 2025 to September 2026

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Dr Bethan Hatherall, bethan.hatherall@citystgeorges.ac.uk
Jessica Catchpole, jessica.catchpole@citystgeorges.ac.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Acceptability of intervention and study delivery as assessed by focus group/interviews at 3 and 6-months.</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Participant recruitment and retention rate is measured using study records at baseline, 3 months, and 6 months  
2. Waist circumference is measured using tape measurement at baseline, 3 months, and 6 months  
3. Hip circumference is measured using tape measurement at baseline, 3 months, and 6 months  
4. Body mass index (BMI) is measured using height and weight measurements at baseline, 3 months, and 6 months  
5. Triglycerides are measured using fasting blood sample at baseline, 3 months, and 6 months  
6. HDL-cholesterol is measured using fasting blood sample at baseline, 3 months, and 6 months  
7. LDL-cholesterol is measured using fasting blood sample at baseline, 3 months, and 6 months  
8. Total cholesterol is measured using fasting blood sample at baseline, 3 months, and 6 months  
9. HbA1c is measured using blood sample at baseline, 3 months, and 6 months  
10. Blood pressure is measured using automated sphygmomanometer at baseline, 3 months, and 6 months  
11. Psychiatric symptoms are measured using the Modified Colorado Symptom Index at baseline, 3 months, and 6 months  
12. Dietary behaviour is measured using the Dietary Instrument for Nutrition Education (DINE) adapted by IMPaCT at baseline, 3 months, and 6 months  
13. Physical activity is measured using the International Physical Activity Questionnaire - Short Form (IPAQ-SF) at baseline, 3 months, and 6 months  
14. Tobacco, cigarette, and betel nut or paan use is measured using self-report questionnaire at baseline, 3 months, and 6 months  
15. Alcohol consumption is measured using the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C) at baseline, 3 months, and 6 months  
16. Health-related quality of life is measured using the EQ-5D-5L at baseline, 3 months, and 6 months  
17. Depression is measured using the Patient Health Questionnaire-9 (PHQ-9) at baseline, 3 months, and 6 months  
18. Self-efficacy is measured using the Generalised Self-Efficacy Scale at baseline, 3 months, and 6 months  
19. Social network is measured using the Lubben Social Network Scale at baseline, 3 months, and 6 months  
20. Therapeutic relationship is measured using the Scale to Assess the Therapeutic Relationship (STAR) at baseline, 3 months, and 6 months  
21. Progress towards achievement of personalised lifestyle goals is measured using the Goal-Based Outcome Tool at baseline, 3 months, and 6 months  
22. Health and social care service use is measured using the DIAMONDS Service Use Survey at baseline, 3 months, and 6 months  
23. Physical activity levels are measured using one-week accelerometer wear at baseline, 3 months, and 6 months</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="1f88c1ee-b2cf-4b0b-bd2d-05b0af4fe72e" approvalStatus="approved" statusDate="2024-10-15T00:00:00.000Z">
	  <committeeName>Wales Research Ethics Committee 7</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>24/WA/0289</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN29596999</doi>
      <eudraCTNumber/>
      <irasNumber>326517</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 59641, NIHR: 204418</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="e9ca052a-959c-4183-9070-ea698e0a9f29" numberType="iras" canonicalSecondaryNumber="IRAS326517">326517</secondaryNumber>
	<secondaryNumber id="f6c8efd2-2586-40e6-9f5b-7929d675af5f" numberType="cpms" canonicalSecondaryNumber="CPMS59641">59641</secondaryNumber>
	<secondaryNumber id="ff92b300-a330-4ec9-aa02-970ceee9da40" numberType="nihr" canonicalSecondaryNumber="NIHR204418">204418</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional non-randomized</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2026-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="97d7793d-5e36-49d0-8f6e-5e7cba64f4b1">
	  <name>East London NHS Foundation Trust</name>
	  <address>Robert Dolan House
9 Alie Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 8DE</zip>
	  <rtsId>RWK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1d7ff4e4-74aa-4121-ac4b-44806577e800">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="38a0a35f-62ff-4c6f-8d4d-2510de6e34d2">
	  <name>Birmingham and Solihull Mental Health NHS Foundation Trust</name>
	  <address>Unit 1
50 Summer Hill Road</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B1 3RB</zip>
	</trialCentre>
	<trialCentre id="392cfaf5-eb16-4823-b48c-bacb36622863">
	  <name>South West London and St George's Mental Health NHS Trust</name>
	  <address>Springfield Hospital
61 Glenburnie Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW17 7DJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Current key inclusion criteria as of 18/12/2025: 

Service users participants will:
1. Be aged 18 to 75 years
2. Have capacity to consent to participate in research
3. Currently on the caseload of mental health services in community settings or on GP/ ICS severe mental illness (SMI) list
4. Current primary diagnosis of schizophrenia-spectrum disorders (ICD-10 diagnoses F20–29) or bipolar disorder (F31) or in Early Intervention for Psychosis Services (EIPS) with formal diagnosis of psychosis (ICD-10 diagnoses of F29) or an aforementioned diagnosis.
5. If on psychotropic medication, on stable dose for 90 days (N.B. This refers specifically to either adding or changing to a new antipsychotic medication, but not applies to dosage adjustment of a pre-existing antipsychotic medication.)
6. Enhanced CVD risk as indicated by any one of:
i) Obesity defined as: waist circumference over 102cm in men (or &gt;90cm in non-white men) or over 88cm in women (or &gt;80cm in non-white women) or BMI≥25 kg/m2 (or ≥23 kg/m2 in non-white people)
ii) Hypertension defined as: blood pressure over 130/85 mmHg or documented hypertension on medication
iii) Dyslipidaemia defined as: fasting triglyceride level over 1.7mmol/l or total cholesterol ≥5.0 mmol/L or on medication for hyperlipidaemia (e.g. statin) or high-density lipoprotein (HDL) cholesterol level less than 0.9mmol/l (men)/1mmol/l (women)
iv) Hyperglycaemia defined as: HbA1c &gt; 37 mmol/mol (5.5%) or fasting plasma glucose level ≥5.6 mmol/l or documented Type-2 diabetes (T2D)
7. If on treatment for T2D, hypertension or hyperlipidaemia, on stable dose medication for at least 90 days

Intervention staff:
1. Peer (support) workers and registered mental health nurses (or other healthcare professionals or practitioners with appropriate training)
2. Based at one of the participating sites/Trusts
3. Have been trained and engaged with the PEGASUS programme to deliver (co-facilitate) the PEGASUS intervention for the purposes of this study

_____

Previous key inclusion criteria:

Service users participants will:
1.  Be aged 18 to 75 years
2. Have capacity to consent to participate in research
3. Service Involvement:
   3.1 Currently on the caseload of mental health services in community settings  
   3.2 Or on GP/ICS severe mental illness (SMI) list
4. Diagnosis:
   4.1 Current primary diagnosis of schizophrenia-spectrum disorders (ICD-10 diagnoses F20–29)  
   4.2 Or bipolar disorder (F31)  
   4.3 Or in Early Intervention for Psychosis Services (EIPS) with formal diagnosis of the above conditions
5. If on psychotropic medication, must be on a stable dose for 90 days
6. Enhanced Cardiovascular Disease (CVD) Risk as indicated by metabolic syndrome (NCEP ATP III definition), confirmed at screening by any three of the following:
    6.1 Waist circumference over 102 cm (men) or 88 cm (women)  
    6.2 Blood pressure over 130/85 mmHg or documented hypertension on medication  
    6.3 Fasting triglyceride level over 1.7 mmol/l  
    6.4 HDL cholesterol level less than 0.9 mmol/l (men), 1 mmol/l (women)  
    6.5 HbA1c &gt; 37 mmol/mol (5.5%) or documented Type-2 diabetes (T2D) and on medication  
    6.6 If on treatment for T2D, hypertension or hyperlipidaemia, must be on stable dose medication for at least 90 days

Intervention staff:
1. Peer (support) workers and registered mental health nurses (or other healthcare professionals or practitioners with appropriate training)
2. Based at one of the five sites/Trusts
3. Have been trained and engaged with the PEGASUS programme to deliver (co-facilitate) the PEGASUS intervention for the purposes of this study</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="75.0">75 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment>18</totalFinalEnrolment>
      <exclusion>Current key exclusion criteria as of 18/12/2025: 

Service users who:
1. Are currently admitted to acute psychiatric care (i.e. inpatient admission or current referral to a Crisis &amp; Home Treatment Team)
2. Have a primary diagnosis of alcohol or substance misuse
3. Are awaiting/going through assessment with EIPS but without formal diagnosis
4. Have a diagnosis of an organic mental health disorder (e.g. dementia)
5. Are currently in receipt of a highly structured and/ or multi-goal healthy lifestyle intervention (e.g. an intervention that combines structured diet and exercise goals, or a highly structured research-based intervention such as DIAMONDS or PRIMROSE-A). Note: referral to single goal lifestyle support, as typically provided in the voluntary-sector or as online NHS advice, is considered as part of care as usual and will be assessed in both trial groups
6. Blood pressure or hyperlipidaemia managed outside of primary care
7. Type 1 diabetes

Intervention staff:
Peer (Support) Workers, registered mental health nurses or other healthcare professionals or practitioners who are not trained for nor delivering the PEGASUS intervention for the purposes of this study.

_____

Previous key exclusion criteria:

Service users who:
1. Are currently admitted to acute psychiatric care (i.e. inpatient admission or current referral to a Crisis &amp; Home Treatment Team)
2. Have a primary diagnosis of alcohol or substance misuse
3. Are awaiting/going through assessment with EIPS but without formal diagnosis 
4. Have a diagnosis of an organic mental health disorder (e.g. dementia)
5. Are currently in receipt of a highly structured and/ or multi-goal healthy lifestyle intervention (e.g. an intervention that combines structured diet and exercise goals, or a highly structured research-based intervention such as DIAMONDS or PRIMROSE-A). Note: referral to single goal lifestyle support, as typically provided in the voluntary-sector or as online NHS advice, is considered as part of care as usual and will be assessed in both trial groups
6. HbA1c &gt; 86 mmol/mol
7. Blood pressure or hyperlipidaemia managed outside of primary care
8. Type 1 diabetes

Intervention staff:
Peer (Support) Workers, registered mental health nurses or other healthcare professionals or practitioners who are not trained for nor delivering the PEGASUS intervention for the purposes of this study.</exclusion>
      <recruitmentStart>2025-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe mental illness and metabolic syndrome</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The PEGASUS intervention is a therapeutic group programme for people with severe mental illness at risk of cardiovascular disease and has been co-produced by peer workers, clinicians, and most importantly people with lived experience. The programme consists of 10 group sessions over the course of 6 months. The duration of each session is 2 hours. Each session consists of the same group of 8-12 people and the same two facilitators; a mental health peer support worker (someone who has lived experience of mental health difficulties and is using such experience in their work to support others) and a health care professional (this might be a nurse, dietician or occupational therapist). Each session will have a focus on different aspects of health and wellbeing that our previous research has identified as important to people with SMI and cardiovascular disease risk.  Participants are also offered an ‘onboarding’ session with one of the facilitators in advance of the first group session, and 4 additional one-to-one sessions with the peer support worker over the course of the programme. A reunion session will be offered within 3 months of the programme finishing.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study are/will be available upon request from the Study Team, in accordance with the policies and conditions set out by the ethical or legal restrictions.
bethan.hatherall@citystgeorges.ac.uk
Jessica.catchpole@citystgeorges.ac.uk</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="388826dd-a3ef-4fe8-8562-8cacdc8b01f8" outputType="pis" artefactType="LocalFile" dateCreated="2024-10-15T00:00:00.000Z" dateUploaded="2025-08-15T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="9ac28dec-d594-4119-88d4-c9a0e16b2087" originalFilename="47785 PIS PEGASUS feasibility study v1.1 15Oct24.pdf" downloadFilename="47785 PIS PEGASUS feasibility study v1.1 15Oct24.pdf" version="1.1" mimeType="application/pdf" length="241085" md5sum="fdee9d5c0d31e98315ac818ffbc7b4a2"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="10b4c7ee-3d32-4a6d-8aa7-70e23623bf6c" outputType="protocolfile" artefactType="LocalFile" dateCreated="2020-11-25T00:00:00.000Z" dateUploaded="2025-12-18T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="922d756d-cd07-4750-bd30-244630aef9a1" originalFilename="ISRCTN29596999 Feasibility study protocol_V2.3_2025Nov20 (1).pdf" downloadFilename="ISRCTN29596999 Feasibility study protocol_V2.3_2025Nov20 (1).pdf" version="2.3" mimeType="application/pdf" length="714096" md5sum="9943e25311a4a518b90678655bd1a259"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="d78f0612-9a06-47ad-a181-5b3c4288c978" outputType="trialwebsite" artefactType="ExternalLink" dateCreated="2025-11-11T00:00:00.000Z" dateUploaded="2025-11-11T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="Migration">
	<externalLink url="https://city.ac.uk/pegasus"/>
	<description>Study website</description>
	<productionNotes>Migrated from study website field</productionNotes>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>0e508769-419b-4e62-b5e9-991a81efdbff</funderId>
      <contactId>ae64e40b-031b-4cfc-9124-f96ef3755d99</contactId>
      <contactId>799204df-3a73-4022-9e5d-6eb2f8ce94e3</contactId>
      <sponsorId>33193943-4046-42ed-b670-18d3e783ab7b</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/9ac28dec-d594-4119-88d4-c9a0e16b2087/47785">
	<description>Participant information sheet</description>
	<name>47785 PIS PEGASUS feasibility study v1.1 15Oct24.pdf</name>
	<id>9ac28dec-d594-4119-88d4-c9a0e16b2087</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>241085</length>
	<md5sum>fdee9d5c0d31e98315ac818ffbc7b4a2</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/922d756d-cd07-4750-bd30-244630aef9a1/47785">
	<description>Protocol file</description>
	<name>ISRCTN29596999 Feasibility study protocol_V2.3_2025Nov20 (1).pdf</name>
	<id>922d756d-cd07-4750-bd30-244630aef9a1</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>714096</length>
	<md5sum>9943e25311a4a518b90678655bd1a259</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="ae64e40b-031b-4cfc-9124-f96ef3755d99">
    <title>Dr</title>
    <forename>Bethan</forename>
    <surname>Hatherall</surname>
    <orcid>https://orcid.org/0000-0001-8114-9648</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Health and Medical Sciences, City St George's University of London, Northampton Square</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>EC1V 0HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bethan.Hatherall@citystgeorges.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="799204df-3a73-4022-9e5d-6eb2f8ce94e3">
    <title>Mx</title>
    <forename>Jessica</forename>
    <surname>Catchpole</surname>
    <orcid>https://orcid.org/0000-0001-7901-1797</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>(Lived Experience Researcher), School of Health and Medical Sciences, City St George's University of London, Northampton Square</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>EC1V 0HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44(0)7423 637934</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Jessica.catchpole@citystgeorges.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="33193943-4046-42ed-b670-18d3e783ab7b">
    <organisation>City, University of London</organisation>
    <sponsorType>University/education</sponsorType>
    <rorId>https://ror.org/04489at23</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="0e508769-419b-4e62-b5e9-991a81efdbff">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-18T09:38:30.890742644Z" version="51" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN11440256" publicIdentifierDateAssigned="2025-07-07T13:17:47.076252Z">
    <isrctn dateAssigned="2025-07-07T13:17:47.076252Z">11440256</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Piloting, psychometric testing and feasibility studies of adapted DIALOG+ in people with mild to moderate learning disability</title>
      <scientificTitle>Improving quality of life and behaviour that challenges in people with mild to moderate intellectual disability through person-centred solution focused communication (ICONIC)</scientificTitle>
      <acronym>ICONIC</acronym>
      <studyHypothesis>Current study objectives as of 16/04/2026:

1. To pilot the adapted DIALOG quality of life scale and intervention (aDIALOG+) and obtain feedback on what aspects of the intervention (including the aDIALOG scale, supporting app, training and manual) worked well or did not work well and suggestions for improvement.  
2. To test the psychometric properties of the aDIALOG scale to establish whether the aDIALOG scale is a useful quality of life measure in people with learning disability, and to compare it with the original DIALOG scale in people with mental health issues.
3. To conduct a feasibility study of aDIALOG+ delivered by clinicians from community learning disability services to assess recruitment and retention of service users and clinicians. 
4. To conduct a feasibility study of aDIALOG+ delivered by care workers from care homes (supported living or residential care) for people with learning disability to assess recruitment and retention of care homes, care workers and service users.

_____

Previous study objectives:

1. To pilot the adapted DIALOG quality of life scale and intervention (aDIALOG+) and obtain feedback on what aspects of the intervention (including the aDIALOG scale, supporting app, training and manual) worked well or did not work well and suggestions for improvement.  
2. To test the psychometric properties of the aDIALOG scale to establish whether the aDIALOG scale is a useful quality of life measure in people with learning disability. 
3. To conduct a feasibility study of aDIALOG+ delivered by clinicians from community learning disability services to assess recruitment and retention of service users and clinicians. 
4. To conduct a feasibility study of aDIALOG+ delivered by care workers from care homes (supported living or residential care) for people with learning disability to assess recruitment and retention of care homes, care workers and service users.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
This research is part of the ICONIC programme, which aims to improve quality of life and behaviour that challenges in people with mild to moderate learning disability through person-centred solution focused communication. DIALOG+ is an evidence based, face-to-face intervention delivered by health professionals using a tablet, which structures routine care sessions to ensure that care planning is personalised, holistic and co-produced. DIALOG+ involves collaboratively completing a quality-of-life scale and then using those ratings to have a solution focused discussion in order to set actions and improve service user satisfaction. Studies have found that it can enhance the communication between service users and those who support them, and can improve quality of life in people with mental health problems, but it has not been used in people with learning disabilities. We want to make DIALOG+ accessible and suitable for people with learning disability and to use it to help individuals think about things in their life they want to improve (e.g. leisure activities, accommodation) by using resources available to them or their carers. Our aim is to test if it improves quality of life and behaviour. 

Who can participate?
Piloting Study:
Service users will be eligible to take part if they are aged 18 or over, have mild or moderate learning disability based on service records/clinical notes, have a current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property in the last 3 months), are living in any setting including the family home and supported living/ residential home, and can provide informed verbal or written consent.

Psychometric Testing Study:
Service users will be eligible to take part if they are aged 18 or over, have mild or moderate learning disability based on service records / clinical notes, are known to community ID services from participating NHS trusts or to voluntary groups for people with ID, and can provide informed verbal or written consent.

Comparison Testing Study:
Service users will be eligible to take part if they are aged between 18 and 65 years, are under the care of a community psychiatric team or currently an inpatient in a psychiatric hospital in East London NHS Foundation Trust, have a primary diagnosis of a mental health issue, and can provide informed verbal or written consent.

Clinical Services Feasibility Study:
Service users will be eligible to take part if they are aged 18 or over, have mild or moderate learning disability based on service records / clinical notes, have a history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property) OR have a diagnosis of a mental health condition and are currently receiving or waiting for treatment, are living in any setting including the family home and supported living/ residential home, and can provide informed verbal or written consent.

Care Homes Feasibility Study:
Service users will be eligible to take part if they are aged 18 or over, have mild or moderate learning disability based on service records / clinical notes, have a history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property) OR have a diagnosis of a mental health condition and are currently receiving or waiting for treatment, are residing in supported living or residential care, and can provide informed verbal or written consent.

What does the study involve?
Comparison Testing Study:
A resident trainee, clinical studies officer or a member of the research team will arrange a face-to-face or remote (via Teams or Zoom) meeting with at least 200 service users with any mental health diagnosis (without learning disability) to complete the a DIALOG scale, along with the original DIALOG scale, and some demographic questions (e.g. gender, age, ethnicity, primary mental health diagnosis, how they receive their care and the number of years of treatment). Alternatively, service users can be sent the consent form and questionnaires to complete via email or post.

Clinical Services Feasibility Study:
In this study, we will be assessing whether it is feasible for clinicians to deliver an adapted version of aDIALOG+ to service users with mild or moderate learning disability who have behaviours that challenge (such as physical or verbal aggression towards others or property, anger / frustration outbursts, and self-injurious behaviour). Our aim is to establish whether it is possible to recruit 8-12 clinicians, 30 service users and 30 participant carers (if applicable) into the study. We will also examine the number of sessions of aDIALOG+ that are delivered over 6 months, the quality of the sessions, and the experiences and views of clinicians, service users and participant carers about the intervention, what worked well and what needs to be improved. We will also examine if there are any potential benefits of the intervention by looking at changes in outcome measures such as behaviour, community participation, quality of life and service use.

Care Homes Feasibility Study:
In this study, we will be assessing whether it is feasible for care workers to deliver an adapted version of DIALOG+ (aDIALOG+) to service users with mild or moderate learning disability who have behaviours that challenge (such as physical or verbal aggression towards others or property, anger / frustration outbursts, and self-injurious behaviour).

What are the possible benefits and risks of participating?
For the piloting study, service users and care workers will receive a £20 shopping voucher for participating in the interview/focus group following the 6-week intervention period to thank them for their time, and service users will also receive a £20 voucher after taking part in the psychometric testing study. For the psychometric comparison study service users will receive a £10 voucher for taking part. For the clinical services and care homes feasibility studies, service users, participant carers and care workers will receive a £20 shopping voucher for completing qualitative interviews, and service users will receive £20 after completing the baseline assessment and £20 prior to the 6-month follow-up assessments to thank them for their time. Participant carers and care workers will also receive £20 following completion of the baseline assessment and prior to the 6-month follow-up assessments. By sharing experience and views on the aDIALOG+ software, it will help us to improve it and adapt it for clinicians and care workers who use aDIALOG+ in the future. We know that using the original DIALOG+ intervention improved the quality of life of people with psychosis when they used it face to face and we are hoping we can replicate those benefits in service users with learning disability.

Where is the study run from? 
The research is coordinated at the Unit for Adult Mental Health and Wellbeing, Queen Mary University of London. Dr Afia Ali has overall responsibility for the study and it is sponsored by East London NHS Foundation Trust.

When is the study starting and how long is it expected to run for?
The piloting study started in January 2026 and is expected to run for 3 months. The psychometric testing study started in July 2025 and is expected to run for 17 months. The comparison testing study started in May 2026 and is expected to run for 12 months. The clinical services and care homes feasibility studies started in May 2026 and are expected to run for 13 months. The completion date is June 2027.

Who is funding the study? 
National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?
Dr Afia Ali (Chief Investigator), afia.ali@qmul.ac.uk / afia.ali6@nhs.net
Miss Laura Miller (Programme Manager), l.miller@qmul.ac.uk / laura.miller58@nhs.net</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Current primary outcomes as of 16/04/2026:

WP1a Piloting:
1. Acceptability of / feedback on the intervention is measured using semi-structured interviews / focus groups after 2-4 weeks.
2. Intervention implementation processes from the perspective of clinicians and care workers are assessed using the NoMAD questionnaire after 2-4 weeks.

WP1b Psychometric Testing:
1. Construct and concurrent validity of the aDIALOG scale are measured using the Mini-MANS LD and the WHOQOL Disabilities module and Clinical Outcome in Routine Evaluation- Learning Disability (CORE-LD), 14 item version (measure of psychological distress) at baseline.
2. Test re-test reliability of the aDIALOG scale is measured by completing the scale at baseline and again 24 hours to 1 week later.

WP1b Comparison Testing: 
1. Reliability of the aDIALOG scale through measuring the internal consistency and comparing to the original DIALOG scale. 
2. Validity of the aDIALOG scale measured using evenness of distribution of scores compared to the original DIALOG scale and confirmatory factor analysis. 

_____

Previous primary outcomes:

WP1a Piloting:
1. Acceptability of / feedback on the intervention is measured using semi-structured interviews / focus groups with at 6 weeks. 
2. Intervention implementation processes from the perspective of clinicians and care workers are assessed using the NoMAD questionnaire at 6 weeks. 

WP1b Psychometric Testing:
1. Construct and concurrent validity of the aDIALOG scale are measured using the Mini-MANS LD and the WHOQOL Disabilities module and Clinical Outcome in Routine Evaluation- Learning Disability (CORE-LD), 14 item version (measure of psychological distress) at baseline. 
2. Test re-test reliability of the aDIALOG scale is measured by completing the scale at baseline and again 24 hours to 1 week later. 

Feasibility studies:
1.  Changes in behaviour in service users is measured using the Aberrant Behaviour Checklist (ABC) – Irritability subscale at baseline and 6 months</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>Feasibility studies:
1.	Quality of life in service users is measured using the 13- item WHOQOL Disabilities module (WHOQOL-DIS) at baseline and 6 months
2.	Community and Leisure participation in service users is measured using the Guernsey Community Participation and Leisure Assessment – Revised (GCPLA-R) at baseline and 6 months
3.	Changes in psychological distress in service users is measured using the Learning Disability – Clinical Outcomes in Routine Evaluation, 14 item version (LD-CORE-14) at baseline and 6 months 
4.	Changes in the presence of psychiatric disorders in service users is measured using the Moss Psychiatric Assessment Schedule - Check (Moss-PAS Check) at baseline and 6 months 
5.	Changes in behaviour and functioning in service users as a result of the intervention is measured using a modified version of the Clinical Global Impressions Scale – Improvement version (CGI-I) at 6 months
6.	Paid and family carer distress in participant carers is measured using the Kessler Psychological Distress Scale - K6 at baseline and 6 months
7.	Changes in health-related quality of life in service users is measured using the EuroQol Five Dimensions - Learning Disability modified version of the EQ-5D-3L at baseline and 6 months. A proxy version of the EQ-5D-5L will also be completed by participant carers at baseline and 6 months. 
8.	Health related quality of life in participant carers is measured using the EQ-5D-5L at baseline and 6 months. 
9.	Health and social care contacts and medication in service users is measured using a modified version of the Client Services Receipt Inventory (CSRI) at baseline and 6 months. 
10.	Treatment costs of delivering the intervention are measured using staff time, room bookings and other resource use in participating clinical services and care homes. 
11.	Intervention implementation processes from the perspective of clinicians and care workers are assessed using the NoMAD questionnaire at 6 months. 
12.	Recruitment is measured using screening logs of the number of clinicians, care workers and eligible service users who were approached agreed to take part throughout the study at 6 months. 
13.	Retention is measured using withdrawal forms completed to record clinicians, care workers and service users who drop out of the study and the reasons why, as well as the number of participants that complete the follow-up assessment at 6 months. 
14.	Intervention adherence is measured using session completion data from the aDIALOG+ app at 6 months. 
15.	Intervention fidelity is measured using audio/video recordings of sessions, action plans from the aDIALOG+ app and completed session fidelity checklists at 6 months. 
16.	Acceptability of the intervention is measured using semi-structured interviews / focus groups with at 6 months.</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="f7d80ccb-ca24-4a86-bcff-c35fcc7b7b46" approvalStatus="approved" statusDate="2025-06-23T00:00:00.000Z">
	  <committeeName>South West - Cornwall &amp; Plymouth Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/SW/0055</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11440256</doi>
      <eudraCTNumber/>
      <irasNumber>349711</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 68145, NIHR: 205440</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="0908fb31-1bd2-45df-bcdd-93810ee2b316" numberType="iras" canonicalSecondaryNumber="IRAS349711">349711</secondaryNumber>
	<secondaryNumber id="296ae96a-46d6-4d75-b5f9-12b94e876125" numberType="cpms" canonicalSecondaryNumber="CPMS68145">68145</secondaryNumber>
	<secondaryNumber id="1e0b6ce8-a297-4941-9041-a10e5be3eec9" numberType="nihr" canonicalSecondaryNumber="NIHR205440">205440</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional non-randomized</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2027-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1a610a5c-9f4f-447c-819f-230f287b0b7a">
	  <name>East London NHS Foundation Trust</name>
	  <address>Robert Dolan House
9 Alie Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 8DE</zip>
	  <rtsId>RWK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e018a2fd-182f-4ca9-825f-dc4bb231c661">
	  <name>Cornwall Partnership NHS Foundation Trust</name>
	  <address>Carew House
Beacon Technology Park
Dunmere Road</address>
	  <city>Bodmin</city>
	  <state/>
	  <country>England</country>
	  <zip>PL31 2QN</zip>
	  <rtsId>RJ8@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e38bc70b-b4f9-4a28-aec8-192ae389d3e7">
	  <name>North London NHS Foundation Trust</name>
	  <address>Camden Learning Disability Service
5 Pancras Square</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>N1C 4AG</zip>
	</trialCentre>
	<trialCentre id="f9bb3496-77d5-471c-842d-25ff16c0a837">
	  <name>Cambridgeshire and Peterborough NHS Foundation Trust</name>
	  <address>Elizabeth House
Fulbourn Hospital
Fulbourn</address>
	  <city>Cambridge</city>
	  <state/>
	  <country>England</country>
	  <zip>CB21 5EF</zip>
	  <rtsId>RT1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6aea2b17-922b-4a63-95c8-ec1a262c2114">
	  <name>Derbyshire Healthcare NHS Foundation Trust</name>
	  <address>Trust Headquarters
Kingsway Hospital
Kingsway</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3LZ</zip>
	  <rtsId>RXM@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c58060eb-a4c7-4807-81cd-dc17f3dd550b">
	  <name>Hampshire and Isle of Wight Healthcare NHS Foundation Trust</name>
	  <address>Tatchbury Mount Hospital
Calmore</address>
	  <city>Southampton</city>
	  <state/>
	  <country>England</country>
	  <zip>SO40 2RZ</zip>
	  <rtsId>RW1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="ef3fecfc-7a49-4358-a7b9-b9d53f729209">
	  <name>Rotherham Doncaster and South Humber NHS Foundation Trust</name>
	  <address>Woodfield House
Tickhill Road</address>
	  <city>Doncaster</city>
	  <state/>
	  <country>England</country>
	  <zip>DN4 8QN</zip>
	  <rtsId>RXE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="eae7576a-a7c9-4d21-ac59-9a7e6221ec0a">
	  <name>Livewell Southwest</name>
	  <address>Local Care Centre
200 Mount Gould Road</address>
	  <city>Plymouth</city>
	  <state/>
	  <country>England</country>
	  <zip>PL4 7PY</zip>
	  <rtsId>NR501@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="081cdb03-4889-4fdc-bce3-8f6739eff502">
	  <name>South West Yorkshire Partnership Teaching NHS Foundation Trust</name>
	  <address>Trust Headquarters
Fieldhead Hospital
Ouchthorpe Lane</address>
	  <city>Wakefield</city>
	  <state/>
	  <country>England</country>
	  <zip>WF1 3SP</zip>
	  <rtsId>RXG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="ace4642f-0176-4e42-8f25-e907c2b5583f">
	  <name>Bradford District Care NHS Foundation Trust</name>
	  <address>New Mill
Victoria Road
Saltaire</address>
	  <city>Shipley</city>
	  <state/>
	  <country>England</country>
	  <zip>BD18 3LD</zip>
	  <rtsId>TAD@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4b1d4606-307b-40bf-9753-d7c0dbb4bf8d">
	  <name>Norfolk Community Health and Care NHS Trust</name>
	  <address>Research Office, Ground Floor, West Pottergate Medical Centre, Earlham Road</address>
	  <city>Norwich</city>
	  <state/>
	  <country>England</country>
	  <zip>NR2 4BX</zip>
	</trialCentre>
	<trialCentre id="5f61c966-38c4-488d-a2c2-bd4cbec27c48">
	  <name>Dane View Care Home with Nursing</name>
	  <address>165 Glenfield Road</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE3 6DP</zip>
	  <rtsId>VNC2X@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="5702ac56-c039-4264-bd20-a5307b1b5218">
	  <name>Central and North West London NHS Foundation Trust</name>
	  <address>Northwick Park Hospital, Mental Health Unit, Watford Road</address>
	  <city>Harrow</city>
	  <state/>
	  <country>England</country>
	  <zip>HA1 3UJ</zip>
	</trialCentre>
	<trialCentre id="c2b70f43-1f20-44fd-8506-9a36f4169c47">
	  <name>Mersey Care NHS Foundation Trust</name>
	  <address>Community Forensic Learning Disability Service
Secure Care Division, Alexander House
Station Brow Road</address>
	  <city>Leyland</city>
	  <state/>
	  <country>England</country>
	  <zip>PR25 3NZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Current key inclusion criteria as of 17/11/2026: 
WP1a:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property in the last 3 months)
4. Living in any setting including the family home and supported living/residential home
5. Can provide informed verbal or written consent
 
WP1b Psychometric Testing:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Are known to community ID services from participating NHS trusts or to voluntary groups for people with ID
4. Can provide informed verbal or written consent

WP1b Comparison Testing:
Service Users Inclusion Criteria:
1. Aged between 18 and 65 years
2. Under the care of a community psychiatric team or currently an inpatient in a psychiatric hospital in East London NHS Foundation Trust
3. Have a primary diagnosis of a mental health issue
4. Can provide informed verbal or written consent

WP2:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. History of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property) OR have a diagnosis of a mental health condition and are currently receiving or waiting for treatment
4. Living in any setting including the family home and supported living/residential home
5. Can provide informed verbal or written consent

WP3:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. History of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property) OR have a diagnosis of a mental health condition and are currently receiving or waiting for treatment
4. Residing in supported living or residential care
5. Can provide informed verbal or written consent


_____


Previous key inclusion criteria as of 01/09/2026: 

WP1a:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property in the last 3 months)
4. Living in any setting including the family home and supported living/residential home
5. Can provide informed verbal or written consent
 
WP1b Psychometric Testing:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Are known to community ID services from participating NHS trusts or to voluntary groups for people with ID
4. Can provide informed verbal or written consent

WP1b Comparison Testing:
Service Users Inclusion Criteria:
1. Aged between 18 and 65 years
2. Under the care of a community psychiatric team or currently an inpatient in a psychiatric hospital in East London NHS Foundation Trust
3. Have a primary diagnosis of a mental health issue
4. Can provide informed verbal or written consent

WP2:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property in the last 3 months)
4. Living in any setting including the family home and supported living/residential home
5. Can provide informed verbal or written consent

WP3:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, anger / frustration outbursts, or damage to property in the last 3 months)
4. Residing in supported living or residential care
5. Can provide informed verbal or written consent

WP1a
Clinicians Inclusion Criteria:
1. Aged 18 or over
2. Currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID
3. From any profession (e.g. psychology, nursing, speech and language therapy, psychiatry, social work), with a minimum of six months experience working with people with ID
4. Consent to participation

WP2 
Clinicians Inclusion Criteria:
1. Aged 18 or over
2. Currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID
3. From any profession (e.g. psychology, nursing, speech and language therapy, psychiatry, social work), with a minimum of six months experience working with people with ID
4. Consent to participation

WP3 
Care Workers Inclusion Criteria:
1. Aged 18 or over
2. Have worked in the care home for at least three months
3. Provide at least one day of support per week to service users
4. Consent to participation

_____

Previous inclusion criteria as of 16/04/2026:

WP1a:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, temper tantrums / outbursts, or damage to property in the last 3 months)
4. Living in any setting including the family home and supported living/residential home
5. Can provide informed verbal or written consent

WP1b Psychometric Testing:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Under community ID services from the East London Foundation Trust - Updated 04/11/2025: from participating NHS trusts
4. Can provide informed verbal or written consent

WP1b Comparison Testing:
Service Users Inclusion Criteria:
1. Aged between 18 and 65 years
2. Living in the community and treated as out-patients by community psychiatric teams from participating NHS trusts 
3. Have a primary diagnosis of a mental health issue 
4. Can provide informed verbal or written consent 

WP2:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, temper tantrums / outbursts, or damage to property in the last 3 months)
4. Living in any setting including the family home and supported living/residential home
5. Can provide informed verbal or written consent

WP3:
Service Users Inclusion Criteria:
1. Aged 18 years or over
2. Mild or moderate ID based on service records / clinical notes
3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical or verbal aggression, temper tantrums / outbursts, or damage to property in the last 3 months)
4. Residing in supported living or residential care
5. Can provide informed verbal or written consent

_____

Previous inclusion criteria:

WP1a
1. Service Users Inclusion Criteria:
   1. Aged 18 or over  
   2. Mild or moderate ID based on service records / clinical notes  
   3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical aggression or damage to property in the last 3 months)  
   4. Living in any setting including the family home and supported living/residential home  
   5. Can provide informed verbal or written consent  
2. Clinicians Inclusion Criteria:
   1. Aged 18 or over  
   2. Currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID  
   3. From any profession (e.g. psychology, nursing, speech and language therapy, psychiatry, social work), grade 4 and above with a minimum of six months experience working with people with ID  
   4. Consent to participation  
3. Care Workers Inclusion Criteria:
   1. Aged 18 or over  
   2. Have worked in the care home for at least three months  
   3. Provide at least one day of support per week to service users  
   4. Consent to participation  

WP1b
1. Service Users Inclusion Criteria:
   1. Aged 18 or over  
   2. Mild or moderate ID based on service records / clinical notes  
   3. Under community ID services from the East London Foundation Trust  - Updated 04/11/2025: from participating NHS trusts
   4. Can provide informed verbal or written consent  

WP2
1. Service Users Inclusion Criteria:
   1. Aged 18 or over  
   2. Mild or moderate ID based on service records / clinical notes  
   3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical aggression or damage to property in the last 3 months)  
   4. Living in any setting including the family home and supported living/residential home  
   5. Can provide informed verbal or written consent  
2. Clinicians Inclusion Criteria:
   1. Aged 18 or over  
   2. Currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID  
   3. From any profession (e.g. psychology, nursing, speech and language therapy, psychiatry, social work), grade 4 and above with a minimum of six months experience working with people with ID  
   4. Consent to participation  
   5. Have not participated in other work packages  
3. Participant Carers Inclusion Criteria:
   1. Aged 18 or over  
   2. Are paid or unpaid (e.g. family carer); if a paid carer, need to have worked with the person for at least six months and should know the person well and support the person on a regular basis  
   3. Consent to participation  

WP3
1. Service Users Inclusion Criteria:
   1. Aged 18 or over  
   2. Mild or moderate ID based on service records / clinical notes  
   3. Current history of behaviour that challenges (at least one incident of self-injurious behaviour, physical aggression or damage to property in the last 3 months)  
   4. Residing in supported living or residential care  
   5. Can provide informed verbal or written consent  
2. Care Homes Inclusion Criteria:
   1. Supported living or residential placements for service users with ID in the participating areas  
   2. Service manager has agreed for the care home to take part  
3. Care Workers Inclusion Criteria:
   1. Aged 18 or over  
   2. Have worked in the care home for at least three months  
   3. Provide at least one day of support per week to service users  
   4. Consent to participation  
   5. Have not participated in other work packages</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>502</targetEnrolment>
      <totalFinalEnrolment>472</totalFinalEnrolment>
      <exclusion>Current key exclusion criteria as of 01/09/2026: 

WP1a
Clinicians Exclusion Criteria:
1. Under 18 years of age
2. Not currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID
3. Less than 6 months experience working with people with ID
4. Do not consent to participation

WP1b Psychometric Testing:
Service Users Exclusion Criteria:
1. Under 18 years of age
2. Severe ID based on service records/clinical notes
3. Not known to community ID services from participating NHS trusts or to voluntary groups for people with ID
4. Unable to provide informed verbal or written consent

WP1b Comparison Testing:
1. Under 18 years of age and over 66 years of age
2. Do not have a primary mental health diagnosis (e.g., substance misuse disorder)
3. Unable to provide informed verbal or written consent

WP2
Clinicians Exclusion Criteria:
1. Under 18 years of age
2. Not currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID
3. Less than 6 months experience working with people with ID
4. Do not consent to participation

WP3
Care Workers Exclusion Criteria:
1. Under 18 years of age
2. Have worked in the care home for less than 3 months
3. Do not provide at least one day of support per week to service users
4. Do not consent to participation

_____

Previous exclusion criteria as of 16/04/2026:

WP1b Psychometric Testing:
Service Users Exclusion Criteria:
1. Under 18 years of age
2. Severe ID based on service records/clinical notes
3. Not under community ID services from the East London Foundation Trust - Updated 04/11/2025: from participating NHS trusts
4. Unable to provide informed verbal or written consent

WP1b Comparison Testing:
1. Under 18 years of age and over 66 years of age 
2. Currently in an inpatient in a psychiatric hospital 
3. Do not have a primary mental health diagnosis (e.g., substance misuse disorder)
4. Unable to provide informed verbal or written consent

_____

Previous exclusion criteria:

WP1a
1. Service Users Exclusion Criteria:
   1. Under 18 years of age  
   2. Severe ID based on service records / clinical notes  
   3. Likely to move out of borough within the next 3 months or at imminent risk of hospital admission  
   4. Unable to provide informed verbal or written consent  
2. Clinicians Exclusion Criteria:
   1. Under 18 years of age  
   2. Not currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID  
   3. Below grade 4 and less than 6 months experience working with people with ID  
   4. Do not consent to participation  
3. Care Workers Exclusion Criteria:  
   1. Under 18 years of age  
   2. Have worked in the care home for less than 3 months  
   3. Do not provide at least one day of support per week to service users  
   4. Do not consent to participation  

WP1b
1. Service Users Exclusion Criteria: 
   1. Under 18 years of age  
   2. Severe ID based on service records / clinical notes  
   3. Not under community ID services from the East London Foundation Trust  - Updated 04/11/2025: from participating NHS trusts
   4. Unable to provide informed verbal or written consent  

WP2
1. Service Users Exclusion Criteria:
   1. Under 18 years of age  
   2. Severe ID based on service records / clinical notes  
   3. Already participating in WP3 or involved in another clinical trial  
   4. Likely to move out of borough within the next 6 months or at imminent risk of hospital admission  
   5. Unable to provide informed verbal or written consent  
2. Clinicians Exclusion Criteria:  
   1. Under 18 years of age  
   2. Not currently working within a community ID service, intensive support team or in a local authority or social care organisation for people with ID  
   3. Below grade 4 and less than 6 months experience working with people with ID  
   4. Do not consent to participation  
   5. Have participated in other work packages 
3. Participant Carers Exclusion Criteria:
   1. Under 18 years of age  
   2. If a paid carer and have worked with the person for less than six months and/or do not know the person well and/or support the person on a regular basis  
   3. Do not consent to participation 

WP3
1. Service Users Exclusion Criteria:  
   1. Under 18 years of age  
   2. Severe ID based on service records / clinical notes  
   3. Already participating in WP2 or involved in another clinical trial  
   4. Likely to move out of the care home within the next six months or are at imminent risk of hospital admission  
   5. Unable to provide informed verbal or written consent  
2. Care Homes Exclusion Criteria:
   1. Not supported living or residential placements for service users with ID and/or not in the participating areas  
   2. Service manager does not agree for the care home to take part  
3. Care Workers Exclusion Criteria:
   1. Under 18 years of age  
   2. Have worked in the care home for less than 3 months  
   3. Do not provide at least one day of support per week to service users  
   4. Do not consent to participation  
   5. Have participated in other work packages</exclusion>
      <recruitmentStart>2025-08-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild to moderate intellectual disability</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Current interventions as of 16/04/2026:

An adapted version of DIALOG+ (a brief, low-cost solution-focused intervention that improves the therapeutic effectiveness of routine clinical meetings between patients and clinicians) for individuals with learning disability will be piloted for 2-4 weeks, the adapted scale tested for psychometric properties at 2 timepoints (within 24 hours-1 week) and comparison tested with the original DIALOG scale, and delivered in clinical and care home feasibility studies for 6 months.

_____

Previous interventions:

An adapted version of DIALOG+ (a brief, low-cost solution-focused intervention that improves the therapeutic effectiveness of routine clinical meetings between patients and clinicians) for individuals with learning disability will be piloted for 4-6 weeks, tested for psychometric properties at 2 timepoints (within 24 hours-1 week), and delivered in clinical and care home feasibility studies for 6 months.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8d9a82e3-b660-4cca-98fb-1ca96680be30" outputType="protocolfile" artefactType="LocalFile" dateCreated="2025-05-30T00:00:00.000Z" dateUploaded="2025-06-30T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="6003dfb0-844c-4af6-a553-045bcb24459d" originalFilename="47564 ICONIC_ WP1 2 and 3 Protocol v1.0 30.05.2025.pdf" downloadFilename="47564 ICONIC_ WP1 2 and 3 Protocol v1.0 30.05.2025.pdf" version="1.0" mimeType="application/pdf" length="651827" md5sum="4568e0d65fbd906a796445e923b512a4"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="cc1819be-b7b9-4b06-a102-2888d268ad93" outputType="protocolfile" artefactType="LocalFile" dateCreated="2025-10-14T00:00:00.000Z" dateUploaded="2025-11-04T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="7969177c-3c73-44d2-8686-e72b1ec0a78e" originalFilename="ISRCTN11440256_PROTOCOL_V3.0_14Oct2025.pdf" downloadFilename="ISRCTN11440256_PROTOCOL_V3.0_14Oct2025.pdf" version="3.0" mimeType="application/pdf" length="746942" md5sum="3152c1ad486bbc76c7d41a04e951bc25"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="ae99c668-3613-40e0-b2ae-eb60e62ee9ef" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-04-02T00:00:00.000Z" dateUploaded="2026-04-16T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="4f2b9443-e9af-4f49-9086-51d2b8b13c3d" originalFilename="ISRCTN11440256_WP1 2 and 3_PROTOCOL_V5.0_02Apr2026.pdf" downloadFilename="ISRCTN11440256_WP1 2 and 3_PROTOCOL_V5.0_02Apr2026.pdf" version="5.0" mimeType="application/pdf" length="784320" md5sum="096cbe3095124bcd27c3728b1f59aa94"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="4ae0183f-d82b-46c8-bdfc-0de672b57e8d" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-08-07T00:00:00.000Z" dateUploaded="2026-09-01T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="f4e82e02-6c9d-4771-b8bb-e7ce9f38ac7b" originalFilename="ISRCTN11440256 ICONIC_WP1 2 and 3 protocol v7.0 07.08.2026.pdf" downloadFilename="ISRCTN11440256 ICONIC_WP1 2 and 3 protocol v7.0 07.08.2026.pdf" version="7.0" mimeType="application/pdf" length="679559" md5sum="508e1db2b92f3a1d7372b6369bbd9c49"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="34c67564-d3d3-48d6-b2b0-632335427626" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-09-16T00:00:00.000Z" dateUploaded="2026-09-24T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="e806e700-96ca-4eec-b82d-e3047e0cc8a3" originalFilename="ISRCTN11440256_PROTOCOL_V8.0_16Sep2026.pdf" downloadFilename="ISRCTN11440256_PROTOCOL_V8.0_16Sep2026.pdf" version="8.0" mimeType="application/pdf" length="785067" md5sum="5b5323785ca6ea45878d669d18fae9a0"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="aa5352ee-672e-46c7-8bef-6e407dc274a7" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-10-15T00:00:00.000Z" dateUploaded="2026-11-18T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="18b7d033-43f0-404d-bc91-9700658e8bfe" originalFilename="ISRCTN11440256_Protocol WP1 2 and 3_v9.0_15Oct2026.pdf" downloadFilename="ISRCTN11440256_Protocol WP1 2 and 3_v9.0_15Oct2026.pdf" version="9.0" mimeType="application/pdf" length="797085" md5sum="d8ccafb62089f86ee0023e3711db5f29"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>086586ae-3919-40ae-b565-48eaf7fd7840</funderId>
      <contactId>5bfd6e0a-f6be-42db-af32-79e65800296e</contactId>
      <contactId>174d80bc-3550-48b2-8785-521553bef35e</contactId>
      <sponsorId>bd3c8ad4-709e-4148-8736-f221f3b481aa</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/6003dfb0-844c-4af6-a553-045bcb24459d/47564">
	<description>Protocol file</description>
	<name>47564 ICONIC_ WP1 2 and 3 Protocol v1.0 30.05.2025.pdf</name>
	<id>6003dfb0-844c-4af6-a553-045bcb24459d</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>651827</length>
	<md5sum>4568e0d65fbd906a796445e923b512a4</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/7969177c-3c73-44d2-8686-e72b1ec0a78e/47564">
	<description>Protocol file</description>
	<name>ISRCTN11440256_PROTOCOL_V3.0_14Oct2025.pdf</name>
	<id>7969177c-3c73-44d2-8686-e72b1ec0a78e</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>746942</length>
	<md5sum>3152c1ad486bbc76c7d41a04e951bc25</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/4f2b9443-e9af-4f49-9086-51d2b8b13c3d/47564">
	<description>Protocol file</description>
	<name>ISRCTN11440256_WP1 2 and 3_PROTOCOL_V5.0_02Apr2026.pdf</name>
	<id>4f2b9443-e9af-4f49-9086-51d2b8b13c3d</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>784320</length>
	<md5sum>096cbe3095124bcd27c3728b1f59aa94</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/f4e82e02-6c9d-4771-b8bb-e7ce9f38ac7b/47564">
	<description>Protocol file</description>
	<name>ISRCTN11440256 ICONIC_WP1 2 and 3 protocol v7.0 07.08.2026.pdf</name>
	<id>f4e82e02-6c9d-4771-b8bb-e7ce9f38ac7b</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>679559</length>
	<md5sum>508e1db2b92f3a1d7372b6369bbd9c49</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/e806e700-96ca-4eec-b82d-e3047e0cc8a3/47564">
	<description>Protocol file</description>
	<name>ISRCTN11440256_PROTOCOL_V8.0_16Sep2026.pdf</name>
	<id>e806e700-96ca-4eec-b82d-e3047e0cc8a3</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>785067</length>
	<md5sum>5b5323785ca6ea45878d669d18fae9a0</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/18b7d033-43f0-404d-bc91-9700658e8bfe/47564">
	<description>Protocol file</description>
	<name>ISRCTN11440256_Protocol WP1 2 and 3_v9.0_15Oct2026.pdf</name>
	<id>18b7d033-43f0-404d-bc91-9700658e8bfe</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>797085</length>
	<md5sum>d8ccafb62089f86ee0023e3711db5f29</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="5bfd6e0a-f6be-42db-af32-79e65800296e">
    <title>Miss</title>
    <forename>Laura</forename>
    <surname>Miller</surname>
    <orcid>https://orcid.org/0000-0001-8802-3554</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Unit for Adult Mental Health and Wellbeing
Centre for Psychiatry and Mental Health (CPMH)
Wolfson Institute of Population Health
Queen Mary University of London
Yvonne Carter Building, 58 Turner Street</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>E1 2AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7352 980401</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.miller@qmul.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="174d80bc-3550-48b2-8785-521553bef35e">
    <title>Dr</title>
    <forename>Afia</forename>
    <surname>Ali</surname>
    <orcid>https://orcid.org/0000-0002-0104-9370</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Unit for Adult Mental Health and Wellbeing
Centre for Psychiatry and Mental Health (CPMH)
Wolfson Institute of Population Health
Queen Mary University of London
Yvonne Carter Building, 58 Turner Street</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>E1 2AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7836 584017</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">afia.ali@qmul.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="bd3c8ad4-709e-4148-8736-f221f3b481aa">
    <organisation>North East London NHS Foundation Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/023e5m798</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="086586ae-3919-40ae-b565-48eaf7fd7840">
    <name>NIHR Central Commissioning Facility (CCF)</name>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-03-26T16:06:05.185285356Z" version="56" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN20868432" publicIdentifierDateAssigned="2023-08-21T10:21:10.013131Z">
    <isrctn dateAssigned="2023-08-21T10:21:10.013131Z">20868432</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Compassion focused therapy - for mood in dementia</title>
      <scientificTitle>Being kind to ourselves: A randomised controlled trial of compassion focused therapy (CFT) to improve symptoms of depression and anxiety in dementia</scientificTitle>
      <acronym/>
      <studyHypothesis>Secondary study objectives:
The aims/objectives will be to: 
1. Evaluate the efficacy of CFT in improving depression (primary outcome, measured by the Cornell Scale for Depression in Dementia, anxiety, quality of life, cognition, self-compassion, and the caregiver-patient relationship in people with dementia, compared to TAU; at 16 weeks and 6 months.
2. Evaluate caregiver burden and caregiver perception of the caregiver-patient relationship (if caregiver is available to participate), compared to TAU, at 16 weeks and 6 months. 
3. Assess the cost-effectiveness of group CFT compared to TAU at 16 weeks by estimating the incremental cost per ‘Quality Adjusted Life Year’ (QALY) gained. 
4. Explore: 
4.1. Differences in outcomes between face-to-face and online groups
4.2. Participants’ preferences for delivery format and
4.3. Potential predictors of success in the intervention (such as baseline mood, cognitive impairment, engagement (or not) of a caregiver and demographic factors) as part of a secondary, exploratory analysis. 

Previous study objectives:
As this is an unpowered feasibility study, we are not hypothesising significant changes in any outcomes. However, we will explore changes in outcomes pre- and post-intervention, comparing the treatment and control groups (TAU), and may expect some positive trends. We are also exploring the differences between online and f2f groups and have no current hypothesis in terms on superiority. 
The main objectives of the study are: 
1. To undertake a feasibility Randomised Controlled Trial (RCT) to assess critical elements of a full RCT of Compassion Focused Therapy (CFT) in dementia. These include eligibility rates, recruitment and attrition rates, data collection and intervention delivery; 
2. To establish acceptability of CFT as an online or face-to-face intervention for people with dementia; 
3. To assess intervention fidelity; 
4. To establish preliminary intervention efficacy; 
5. To establish suitability of study outcome measures including cost-effectiveness measures; 
6. To gather data to inform the decision of the primary outcome for a full RCT and obtain estimates of parameters to inform the calculation of the required sample size for a full RCT; 
7. To use qualitative and quantitative findings to modify the treatment manual (if required).</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Of the 850,000 people with dementia in the UK, many experience depression, anxiety or both. This can worsen cognition (e.g., memory and language) and behavioural problems, lead to relationship difficulties, and increase care home admissions. With medications for mood in dementia often ineffective, recent trends have moved towards nondrug interventions. However, the lack of interventions available with proven effects results in significant unmet needs. Compassion Focused Therapy is a talking therapy which addresses feelings of shame and stigma. Our team tested Compassion Focused Therapy with seven people with dementia, finding small improvements in depression, anxiety and self-criticism. One person said: “I have accepted the fact that I have a ‘memory problem’ and am happy being me. I do not blame myself anymore for something that’s not my fault.”
This project will assess Compassion Focused Therapy in the form of a randomised controlled trial, following encouraging results from our feasibility study. Participants will be randomly allocated to either the intervention (twelve sessions of group Compassion Focused Therapy, delivered online or face-to-face) or the control group (usual care only). The outcome measures will be depression, anxiety, quality of life, cognition, self-compassion, relationship between caregiver and caregiver burden (where relevant) and costs, measured before and after the intervention period. These will be assessed at the start of the study, after the intervention, and at the 6-month follow-up. We will also explore participants’ preferences for how the therapy is delivered, differences between online and face-to-face groups, and factors that may influence how well the intervention works.
This randomised controlled trial builds directly on our earlier feasibility study, with that data included as part of the final analysis. Our aim is to see whether Compassion-Focused Therapy helps people with dementia who are experiencing low mood and whether it is a cost-effective approach.

Who can participate?
A person can put themselves forward to the research team if they:
1. Have been diagnosed with mild to moderate dementia
2. Experience symptoms of anxiety or depression
3. Have capacity to consent to take part in research
4. Can communicate in English
5. Have access to WiFi, enabling them to partake in online Compassion Focused Therapy groups, OR the ability to attend a face-to-face group
6. Are not participating in another interventional research programme concurrently
7. Have sufficient hearing to engage in group discussions (with or without hearing aids)
8. Aged 18 years and over
9. People can be included whether or not they have a caregiver

What does the study involve?
If a participant chooses to take part, they will be randomly assigned to either the Compassion Focused Therapy group or a ‘control’ group. There is an equal, 50/50 chance of them being in either group. If they are in the control group, they will not receive any additional treatment.
The participants' preference towards virtual or face-to-face meetings will be recorded and we will aim to allocate delivery of these Compassion Focused Therapy sessions accordingly. If the participant is randomly allocated to the intervention group, they will be invited to attend twelve, 60-minute online or face-to-face small group Compassion Focused Therapy sessions. These will occur once a week for twelve weeks. The sessions will involve meeting with a clinical professional and other people with dementia to discuss topics such as low mood, memory problems, and coping mechanisms. During the sessions the participant will also do activities such as gentle breathing and self-compassion exercises. There will be time to reflect as a group on the emotional experience of living with dementia. Sessions will end with suggesting home practices, with participants given session summaries. There will be time for social interaction before and after the session, either over a video conference platform or face-to-face.
If the participant is randomised to the Compassion Focused Therapy group, we will run a brief workshop for carers/supporters (if applicable) around the beginning of the Compassion Focused Therapy programme. This will provide information on the principles of Compassion Focused Therapy, an outline of what we intend to do in sessions and tips on what can be done at home to support the person receiving therapy in between sessions. 
Regardless of which group the participant is allocated to (Compassion Focused Therapy or control), they will continue to have access to their usual care, including input from health and social care professionals, dementia medication, and their usual day activities.
Following discussion of any questions they may have with a researcher and signing the consent form, all participants will be asked to:
1. Meet with a researcher for approximately 1.5 hours to answer questions about their mood, anxiety, quality of life, and thinking. If applicable, we will also invite carers/supporters to attend this meeting.
2. Meet with a researcher again after the 12 Compassion-Focused Therapy sessions to answer the same questions as before and again 6 months after the initial assessment. Each follow-up will take approximately 1.5 hours.

What are the possible benefits and risks of participating?
We appreciate that when an individual experiences memory problems, it may be hard to talk about things like mood and quality of life. The researchers carrying out the assessment, intervention, and interview have clinical experience and are working under supervision. The participant will be encouraged but never forced to take part in a particular activity during the sessions.
Overall, the risks of taking part in this study are minimal. However, some people find that certain types of therapy do not help them or make them feel worse. If a participant finds any part of the study distressing, let us know and we can try to resolve the difficulty together or discuss other options of support. The participant is always free to withdraw from the study at any point.
If the participant loses capacity to consent, they will be withdrawn from the study and no further data will be collected; however, data collected up until that point will be retained for use in the study. Withdrawing from the study will not affect the standard of care the participant receives.
If a participant takes part in the study and is allocated to the intervention group, we hope that their attendance at the sessions is a helpful experience. Previous research into compassion suggests that people can experience greater awareness, acceptance, control, improved coping and wellbeing. Regardless of whether the participant receives the intervention or not, the information we get from this study may help us to support people with dementia and their carers/supporters better in future.

Where is the study run from?
Recruitment will primarily take place through the NHS Foundation Trusts of North East London, Oxford Health, Norfolk and Suffolk, Black Country Healthcare, Central and North West London, Lincolnshire Partnership, Cheshire and Wirral Partnership and Devon Partnership. We will also recruit through ‘Join Dementia Research’, an online recruitment platform.

When is the study starting and how long is it expected to run for?
November 2023 to October 2028 

Who is funding the study?
National Institute for Health and Research, the Research for Patient Benefit Programme (UK)

Who is the main contact?
Melissa Melville, Melissa.melville@nelft.nhs.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Current primary outcomes as of 26/03/2026:
Symptoms of depression measured by the Cornell Scale for Depression in Dementia (Cornell) at 16 weeks (post-intervention) 

Previous primary outcomes:
Feasibility outcomes:
1. Feasibility of recruitment and retention, assessed by:
1.1. Successful recruitment of the target sample (50 people) in 14-months
1.2. Retention rate of at least 75% of participants to 16 week follow up. We will also evaluate how feasible it is to recruit anxious people to a group intervention how anxiety impacts upon uptake.
2. Acceptability of the intervention, assessed by:
2.1. Overall attendance and retention rates amongst the CFT participants (over 60%)
2.2. Any negative or adverse events related to the intervention
2.3. Level of engagement in the sessions, measured using participation forms developed alongside the CFT manual, (d) preference of virtual or face-to-face. 
3. Fidelity, assessed by:
3.1. Therapist completion of the fidelity checklist following each session and
3.2. Audio recording all sessions and an independent researcher rating fidelity with a random 10% of the recordings. A total, mean fidelity score and percentage will be calculated for each CFT session. These scores will be compared across site and provider. We will also compare self-report with observer ratings, providing some idea about the utility of self-report in a future trial.</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>Current secondary outcomes as of 26/03/2026:
1. Symptoms of depression measured by the Cornell Scale for Depression in Dementia (Cornell) at 6 months
2. Symptoms of anxiety measured by the Rating Anxiety in Dementia Scale (RAID) at 16 weeks (post-intervention) and 6 months
3. Quality of life and proxy quality of life measured by the Dementia Quality of Life Scale (DEMQOL) at 16 weeks (post-intervention) and 6 months
4. Health-related quality of life measured by the EQ-5D-5L at 16 weeks (post-intervention) and 6 months
5. Cognitive function measured by the Montreal Cognitive Assessment (MoCA) at 16 weeks (post-intervention) and 6 months
6. Self compassion measured by the Short Self-Compassion Scale (SCS-SF) at 16 weeks (post-intervention) and 6 months
7. Relationship with caregiver measured by the Quality of Caregiver and Patient Relationship scale (QCPRS) at 16 weeks (post-intervention) and 6 months
8. Resource use measured by the Client Service Receipt Inventory (CSRI) at 16 weeks (post-intervention) and 6 months
9. Relationship with caregiver, from both the perspective of the person with dementia and the caregiver, measured by the 10. Quality of Caregiver and Patient Relationship scale (QPCR) at 16 weeks (post-intervention) and 6 months
11. Caregiver burden measured by the Zarit Burden Interview (ZBI) at 16 weeks (post-intervention) and 6 months

Previous secondary outcomes:
1. Symptoms of depression are measured by the Cornell Scale for Depression in Dementia, at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months.
2. Symptoms of anxiety is measured using the Rating Anxiety in Dementia Scale (RAID) scale, at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
3. Quality of life is measured using the EQ-5D-5L scale, at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months 
4. Quality of life  is measured using the DEMQOL scale, DEMQOL-proxy is collected from the carer (if available), at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
5. Carer burden is measured using the Zarit Burden Interview scale, at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
6. Resource use is measure by the Client Service Receipt Inventory, at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
7. Relationship with caregiver is measured by the Quality of Caregiver and Patient Relationship scale (QCPR) at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
8. Self compassion is measured by the Short-Self-Compassion Scale (SCS-SF), at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
9. Cognitive function is measured by the Montreal Cognitive Assessment (MoCA), at baseline (pre-intervention), 16 weeks (post-intervention) and 6 months
10. Secondary outcomes also include the post intervention qualitative interviews with carers /supporters, service managers, clinical professionals facilitating CFT and participants receiving CFT. Qualitative interviews will be used to gather participant, carer/ supporter and clinician perspectives on the value, acceptability and feasibility of the intervention. We will conduct semi-structured, audio-recorded interviews (performed over videoconferencing software or face-to-face) with up to 20 participants with dementia (including up to 10 control group participants with dementia, in order to explore trial procedures from perspective of those who did not participate in the intervention). We will also interview up to 15 carers / supporters (including those who did not attend the workshop to better explore barriers to attendance). We will approach and plan to interview up to 10 NHS personnel (including group facilitators and service managers) for qualitative interviews to determine feasibility of implementation. Qualitative analysis will follow Braun and Clarke’s methods of thematic analysis and will be done using NVivo.</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="dab80680-62ce-4bb4-9383-15d7db52afad" approvalStatus="approved" statusDate="2023-08-11T00:00:00.000Z">
	  <committeeName>London Riverside</committeeName>
	  <contactDetails>
	    <address>2 Redman Place,  Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>23/LO/0535</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20868432</doi>
      <eudraCTNumber/>
      <irasNumber>327086</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 57107, NIHR: 203524</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="ae319cc5-5650-4da7-926f-97c1ea0f8be9" numberType="iras" canonicalSecondaryNumber="IRAS327086">327086</secondaryNumber>
	<secondaryNumber id="a9da6304-4724-4c5b-897c-d194ff84ee19" numberType="cpms" canonicalSecondaryNumber="CPMS57107">57107</secondaryNumber>
	<secondaryNumber id="b9fd7b93-be1e-448a-9a9a-9cd7bd59b6be" numberType="nihr" canonicalSecondaryNumber="NIHR203524">203524</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2028-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="91845ea6-98bc-44b3-860c-e5d42c1c83d4">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="27ae0b03-9253-4d87-96ce-9cc7c3575ab9">
	  <name>Oxford Health NHS Foundation Trust</name>
	  <address>Warneford Hospital
Warneford Lane
Headington</address>
	  <city>Oxford</city>
	  <state/>
	  <country>England</country>
	  <zip>OX3 7JX</zip>
	  <rtsId>RNU@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="68650086-cf98-4853-aebc-7742523a7721">
	  <name>Norfolk and Suffolk NHS Foundation Trust</name>
	  <address>Drayton High Rd</address>
	  <city>Norwich</city>
	  <state/>
	  <country>England</country>
	  <zip>NR6 5BE</zip>
	</trialCentre>
	<trialCentre id="a6520ca6-ce42-4398-8f52-f75599e50033">
	  <name>Black Country Healthcare NHS Foundation Trust</name>
	  <address>2nd Floor, Trafalgar House, 47-49 King St</address>
	  <city>Dudley</city>
	  <state/>
	  <country>England</country>
	  <zip>DY2 8PS</zip>
	</trialCentre>
	<trialCentre id="6110d01b-da49-4967-886a-a763a2052b3d">
	  <name>Central and North West London NHS Foundation Trust</name>
	  <address>Trust Headquarters
350 Euston Road
Regents PLACE</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 3AX</zip>
	  <rtsId>RV3@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="eeef64a3-a561-4acb-a572-5c07a11631ce">
	  <name>Lincolnshire Partnership NHS Foundation Trust</name>
	  <address>St George's
Long Leys Road</address>
	  <city>Lincoln</city>
	  <state/>
	  <country>England</country>
	  <zip>LN1 1FS</zip>
	  <rtsId>RP7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e11d241c-c5ff-45ea-9d38-dcdcdade2e46">
	  <name>Cheshire and Wirral Partnership NHS Foundation Trust</name>
	  <address>Trust Headquarters Redesmere
The Countess of Chester Health Park
Liverpool Road</address>
	  <city>Chester</city>
	  <state/>
	  <country>England</country>
	  <zip>CH2 1BQ</zip>
	  <rtsId>RXA@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bcaaaa79-593a-421e-bb7f-a984e15baa10">
	  <name>Devon Partnership NHS Trust</name>
	  <address>Wonford House Hospital
Dryden Road</address>
	  <city>Exeter</city>
	  <state/>
	  <country>England</country>
	  <zip>EX2 5AF</zip>
	  <rtsId>RWV@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Current inclusion criteria as of 26/03/2026:
1. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for dementia of any type
2. Mild to moderate dementia as determined by the following: 
2.1. A confirmed dementia diagnosis based on DSM-IV criteria for any type of dementia, AND
2.2. A Clinical Dementia Rating (CDR) score of 0.5, 1, or 2 (Morris, 1997). 
3. Experience symptoms of depression and/or anxiety as determined by either:
3.1. A HADS score ≥ 8 on the anxiety and/or depression subscale (Zigmond &amp; Snaith, 1983), OR
3.2. A HADS score of 5–7, accompanied by evidence of low mood as reported by a caregiver or clinician, OR
3.3. Significant psychological distress, as assessed by a clinician or researcher, regardless of the HADS score. 
4. Have capacity to consent to take part in research
5. Can communicate in English
6. Have access to WiFi, enabling them to partake in virtual CFT groups, OR the ability to attend a face-to-face group
7. Are not participating in another interventional research programme concurrently
8. Have sufficient hearing to engage in group discussions (with or without hearing aids).
9. Aged 18 years and over
10. People can be included whether or not they have a caregiver.

Previous inclusion criteria as of 05/09/2024: 
1. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for dementia of any type
2. Mild to moderate dementia as determined by the Clinical Dementia Rating (CDR)
3. Experience symptoms of depression and/or anxiety (8 ≥) as measured by the Hospital Anxiety and Depression Scale (HADS) OR a minimum score of 5 and experience of depression and/or anxiety as reported by either the caregiver or clinician
4. Have capacity to consent to take part in research
5. Can communicate in English
6. Have access to WiFi, enabling them to partake in virtual CFT groups, OR the ability to attend a face-to-face group
7. Are not participating in another interventional research programme concurrently
8. Aged 18 years and over
9. People can be included whether or not they have a caregiver.

Original inclusion criteria: 
1. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for dementia of any type
2. Mild to moderate dementia as determined by the Clinical Dementia Rating (CDR)
3. Experience symptoms of depression and/or anxiety (8 &gt; = ) as measured by the Hospital Anxiety and Depression Scale (HADS);
4. Have capacity to consent to take part in research; 
5. Can communicate in English, 
6. Have access to WiFi, enabling them to partake in virtual CFT groups, OR the ability to attend a face-to-face group; 
7. Are not participating in another interventional research programme concurrently. 
8. Aged 18 years and over
9. People can be included whether or not they have a caregiver.</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>304</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Communication is significantly impaired by cognitive decline
2. Unable to speak English
3. The participant is currently participating in another interventional research programme. 
4. The participant has severe cognitive impairment as measured by the Clinical Dementia Rating scale.</exclusion>
      <recruitmentStart>2023-11-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dementia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Current interventions as of 26/03/2026:
This will be a single-blind randomised controlled trial of group CFT versus treatment as usual (TAU). 304 participants will be randomised to either the intervention group or control group (TAU). Randomisation will occur after baseline assessments are completed. Where possible, assessments will be collected by a researcher who is blind to group allocation. Assessments will be delivered virtually or face-to-face, depending on patient preference. Demographics and general information will be collected including age, gender, ethnic group, use of medication (including antidepressants, anxiolytics and cholinesterase inhibitors), treatment preference, participation in other activities and presence / absence of a carer/ supporter. Baseline assessments will include measures of quality of life, symptoms of depression and symptoms of anxiety, a measure of self-compassion, cognitive function, resource use, relationship with caregiver and caregiver burden (if applicable). Each arm will have approximately 150 participants and they will be allocated to one CFT group with up to 7 participants in each group.

The duration of the intervention will be 15 weeks, consisting of 12 CFT therapy sessions. Given that it can prove difficult to always fit the 12 sessions into 12 consecutive weeks (due to factors such as weather issues, therapist annual leave, strikes, illness), the additional 3 weeks provides a buffer and may increase the likelihood that participants could receive all 12 sessions. There will be assessments at baseline during the week prior to randomisation, and at the end of the intervention at 16 weeks and at 6 months follow-up. Twelve, 60-minute virtual or face-to-face group CFT sessions including three phases. Phase 1 involves setting up and introducing CFT including psychoeducation on emotion regulation systems, formulation and goal setting. Phase 2 teaches people techniques to develop self-compassion, including imagery and the writing of compassionate letters. Phase 3 teaches techniques to tolerate difficult feelings, focusing on ending and maintaining benefits. Sessions will include a core CFT practice, for example ‘soothing rhythm breathing’ which involves slowing and deepening the breath. Each session will introduce a new concept, such as the qualities of compassion, mindful awareness and understanding the function of self-criticism. There will be time to reflect on the emotional experience of living with dementia, e.g., how the diagnosis can be experienced as a ‘threat’ to the self and future, triggering fear, anxiety and disconnection. Sessions will end with suggesting home practices, with participants given session summaries. CFT will be adapted to compensate for cognitive changes, including frequent repetition and use of visual and verbal information. Building on the experience of running CST groups, groups will consist of approximately five people. We will factor in time for social interaction before and after the session, either virtually or face-to-face.

Additional carer/supporter workshop: we will run a brief workshop (flexibility for online or face-to-face) for primary carers/supporters (if available) towards the beginning of the CFT programme. This will educate carers on the principles of CFT, providing an outline of what we intend to do in the sessions and giving people tips on what can be done at home to encourage and support the therapy (for example, reminding the person to do breathing or relaxation exercises).

The intervention group will continue to have access to their usual care, which includes input from health and social care professionals, anti-dementia medication and their usual day activities.

Control group:
Defined as standard treatment available to people with dementia and depression and/or anxiety, which might include medication, other therapies, day care, input from health and social care professionals such as psychiatrists, psychologists and social workers or no treatment. We will collect information on all health and care services used by people with dementia (which we can compare with ongoing observational studies such as IDEAL) to describe what TAU involves for each participant; this can be taken into account in a future, fully powered trial. As both groups will have access to TAU, this study will look at the additional impact of CFT.

For those who do not own a tablet and wish to complete the online intervention, ten tablets will be purchased and lent to those participants, aiming to maximise inclusivity.


Previous interventions:
This will be a single blind, feasibility randomised controlled trial of group CFT versus treatment as usual (TAU). Fifty participants will be randomised to either the intervention group or control group (TAU). Randomisation will occur after baseline assessments are completed. Where possible, assessments will be collected by a researcher who is blind to group allocation. Assessments will be delivered virtually or face-to-face, depending on patient preference. Demographics and general information will be collected including age, gender, ethnic group, use of medication (including antidepressants, anxiolytics and cholinesterase inhibitors), treatment preference, participation in other activities and presence / absence of a carer/ supporter. Baseline assessments will include measures of quality of life, symptoms of depression and symptoms of anxiety, a measure of self-compassion, cognitive function, resource use, relationship with caregiver and caregiver burden (if applicable). Each arm will have approximately 25 participants and they will be allocated to one CFT group with up to 5 participants in each group.

The duration of the intervention will be 15 weeks, consisting of 12 CFT therapy sessions.  Given that it can prove difficult to always fit the 12 sessions into 12 consecutive weeks (due to factors such as weather issues / therapist annual leave, strikes, illness), the additional 3 weeks provides a buffer and may increase the likelihood that participants could receive all 12 sessions. There will be assessments at baseline during the week prior to randomisation, and at the end of the intervention at 16 weeks and at 6 months follow-up. Twelve, 60-minute virtual or face-to-face group CFT sessions including three phases. Phase 1 involves setting up and introducing CFT including psychoeducation on emotion regulation systems, formulation and goal setting. Phase 2 teaches people techniques to develop self-compassion, including imagery and the writing of compassionate letters. Phase 3 teaches techniques to tolerate difficult feelings, focusing on ending and maintaining benefits. Sessions will begin with a core CFT practice, for example ‘soothing rhythm breathing’ which involves slowing and deepening the breath. Each session will introduce a new concept, such as the qualities of compassion, mindful awareness and understanding the function of self-criticism. There will be time to reflect on the emotional experience of living with dementia, e.g., how the diagnosis can be experienced as a ‘threat’ to the self and future, triggering fear, anxiety and disconnection. Sessions will end with suggesting home practices, with participants given session summaries. CFT will be adapted to compensate for cognitive changes, including frequent repetition and use of visual and verbal information. Building on the experience of running CST groups, groups will consist of approximately five people. We will factor in time for social interaction before and after the session, either virtually or face-to-face.

Additional carer/supporter workshop: we will run a brief workshop (flexibility for online or face-to-face) for primary carers/supporters (if available) towards the beginning of the CFT programme. This will educate carers on the principles of CFT, providing an outline of what we intend to do in the sessions and giving people tips on what can be done at home to encourage and support the therapy (for example, reminding the person to do breathing or relaxation exercises).

The intervention group will continue to have access to their usual care, which includes input from health and social care professionals, anti-dementia medication and their usual day activities.

Control group:
Defined as standard treatment available to people with dementia and depression and/or anxiety, which might include medication, other therapies, day care, input from health and social care professionals such as psychiatrists, psychologists and social workers or no treatment. We will collect information on all health and care services used by people with dementia (which we can compare with ongoing observational studies such as IDEAL) to describe what TAU involves for each participant; this can be taken into account in a future, fully powered trial. As both groups will have access to TAU, this study will look at the additional impact of CFT.

For those who do not own a tablet and wish to complete the online intervention, ten tablets will be purchased and lent to those participants, aiming to maximise inclusivity.

Qualitative interviews will be used to gather participant, carer/supporter and clinician perspectives on the value, acceptability and feasibility of the intervention.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and analysed during the current study will be available upon request from Professor Aimee Spector (aimee.spector@nelft.nhs.uk). The data will be pseudonymised and uploaded into a repository. Professor Spector will consult with NELFT as the sponsor on a case-by-case basis regarding each data request received.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails>2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/39627126/ (added 04/12/2024)</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4ddf988a-77cf-463c-a43a-77246709a323" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2024-12-03T00:00:00.000Z" dateUploaded="2024-12-04T00:00:00.000Z" peerReviewed="true" patientFacing="false" createdBy="">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/39627126/"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="7b210da2-00d0-40d5-b7f8-d526d61f7415" outputType="pis" artefactType="LocalFile" dateCreated="2023-08-08T00:00:00.000Z" dateUploaded="2023-08-17T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="14a7428e-4c88-41bc-891b-b99b56de1296" originalFilename="44126 PIS v2.0 08Aug2023.pdf" downloadFilename="44126 PIS v2.0 08Aug2023.pdf" version="2.0" mimeType="application/pdf" length="244386" md5sum="461565e84be2c77e4138bea7676a5a43"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="0ed1e375-bebe-4638-901a-1bf86600f5af" outputType="pis" artefactType="LocalFile" dateCreated="2023-10-04T00:00:00.000Z" dateUploaded="2024-09-05T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="2797baae-be93-4879-9b2e-0cf329b5c12a" originalFilename="ISRCTN20868432_PIS_V3.0_04Oct2023.pdf" downloadFilename="ISRCTN20868432_PIS_V3.0_04Oct2023.pdf" version="3.0" mimeType="application/pdf" length="186747" md5sum="6649781fefedee9abe86fda8b9b46f5e"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="9b8fb7fe-a21e-42d6-9de1-d34a61757390" outputType="pis" artefactType="LocalFile" dateCreated="2026-02-02T00:00:00.000Z" dateUploaded="2026-03-26T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="75a170ee-3417-4466-87d4-991b8fbe09bc" originalFilename="ISRCTN20868432_PIS_CarerSupporter_V1.0_02Feb2026.pdf" downloadFilename="ISRCTN20868432_PIS_CarerSupporter_V1.0_02Feb2026.pdf" version="1.0" mimeType="application/pdf" length="281346" md5sum="0c8cfc7fa8130c04f33ecd822a8059a9"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="344c57b0-bd0a-4b10-ae2a-1c58fd22f8be" outputType="pis" artefactType="LocalFile" dateCreated="2026-02-02T00:00:00.000Z" dateUploaded="2026-03-26T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="24f136d9-ba49-4f5f-9537-a71282f76c59" originalFilename="ISRCTN20868432_PIS_Participant_V1.0_02Feb2026.pdf" downloadFilename="ISRCTN20868432_PIS_Participant_V1.0_02Feb2026.pdf" version="1.0" mimeType="application/pdf" length="288369" md5sum="9f027482750f4e0a03616b62fc6637a0"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="bf24a350-d49a-4512-adc5-47fb316b55a1" outputType="protocolfile" artefactType="LocalFile" dateCreated="2023-08-09T00:00:00.000Z" dateUploaded="2023-08-21T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="ed16c5b5-755f-4205-9ae6-2a4d3d82ff6d" originalFilename="44126 CFT_Protocol_V2.0_09.08.23.pdf" downloadFilename="44126 CFT_Protocol_V2.0_09.08.23.pdf" version="2.0" mimeType="application/pdf" length="1506618" md5sum="85747b50b0bdaa58d44c13ab8b9b6096"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="e28ba366-9f04-447d-8da8-5cb4e1ad7203" outputType="protocolfile" artefactType="LocalFile" dateCreated="2024-08-27T00:00:00.000Z" dateUploaded="2024-09-05T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="9be35850-a51a-4e41-b823-965c2e9ba1af" originalFilename="ISRCTN20868432_Protocol_V7.0_27Aug2024.pdf" downloadFilename="ISRCTN20868432_Protocol_V7.0_27Aug2024.pdf" version="7.0" mimeType="application/pdf" length="708284" md5sum="f497040bac88eabe665e112dd58b7e33"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="98388052-f015-4779-a293-a98a1884e771" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-01-21T00:00:00.000Z" dateUploaded="2026-03-26T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="63356482-1428-4da8-b39b-4b999bd98896" originalFilename="ISRCTN20868432_PROTOCOL_V12_21Jan2026.pdf" downloadFilename="ISRCTN20868432_PROTOCOL_V12_21Jan2026.pdf" version="12" mimeType="application/pdf" length="949424" md5sum="9376094a3ab4c0f3a3d6eba1f363dc7b"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>d34c42f7-91a5-4433-a2e9-cc481d5e17d7</funderId>
      <contactId>a59a7449-72fc-495f-b20f-98dd2fb117c2</contactId>
      <sponsorId>d61b73c6-d02a-400a-9d1a-bbc252ca2a16</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/14a7428e-4c88-41bc-891b-b99b56de1296/44126">
	<description>Participant information sheet</description>
	<name>44126 PIS v2.0 08Aug2023.pdf</name>
	<id>14a7428e-4c88-41bc-891b-b99b56de1296</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>244386</length>
	<md5sum>461565e84be2c77e4138bea7676a5a43</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/ed16c5b5-755f-4205-9ae6-2a4d3d82ff6d/44126">
	<description>Protocol file</description>
	<name>44126 CFT_Protocol_V2.0_09.08.23.pdf</name>
	<id>ed16c5b5-755f-4205-9ae6-2a4d3d82ff6d</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1506618</length>
	<md5sum>85747b50b0bdaa58d44c13ab8b9b6096</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/9be35850-a51a-4e41-b823-965c2e9ba1af/44126">
	<description>Protocol file</description>
	<name>ISRCTN20868432_Protocol_V7.0_27Aug2024.pdf</name>
	<id>9be35850-a51a-4e41-b823-965c2e9ba1af</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>708284</length>
	<md5sum>f497040bac88eabe665e112dd58b7e33</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/2797baae-be93-4879-9b2e-0cf329b5c12a/44126">
	<description>Participant information sheet</description>
	<name>ISRCTN20868432_PIS_V3.0_04Oct2023.pdf</name>
	<id>2797baae-be93-4879-9b2e-0cf329b5c12a</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>186747</length>
	<md5sum>6649781fefedee9abe86fda8b9b46f5e</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/63356482-1428-4da8-b39b-4b999bd98896/44126">
	<description>Protocol file</description>
	<name>ISRCTN20868432_PROTOCOL_V12_21Jan2026.pdf</name>
	<id>63356482-1428-4da8-b39b-4b999bd98896</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>949424</length>
	<md5sum>9376094a3ab4c0f3a3d6eba1f363dc7b</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/75a170ee-3417-4466-87d4-991b8fbe09bc/44126">
	<description>Participant information sheet</description>
	<name>ISRCTN20868432_PIS_CarerSupporter_V1.0_02Feb2026.pdf</name>
	<id>75a170ee-3417-4466-87d4-991b8fbe09bc</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>281346</length>
	<md5sum>0c8cfc7fa8130c04f33ecd822a8059a9</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/24f136d9-ba49-4f5f-9537-a71282f76c59/44126">
	<description>Participant information sheet</description>
	<name>ISRCTN20868432_PIS_Participant_V1.0_02Feb2026.pdf</name>
	<id>24f136d9-ba49-4f5f-9537-a71282f76c59</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>288369</length>
	<md5sum>9f027482750f4e0a03616b62fc6637a0</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="a59a7449-72fc-495f-b20f-98dd2fb117c2">
    <title>Miss</title>
    <forename>Melissa</forename>
    <surname>Melville</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>North East London Foundation Trust 
Research and Development Department
1st Floor Maggie Lilley Suite
Goodmayes Hospital
Barley Lane</address>
      <city>Ilford</city>
      <state/>
      <country>United Kingdom</country>
      <zip>IG3 8XJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 300 300 1748</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Melissa.melville@nelft.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="d61b73c6-d02a-400a-9d1a-bbc252ca2a16">
    <organisation>North East London NHS Foundation Trust</organisation>
    <sponsorType>University/education</sponsorType>
    <rorId>https://ror.org/023e5m798</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="d34c42f7-91a5-4433-a2e9-cc481d5e17d7">
    <name>NIHR Central Commissioning Facility (CCF)</name>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-22T10:44:04.270133501Z" version="57" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN68282588" publicIdentifierDateAssigned="2023-08-01T10:54:40.10244Z">
    <isrctn dateAssigned="2023-08-01T10:54:40.10244Z">68282588</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Strengthening programme for ambulant adolescents with cerebral palsy</title>
      <scientificTitle>Clinical effectiveness of an adolescent-specific strengthening programme, compared to usual care, for ambulant adolescents with spastic cerebral palsy (ROBUST trial): a parallel group randomized controlled trial</scientificTitle>
      <acronym>ROBUST</acronym>
      <studyHypothesis>An adolescent-specific muscle strengthening programme has superior clinical effectiveness compared to usual care for ambulant adolescents with spastic cerebral palsy.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Cerebral palsy (CP) is caused when babies suffer brain injury around birth from a lack of oxygen in the brain. Children with CP develop stiff and weak muscles. They often have difficulty walking and moving and that makes it difficult for them to join in activities. Exercises prescribed by physiotherapists become a big part of their lives as it tries to train their muscles and help them participate in activities. When they reach adolescence and their body grows, weakness of muscles in the legs becomes more of a problem.
Exercises to strengthen muscles to maintain or improve movement are often used by physiotherapists in adolescents with CP. However, there is wide variability in the strengthening exercise programmes used. Therefore, professional groups have highlighted the need for evidence-based physiotherapy exercise programmes in adolescents with CP. The aim of this study is to assess the effectiveness of a strengthening programme compared to usual care in adolescents with CP.

Who can participate?
Adolescents aged 12-18 years with spastic cerebral palsy

What does the study involve?
Participants will be randomly allocated into either the intervention (exercise programme) group or the usual NHS physiotherapy group. The intervention will involve six sessions with the physiotherapist over 16 weeks. Adolescents will receive an exercise programme which includes specific individually tailored strengthening exercises. The usual care group will receive the usual NHS physiotherapy treatment, involving one session to receive advice and guidance on their usual exercise and activity programme but does not include specific strengthening exercises. Adolescents or their parents/guardians in both groups will be required to fill out a questionnaire when entering the study and again at 6 and 12 months. Participants will also receive a clinical assessment upon entering the study and again at 6 months.

What are the possible benefits and risks of participating?
As with any form of exercise, adolescents may experience delayed muscle soreness on movement and/or mild altered walking (limping) for a few days after completing some of the exercises suggested by the physiotherapist. The benefit of participating is that the information from this study will be used to help treat other adolescents with CP more effectively.

Where is the study run from?
The study will be centrally managed by the Surgical Intervention Trials Unit (SITU), in collaboration with the Oxford Clinical Trials Unit (OCTRU) (UK)

When is the study starting and how long is it expected to run for?
January 2024 to February 2028

Who is funding the study?
National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme (UK)

Who is the main contact?
1. Sally Hopewell, sally.hopewell@csm.ox.ac.uk
2. Joanna O’Mahoney, joanna.omahoney@ndorms.ox.ac.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Functional mobility measured using the patient/parent-reported Gait Outcomes Assessment List (GOAL) questionnaire at 6 months</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Muscle strength measured using the five time sit-to-stand test for adolescents with CP at 6 months
2. Motor function measured using the Timed Up and Go (TUG) test at 6 months
3. Functional mobility measured using the patient/parent-reported Gait Outcomes Assessment List (GOAL) questionnaire at 12 months 
4. Independence measured using GOAL subdomain A at 6 and 12 months
5. Balance measured using GOAL subdomains A, B, D at 6 and 12 months
6. Pain and discomfort measured using GOAL subdomain C at 6 and 12 months
7. Health-related quality of life measured using EQ-5D-Y at 6 and 12 months 
8. Educational outcomes measured using educational attendance records (days) at 6 and 12 months
9. Patient/parent exercise adherence self-reported at 6 and 12 months
10. Additional physiotherapy treatment self-reported at 6 and 12 months</secondaryOutcome>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved 30/08/2023, South Central - Hampshire A Research Ethics Committee (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, UK; +44 (0)207 104 8388; hampshirea.rec@hra.nhs.uk), ref: 23/SC/0231</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68282588</doi>
      <eudraCTNumber/>
      <irasNumber>325313</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 57227</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="3e7a54b0-d4b7-4509-bac2-4a13974394d6" numberType="iras" canonicalSecondaryNumber="IRAS325313">325313</secondaryNumber>
	<secondaryNumber id="d3d9615d-d4b3-45c3-a610-502151115fc7" numberType="cpms" canonicalSecondaryNumber="CPMS57227">57227</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized; Interventional; Design type: Treatment, Physical, Rehabilitation</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2028-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="08e02b51-c495-457f-9cda-2b92cca57ddf">
	  <name>University Hospitals Dorset NHS Foundation Trust</name>
	  <address>Management Offices
Poole Hospital
Longfleet Road</address>
	  <city>Poole</city>
	  <state/>
	  <country>England</country>
	  <zip>BH15 2JB</zip>
	  <rtsId>R0D@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="842fa0d2-a5c6-40b0-97a5-13d3c82f6667">
	  <name>Derbyshire Healthcare NHS Foundation Trust</name>
	  <address>Trust Headquarters
Kingsway Hospital
Kingsway</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3LZ</zip>
	  <rtsId>RXM@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="548899ea-975e-429b-bad7-c9a78b3fbf8b">
	  <name>Gloucestershire Health and Care NHS Foundation Trust</name>
	  <address>Edward Jenner Court
1010 Pioneer Avenue
Gloucester Business Park</address>
	  <city>Gloucester</city>
	  <state/>
	  <country>England</country>
	  <zip>GL3 4AW</zip>
	  <rtsId>RTQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="11e4c1e8-313e-4530-a6b5-94e851710041">
	  <name>Alder Hey Children's NHS Foundation Trust</name>
	  <address>Alder Hey Hospital
Eaton Road
West Derby</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L12 2AP</zip>
	  <rtsId>RBS25@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="27cad457-c6dd-45ba-8c2f-8cc0a521ab74">
	  <name>Solent NHS Trust</name>
	  <address>Solent NHS Trust Headquarters
Highpoint Venue
Bursledon Road</address>
	  <city>Southampton</city>
	  <state/>
	  <country>England</country>
	  <zip>SO19 8BR</zip>
	  <rtsId>R1C@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4856d68d-e079-4d68-a40c-eb99f4357d62">
	  <name>Isle of Wight NHS - Hq</name>
	  <address>St Mary's Hospital
Parkhurst Road</address>
	  <city>Newport</city>
	  <state/>
	  <country>England</country>
	  <zip>PO30 5TG</zip>
	  <rtsId>R1FHQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b8204776-30a9-480f-ba1f-e4483f5cf727">
	  <name>Barts Health NHS Trust</name>
	  <address>The Royal London Hospital
80 Newark Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 2ES</zip>
	  <rtsId>R1H@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="4c121804-2e9a-4e0e-a2c7-0ac0a1d98232">
	  <name>St George's University Hospitals NHS Foundation Trust</name>
	  <address>St George's Hospital
Blackshaw Road
Tooting</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW17 0QT</zip>
	  <rtsId>RJ7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b53ef4e3-6fd1-4a33-9480-77477cd6f8b5">
	  <name>Leeds Community Healthcare NHS Trust</name>
	  <address>3 White Rose Office Park
Millshaw Park Lane</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS11 0DL</zip>
	  <rtsId>RY6@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="cd920118-fe9d-4684-86ec-85b2d07ac21a">
	  <name>West Suffolk NHS Foundation Trust</name>
	  <address>West Suffolk Hospital
Hardwick Lane</address>
	  <city>Bury St. Edmunds</city>
	  <state/>
	  <country>England</country>
	  <zip>IP33 2QZ</zip>
	  <rtsId>RGR@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="395ff08c-48b9-4b49-b913-1400f31de620">
	  <name>The Royal Wolverhampton NHS Trust</name>
	  <address>New Cross Hospital
Wolverhampton Road
Heath Town</address>
	  <city>Wolverhampton</city>
	  <state/>
	  <country>England</country>
	  <zip>WV10 0QP</zip>
	  <rtsId>RL4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="cc6746d4-feb5-4668-89e7-fa1d5920cfc1">
	  <name>Northern Care Alliance NHS Foundation Trust</name>
	  <address>Salford Royal
Stott Lane</address>
	  <city>Salford</city>
	  <state/>
	  <country>England</country>
	  <zip>M6 8HD</zip>
	  <rtsId>RM3@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f1ecf3e3-9a1a-46f1-8a89-cca5d9449c75">
	  <name>Torbay and South Devon NHS Foundation Trust</name>
	  <address>Torbay Hospital
Newton Road</address>
	  <city>Torquay</city>
	  <state/>
	  <country>England</country>
	  <zip>TQ2 7AA</zip>
	  <rtsId>RA9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="623e7755-536a-453f-a63e-b0612c124958">
	  <name>Mid Cheshire Hospitals NHS Foundation Trust</name>
	  <address>Leighton Hospital
Leighton</address>
	  <city>Crewe</city>
	  <state/>
	  <country>England</country>
	  <zip>CW1 4QJ</zip>
	  <rtsId>RBT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d65212dd-b437-49cf-9feb-02db9ddf671c">
	  <name>Whittington Health NHS Trust</name>
	  <address>Northern Health Centre, 580 Holloway Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>N7 6LB</zip>
	</trialCentre>
	<trialCentre id="eecf9e53-f492-40d4-ba26-29996be936e4">
	  <name>Oxford Health NHS Foundation Trust</name>
	  <address>NIHR Oxford Cognitive Health Clinical Research Facility, Warneford Hospital, Warneford Lane, Headington</address>
	  <city>Oxford</city>
	  <state/>
	  <country>England</country>
	  <zip>OX3 7JX</zip>
	</trialCentre>
	<trialCentre id="362274e5-cd08-4997-aaac-432b2bb44ade">
	  <name>Bedfordshire Hospitals NHS Trust</name>
	  <address>Child Development Centre, Hill Rise</address>
	  <city>Kempston</city>
	  <state/>
	  <country>England</country>
	  <zip>MK42 7EB</zip>
	</trialCentre>
	<trialCentre id="ca8e3a26-9426-459d-8ecc-57357fcd14ac">
	  <name>Betsi Cadwaladr University Health Board</name>
	  <address>Ysbyty Glan Clwyd, Rhuddlan Road</address>
	  <city>Rhyl</city>
	  <state/>
	  <country>Wales</country>
	  <zip>LL18 3RF</zip>
	</trialCentre>
	<trialCentre id="246a5eed-3f02-482c-99a1-6a0406370a25">
	  <name>Cambridgeshire and Peterborough NHS Foundation Trust</name>
	  <address>Elizabeth House
Fulbourn Hospital
Fulbourn</address>
	  <city>Cambridge</city>
	  <state/>
	  <country>England</country>
	  <zip>CB21 5EF</zip>
	  <rtsId>RT1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1a41253b-2882-404e-b9e4-69988548f4ec">
	  <name>Hertfordshire Community NHS Trust</name>
	  <address>Unit 1a Howard Court
14 Tewin Road</address>
	  <city>Welwyn Garden City</city>
	  <state/>
	  <country>England</country>
	  <zip>AL7 1BW</zip>
	  <rtsId>RY4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bbccb169-c149-4dd4-a76a-d04a908a465a">
	  <name>Kingston and Richmond NHS Foundation Trust</name>
	  <address>Galsworthy Road</address>
	  <city>Kingston upon Thames</city>
	  <state/>
	  <country>England</country>
	  <zip>KT2 7QB</zip>
	  <rtsId>RAX@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b233d3ed-363f-470b-9eea-c4732d427923">
	  <name>Leicestershire Partnership NHS Trust</name>
	  <address>Room 100/110 Pen Lloyd Building
County Hall
Leicester Road</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE3 8RA</zip>
	  <rtsId>RT5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="05073159-f64a-4601-98dd-e840fd8ce58e">
	  <name>Maidstone and Tunbridge Wells NHS Trust</name>
	  <address>The Maidstone Hospital
Hermitage Lane</address>
	  <city>Maidstone</city>
	  <state/>
	  <country>England</country>
	  <zip>ME16 9QQ</zip>
	  <rtsId>RWF@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="aaf55404-7fab-4039-b2a8-c24a63da85b6">
	  <name>North East London NHS Foundation Trust</name>
	  <address>West Wing
C E M E Centre
Marsh Way</address>
	  <city>Rainham</city>
	  <state/>
	  <country>England</country>
	  <zip>RM13 8GQ</zip>
	  <rtsId>RAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="24faef1d-2e7f-4f30-9b2b-ad7620366456">
	  <name>Northampton General Hospital NHS Trust</name>
	  <address>Cliftonville</address>
	  <city>Northampton</city>
	  <state/>
	  <country>England</country>
	  <zip>NN1 5BD</zip>
	  <rtsId>RNS@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1b7451d3-e4e4-449b-a905-2b59b61c91dd">
	  <name>Powys Teaching Local Health Board</name>
	  <address>Bronllys Hospital</address>
	  <city>Brecon</city>
	  <state/>
	  <country>Wales</country>
	  <zip>LD3 0LY</zip>
	  <rtsId>7A7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="ab8127ea-0548-4793-9531-75fa42b8e8f0">
	  <name>Robert Jones &amp; Agnes Hunt Orthopaedic Hospital</name>
	  <address>Gobowen</address>
	  <city>Oswestry</city>
	  <state/>
	  <country>England</country>
	  <zip>SY10 7AG</zip>
	  <rtsId>R1DAC@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="2509cd1b-f937-4281-826e-bc131229331d">
	  <name>Royal Free London NHS Foundation Trust</name>
	  <address>Royal Free Hospital
Pond Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW3 2QG</zip>
	  <rtsId>RAL@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="8276bf3f-2603-4214-aa28-93e5915270d4">
	  <name>Shropshire Community Health NHS Trust</name>
	  <address>Mount Mckinley
Anchorage Avenue
Shrewsbury Business Park</address>
	  <city>Shrewsbury</city>
	  <state/>
	  <country>England</country>
	  <zip>SY2 6FG</zip>
	  <rtsId>R1D@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="3fd4baab-b968-4eb6-a214-ec4fc9b9d126">
	  <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
	  <address>Freeman Hospital
Freeman Road
High Heaton</address>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>England</country>
	  <zip>NE7 7DN</zip>
	  <rtsId>RTD@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f2026895-5879-44a5-a508-a5866cea3349">
	  <name>Wonford House</name>
	  <address>Wonford House Hospital
Dryden Road</address>
	  <city>Exeter</city>
	  <state/>
	  <country>England</country>
	  <zip>EX2 5AF</zip>
	  <rtsId>RWV62@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6118f5d8-c653-44fc-95df-ac882cf9db6c">
	  <name>Chelsea and Westminster Hospital NHS Foundation Trust</name>
	  <address>Chelsea &amp; Westminster Hospital
369 Fulham Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW10 9NH</zip>
	  <rtsId>RQM@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="9b49af6c-1430-4ef1-85c9-830dd84e5078">
	  <name>County Durham &amp; Darlington NHS Foundation Trust</name>
	  <address>Children’s Therapy, Children’s Centre
Chester le Street Community Hospital
Front Street
Chester le Street</address>
	  <city>Durham</city>
	  <state/>
	  <country>England</country>
	  <zip>DH3 3AT</zip>
	</trialCentre>
	<trialCentre id="55c28190-fb1f-40be-82c6-230a25e7c423">
	  <name>Sheffield Children's NHS Foundation Trust</name>
	  <address>Ryegate Children's Centre
Tapton Crescent Road</address>
	  <city>Sheffield</city>
	  <state/>
	  <country>England</country>
	  <zip>S10 5DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adolescents aged 12-18 years (i.e. from their 12th to their 18th birthday)
2. Diagnosis of spastic CP (bilateral or unilateral) Gross Motor Function Classification System (GMFCS) levels I–III
3. Willing for their community physiotherapy service and GP to be informed of their participation in the trial
4. Under 16 years of age: Participant is willing to take part in the study and has a parent/guardian who is willing and able to give informed consent for the child’s participation in the study.
5. Over 16 years of age: Participant is willing and able to give informed consent or a nominated Consultee can advise on behalf of the participant (Outside Scotland)/legal representative can consent on the participant's behalf (Scotland)</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="12.0">12 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="18.0">18 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>334</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Patient has had orthopaedic surgery of the lower limbs or selective dorsal rhizotomy in the past 12 months or planned (i.e. date confirmed) in the next 6 months
2. Patient has had lower limb botulinum toxin injections or serial casting in the past 4 months or planned (i.e. date confirmed) in the next 6 months
3. Patient is regularly performing a structured resistance exercise programme focused on resistance training as part of their usual physiotherapy routine
4. Patient is unable to comply with the assessment procedures and exercise programme with or without support from their carer</exclusion>
      <recruitmentStart>2024-01-29T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cerebral palsy</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Cerebral palsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>ROBUST is a randomised controlled trial with 1:1 allocation. Follow-up assessors will be blinded to the randomisation allocation.

Participants will be identified through the Cerebral Palsy Integrated Pathway (CPIP) Network and recruited from NHS Trusts, providing care for children and young people with CP, where they will be assessed for eligibility by the clinical team, both supported by the local PI and research team in case of uncertainty.

Adolescents and their parent(s) will be approached as part of their annual community physiotherapy CPIP review or other routine CP clinical care attendance. They will have the opportunity at their appointment to ask any questions they have about the study.

Screening forms will be completed at each site. These will include questions on patient demographics and detail any reasons given for exclusion and non-participation.

Participants will be asked to sign an assent form (for adolescents aged 12-15 years) whilst the parent/guardian will be asked to sign a consent form on behalf of their child. For those aged 16-18 years when entering the study, the young person will either be asked to sign a consent form or, if the clinician assesses the young person to be unable to provide informed consent, their parent/guardian (or other relative/friend, if applicable) will be asked to complete a consultee declaration on their behalf.

Randomisation will take place once informed consent has been given, eligibility has been confirmed and baseline assessments have been made. During the baseline assessment participants, with the support of their parent/guardians will be asked to complete a baseline assessment questionnaire, which will include baseline measurements for the primary and secondary outcomes.

Clinician-assessed outcomes (i.e. muscle strength and motor function) at baseline will be recorded electronically by a physiotherapist at site and before learning the outcome of the randomisation. All data will be entered into the study database (REDCap).

Those randomly allocated to the progressive resistance exercise programme will receive six physiotherapy sessions over 16 weeks and will be requested to complete follow-up questionnaires via a link in an email or by paper through the post at 6 and 12 months. Clinician-assessed outcomes will be assessed at a face-to-face clinic appointment at 6 months by a blinded physiotherapist/assistant practitioner who is blind to the treatment allocation and has not been
involved in the delivery of the intervention or usual care.

Those randomly allocated to the usual NHS care arm will receive one session of usual care advice, with a physiotherapist/assistant practitioner. Participants allocated to this group will also be sent a link via email or a paper copy of the questionnaires to complete at 6 months and 12 months. They will also receive a blinded clinician assessment at the 6-month timepoint.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>Upon completion of the trial, and with appropriate participant consent, anonymised research data will be shared with other organisations on request to the Chief Investigator Sally Hopewell (sally.hopewell@csm.ox.ac.uk) and in accordance with the data sharing policies of OCTRU, the Sponsor and funder. Requests for data (anonymised trial participant level data) will be provided at the end of the trial to external researchers who provide a methodologically sound proposal to the trial team (and who will be required to sign a data sharing access agreement with the Sponsor) and in accordance with the NIHR guidance. After the end of the trial an anonymised trial dataset will be created and stored, and may be shared with other researchers upon request. Participant consent for this is included in the informed consent form for the trial.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f178d198-d3d4-4fe4-8e5b-8d8f2a957c47" outputType="pis" artefactType="ExternalLink" dateCreated="" dateUploaded="2024-12-10T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<externalLink url="https://robust-info.digitrial.com/"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="a857f70f-0892-4887-bfc1-282004c60d37" outputType="pis" artefactType="ExternalLink" dateCreated="2025-11-11T00:00:00.000Z" dateUploaded="2025-11-11T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="Migration">
	<externalLink url="https://robust-info.digitrial.com/"/>
	<description>Participant information sheet</description>
	<productionNotes>Migrated from patient info sheet field</productionNotes>
      </output>
      <output id="c56cd471-a61a-45a9-baa4-7b4fa41cdd87" outputType="protocolfile" artefactType="LocalFile" dateCreated="2023-06-15T00:00:00.000Z" dateUploaded="2023-09-05T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="620941c0-0d14-45a7-920a-60d3ebf419f2" originalFilename="ISRCTN68282588 ROBUST Protocol Version 1.0_15Jun2023.pdf" downloadFilename="ISRCTN68282588 ROBUST Protocol Version 1.0_15Jun2023.pdf" version="1.0" mimeType="application/pdf" length="1457329" md5sum="de0d44c7c572a8e50bc5533c61265382"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="4c4c772c-badd-47a3-b0eb-9145edd99696" outputType="protocolfile" artefactType="LocalFile" dateCreated="2023-11-21T00:00:00.000Z" dateUploaded="2024-12-10T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="d16e687c-0735-422d-b96d-473aff0ef3fa" originalFilename="ISRCTN68282588_PROTOCOL_V2.0_21Nov23.pdf" downloadFilename="ISRCTN68282588_PROTOCOL_V2.0_21Nov23.pdf" version="2.0" mimeType="application/pdf" length="1338143" md5sum="02d6ccf12b75c3f85e490fcc9673c154"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="c2877fc9-6872-4b97-8be6-bf2f1113354f" outputType="protocolfile" artefactType="LocalFile" dateCreated="2024-12-12T00:00:00.000Z" dateUploaded="2026-01-15T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="07e2958a-5a7a-4e67-9f65-978ce192d6b7" originalFilename="ISRCTN68282588_Protocol_V3.0_12Dec2024.pdf" downloadFilename="ISRCTN68282588_Protocol_V3.0_12Dec2024.pdf" version="3.0" mimeType="application/pdf" length="2824954" md5sum="41d872d894bd8e99ae98251c6728c6ca"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="c37b2a70-8805-4aee-b47c-7a1215a05fd9" outputType="protocolfile" artefactType="LocalFile" dateCreated="2025-06-09T00:00:00.000Z" dateUploaded="2026-01-15T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="d2350a89-eec6-466c-95ed-7ee7140aaafd" originalFilename="ISRCTN68282588_Protocol_V4.0_09Jun2025.pdf" downloadFilename="ISRCTN68282588_Protocol_V4.0_09Jun2025.pdf" version="4.0" mimeType="application/pdf" length="2904521" md5sum="dea8d497f72ba25291ce5bd0d31d33ca"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="fbfe3beb-d2c9-4f17-8db3-050fd475f2a3" outputType="trialwebsite" artefactType="ExternalLink" dateCreated="2025-11-11T00:00:00.000Z" dateUploaded="2025-11-11T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="Migration">
	<externalLink url="https://robust-study.org/"/>
	<description>Study website</description>
	<productionNotes>Migrated from study website field</productionNotes>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>4871c32f-72a2-4d6d-aaed-8e4da9f09504</funderId>
      <contactId>c5f948d1-8509-4af0-aee6-67cac8b37067</contactId>
      <contactId>33328056-c571-4973-9832-413ad33ea716</contactId>
      <sponsorId>c1a3f6e4-9d19-4ca0-ae63-283aee998b34</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/620941c0-0d14-45a7-920a-60d3ebf419f2/43942">
	<description>Protocol file</description>
	<name>ISRCTN68282588 ROBUST Protocol Version 1.0_15Jun2023.pdf</name>
	<id>620941c0-0d14-45a7-920a-60d3ebf419f2</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1457329</length>
	<md5sum>de0d44c7c572a8e50bc5533c61265382</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/d16e687c-0735-422d-b96d-473aff0ef3fa/43942">
	<description>Protocol file</description>
	<name>ISRCTN68282588_PROTOCOL_V2.0_21Nov23.pdf</name>
	<id>d16e687c-0735-422d-b96d-473aff0ef3fa</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1338143</length>
	<md5sum>02d6ccf12b75c3f85e490fcc9673c154</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/07e2958a-5a7a-4e67-9f65-978ce192d6b7/43942">
	<description>Protocol file</description>
	<name>ISRCTN68282588_Protocol_V3.0_12Dec2024.pdf</name>
	<id>07e2958a-5a7a-4e67-9f65-978ce192d6b7</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>2824954</length>
	<md5sum>41d872d894bd8e99ae98251c6728c6ca</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/d2350a89-eec6-466c-95ed-7ee7140aaafd/43942">
	<description>Protocol file</description>
	<name>ISRCTN68282588_Protocol_V4.0_09Jun2025.pdf</name>
	<id>d2350a89-eec6-466c-95ed-7ee7140aaafd</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>2904521</length>
	<md5sum>dea8d497f72ba25291ce5bd0d31d33ca</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="c5f948d1-8509-4af0-aee6-67cac8b37067">
    <title>Mrs</title>
    <forename>Joanna</forename>
    <surname>O'Mahoney</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Surgical Intervention Trials Unit
The Botnar Research Centre
Windmill Road</address>
      <city>Oxford</city>
      <state/>
      <country>United Kingdom</country>
      <zip>OX3 7LD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 737643</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joanna.omahoney@ndorms.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="33328056-c571-4973-9832-413ad33ea716">
    <title>Prof</title>
    <forename>Sally</forename>
    <surname>Hopewell</surname>
    <orcid>https://orcid.org/0000-0002-6881-6984</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Oxford
Botnar Institute for Musculoskeletal Sciences
Windmill Road</address>
      <city>Oxford</city>
      <state/>
      <country>United Kingdom</country>
      <zip>OX3 7LD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 223458</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sally.hopewell@csm.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="c1a3f6e4-9d19-4ca0-ae63-283aee998b34">
    <organisation>University of Oxford</organisation>
    <sponsorType>University/education</sponsorType>
    <rorId>https://ror.org/052gg0110</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="4871c32f-72a2-4d6d-aaed-8e4da9f09504">
    <name>NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR135150</name>
  </funder>
</fullTrial></allTrials>